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ABSTRACT
Biofilm implant-related infections represent one of the most difficult-to-treat 
pathologies in current healthcare systems.  According to the National Institutes of Health, 
over 80% of infections in the human body are biofilm related.  Biofilms are dynamic 
communities of bacterial cells that are often polymicrobial and which typically develop 
into three-dimensional structures that are attached to a surface.  Due to the 
morphological, physiological and genotypic characteristics of biofilms, they are highly 
resistant to antibiotic therapies.
One of the most practical strategies that has been undertaken to prevent these 
biofilm implant-related infections has been the development of active release coatings on 
biomaterial devices.  Unfortunately, to date, active release coatings have had limited in 
vivo and clinical success due to several important limitations.
To address these limitations, the work that was performed in this dissertation has 
led to or may lead to five areas of development that have the potential to contribute to the 
fields of bioengineering and biofilm research.  First, a membrane biofilm reactor was 
developed to grow biofilms for use as initial inocula both in vitro and in vivo.  Second, in
contrast to the common use of planktonic bacteria for in vitro and in vivo testing, all 
aspects of this project used well-established biofilms of methicillin-resistant 
Staphylococcus aureus using the membrane biofilm reactor to more closely model the 
phenotype of bacteria that reside in natural ecosystem.  Third, a novel antimicrobial
iv
compound was used as an active release agent.  Fourth, the in vitro work performed in 
this study was done using a flow cell system to more closely model an in vivo paradigm. 
Fifth, the animal model that was established for this project presents the first animal 
model in the published literature to use well-established biofilms of MRSA that were 
grown under fluid sheer forces as initial inocula in an animal model of biofilm-related 
infection.
The in vitro results demonstrated that the active release coating was able to 
significantly eradicate biofilms within a 24-hour period.  These results translated to the in 
vivo model wherein the active release coating was able to prevent biofilm implant-related 
infection in 100% of animals tested. Taken together, these results provide a promising 
outlook for the future use of this active release coating to prevent biofilm implant-related 
infections.
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CHAPTER 1
THE IMPACT OF BIOFILMS ON BIOMEDICAL DEVICES
1.1 The Birth of Germ Theory
One decade prior to the birth of Johann Sebastian Bach (1685-1750) and George 
Frideric Handel (1685-1759), amateur microscopist Antony van Leeuwenhoek (1632-
1723) of Delft, Holland observed microscopic “animalcules” for the first time.1 Using 
rudimentary techniques of hand-grinding glass into microscope lenses, van Leeuwenhoek 
viewed the constituents of scrapings from his own teeth.  Based on what he saw, he drew 
pictures of what he believed to be living organisms.  His drawings depicted rod-shaped 
matter and cone-like structures, one of which he drew with a squiggly line trailing behind 
it to indicate that it had motion (Figure 1.1). The pictures he drew were revolutionary at 
the time, but have since become archaic compared to technological advances that now 
permit scientists to look beyond the microcosm to the nanostructures of microbial cells.  
Nevertheless, van Leeuwenhoek's observations are regarded as the benchmark of 
cellular discovery, for, prior to his observations there was no physical evidence that 
living matter existed beyond what the human eye could observe visually. Although these
direct observations were unique, van Leeuwenhoek was not the first to conceptualize the 
existence of microscopic living matter.  For centuries, philosophers and physicians had 
speculated that invisible, living creatures did in fact exist.
2Nearly two millennia prior to the birth of van Leeuwenhoek, Titus Lucretius 
Carus (about 98-55 B.C.), the Roman poet and philosopher, suspected that invisible, 
living creatures were responsible for human disease.2 Lucretius’ belief was furthered by 
Girolamo Fracastoro (1478-1553), an Italian physician, scholar and poet who suggested 
that fomites could foster the seeds, or spores, of contagion and cause infection.3
Lucretius’ and Fracastoro’s theories would later be described as atomist—a theory 
suggesting that minute, discrete, finite and indivisible elements are the ultimate 
constituents of all matter.  
Unfortunately, the intuitive thinking of Carus and Fracastoro, and even the visual 
observations of animalcules by van Leeuwenhoekall of which suggested that living 
matter did exist beyond the bounds of the naked eyewere not widely accepted. Indeed, 
their ideas were considered fanciful at best. This lack of acceptance stemmed from the 
fact that the world had a firm, and long-standing trust in the teachings of one of the most
well known scholars in history: Aristotle Stagiritis, son of Nicomachus (384-322 B.C.).
Indeed, the inaccurate observations of Aristotle were the root cause of a millennium-long 
debate surrounding one of the most important developments of human thoughtthe theory 
of spontaneous generation.2
Near 343 B.C., in volume VI, section 15, S4v of his Historia Animalia, Aristotle 
wrote that “There is a species of mullet that grows spontaneously out of mud and sand.”  
He wrote further, “From the facts above enumerated it is quite proved that certain fishes 
come spontaneously into existence, not being derived from eggs or from copulation.  
Such fish as are neither oviparous nor viviparous arise all from one of two sources, from 
mud, or from sand and from decayed matter that rises thence as a scum; for instance, the 
3so-called froth of the small fry comes out of sandy ground.”  His presumption was that 
living things could be derived from nonliving matter—a presumption otherwise known as 
Aristotelian abiogenesis, i.e., spontaneous generation.
For two millennia, the theory of spontaneous generation challenged the beliefs 
and direct observations of Lucretius, Fracastoro and van Leeuwenhoek. But it was not 
until 1668 that the foundational principles of spontaneous generation would forever be
challenged by the Italian physician, Francesco Redi (1626-1697).  To refute one of the 
most fundamental ideologies of spontaneous generation, i.e., that decaying meat 
produced maggots spontaneously, Redi carried out a series of experiments.  To begin, he
placed meat into three containers, one uncovered, one covered with paper and the other 
covered with fine gauze.  The paper and gauze excluded flies from contacting the 
decaying meat.  Not surprisingly to those of our day, he found that maggots grew only on 
the meat of the uncovered container.  Redi also noted that flies were attracted to the 
gauze-covered container and laid eggs on the gauze; the eggs later produced maggots.2
Redi’s results indicated that decaying meat did not produce maggots 
spontaneously, but rather, the eggs of flies produced maggots.  Redi’s achievements 
appear to have been so revolutionary, that the history of Italian parasitology is now 
subdivided into two periods: pre-Redi and post-Redi.4 But his, and others’ experiments, 
only addressed the spontaneous generation of larger organisms.  With the observation of 
van Leeuwenhoek’s animalcules in 1676, the controversy renewed with some now 
proposing that microorganisms arose by spontaneous generation, while larger organisms 
did not.2
4To support this notion, in 1748 John Needham (1713-1781), an English biologist 
and Roman Catholic priest, boiled mutton broth then tightly sealed the flasks.  The flasks 
later became cloudy and contained microorganisms.  Needham believed that a vital force 
within organic matter could offer to nonliving matter the properties of life.  The 
controversy was tried once again when, two decades later, Italian biologist and naturalist 
Lazzaro Spallanzani expounded on Needham’s experimental design.  
Spallanzani sealed seeds and water in glass flasks then boiled them for ¾ of an 
hour.  No growth occurred so long as the flasks remained sealed.  When they were not 
sealed, growth occurred.  His results led him to propose that germs were carried in the air 
to the medium.  Supporters of spontaneous generation retaliated still, believing that by 
heating the air in the flasks, Spallanzani had limited the air’s ability to donate life.  The
debate continued into the 1800s as Theodore Schwann (1810-1882) and others confirmed 
Spallanzani’s findings whereas those who supported spontaneous generation found new 
hope in French naturalist, Felix Pouchet (1800-1872), who conclusively proved--so he 
believed--that microbial growth could occur without contaminating air.2
The prospontaneous generation claims, however, finally broke the proverbial 
camel’s back and prompted a man by the name of Louis Pasteur (1822-1895), a French 
chemist turned microbiologist, to end the debate.  Pasteur first filtered air through sterile 
cotton.  He noted that plant spore-like particles gathered on the cotton and when placed 
into sterile broth, growth occurred.  Pasteur then placed other nutrient broths in flasks, 
heated their necks with a flame and bent the necks into various configurations (similar to 
a p-trap) with the end of the neck remaining open to the air (Figure 1.2). Pasteur 
observed that dust and germs accumulated in the necks of the flasks, yet no growth 
5occurred in the broth.  Once he broke the necks so as to allow the dust and germs to enter 
the broth, growth occurred straight away.
Pasteur’s results seemed sufficient to shatter the claims of spontaneous 
generation, but what would have happened had Pasteur’s experiments contained bacterial 
spores?  If such were the case, the debate would have likely continued, but not for long.  
Within a matter of years following the work of Pasteur, the English physicist, John 
Tyndall (1820-1893), and the German botanist, Ferdinand Cohn (1828-1898), ultimately 
showed, respectively, that air free of dust did not cause growth in broth and that heat-
resistant bacterial endospores do exist.2
The 60 years following Pasteur's work (from ~1857-1914) resulted in what is now 
considered The Golden Age of Microbiology.5 During this era, Louis Pasteur, Robert 
Koch (1843-1910), Joseph Lister (1827-1912) and Ignaz Semmelweis (1818-1865)
pioneered significant discoveries including the agents of infection, culture techniques, the 
role of immunity in disease, aseptic surgical technique, methods of microscopy and 
chemical activities of microorganisms.  Notably, these discoveries would have a
particular effect on the future of biomedical device development, which was in its infancy 
during the early 1900s.
The late 1800s and 1900s were considered The Golden Age of Microbiology, the 
early- to mid-1900s have been regarded as the Second Golden Age and it has recently 
been suggested that microbiological developments are now in a Third Golden Age.5 This 
Age has included the discovery of nucleic acids and the impact of bacteria on medical
device development.  The latter development became particularly poignant following the 
discoveries of Claude E. Zobell, PhD (1904-1989)6 and John William (Bill) Costerton,
6PhD (1934- ),7 which indicated that bacteria in natural ecosystems predominantly dwell 
in polymicrobial communities of organisms and preferentially adhere to solid surfaces as 
opposed to existing as planktonic cells, or those that are defined as free-floating in a 
solution.
As will be seen in the following sections, these discoveries were so dramatic, that 
they literally altered decades-old misconceptions and provided important insights into the 
development of biomaterial devices.  More specifically, these discoveries have provided 
investigators, clinicians, engineers, and companies an understanding of why there are 
difficult-to-treat infections that accompany the use of biomedical devices as well as the 
foundation for why the majority of patients with medical devices have been largely free 
of bacterial and biofilm contamination/infection for the past 30 years.
1.2 From Germ Theory to Biofilm Theory
Although the direct visual observations of van Leeuwenhoek may have arguably 
been sufficient evidence to suggest that viable, functional "animalcules" existed beyond 
the view of the human eye, a true understanding of what van Leeuwenhoek observed was 
not gained until nearly 300 years later.
In 1948, Dr. Zobell, a marine microbiologist working at the Scripps Institute of 
Oceanography, provided a previously undiscovered insight into the life of 
microorganisms. He also provided early on what is now known to be the rationale for 
why chronic infections that surround the use of medical implants are largely untreatable.
While collecting samples of sea water for microbiological analysis, Dr. Zobell 
observed that bacteria in the water preferentially adhered to the sides of bottles, as 
7opposed to floating freely as planktonic bacterial cells.  He further outlined that an 
increase in the number of bacteria was seen on the surfaces of bottles with increasing 
surface area per volume of sea water.  He concluded that "solid surfaces are beneficial to 
bacteria."6
Similar observations were made by civil engineers working with wastewater
treatment processes in the 1960s. These engineers "Realized that most of the bacteria 
that removed organic molecules from sewage lived in sessile populations on surfaces, and 
they produced elegant models that predicted the efficiency of both biofilms and flocs in 
nutrient removal."8
In 1977, Gordon McFeters, PhD and Gill Geesey, PhD added to these 
observations by plating and culturing samples of water from icy streams in the Absorka 
and Bugaboo mountains of Canada.  By culture, they were only able to quantify ±10 
bacterial cells per milliliter (mL) of water, but "it soon became obvious that rocks in the 
streams were covered with slippery biofilms, and direct examination of these clear slime 
layers showed the presence of millions of bacterial cells encased in transparent 
matrices."8,9
By 1978, Costerton et al.7 collated and coordinated these early findings into a 
general hypothesis that bacteria in natural ecosystems preferentially dwell in complex 
communities.  Costerton later defined these communities as bacterial biofilms, which, 
according to Merriam Webster, are defined as "a thin usually resistant layer of 
microorganisms (as bacteria) that form on and coat various surfaces." Today, more than 
30 years later, and with tens of thousands of publications on the topic, biofilm research 
has become one of the most noted fields of research with many new investigators 
8entering its ranks each year and Dr. Bill Costerton is considered by nearly all of those 
who work in this field as the father of biofilm discovery and research.
As will be shown throughout the remainder of this chapter, and dissertation as a 
whole, the work that has been performed by myriad investigators with biofilms to date
has led to an in-depth understanding of biofilm morphology, characteristics, metabolic 
state and other intricate aspects.  These findings have further helped investigators, 
clinicians and many others to understand why pathogenic biofilms comprise one of the 
most difficult-to-treat pathologies in the fields of biomaterial device development and 
medicine.10
1.3 Early Observation of Biofilm on a Medical Implant
Following the initial hypothesis of Costerton et al., the biofilm theory quickly 
gained wide acceptance by the medical and microbial research communities based on the 
significant amounts of data that began to support it.11-16 One of the earliest and most 
compelling publications to support the biofilm theory came in 1982.17 After treating a 
patient with a transvenous pacemaker, Thomas Marrie, MD, in collaboration with Dr. 
Costerton, published a case report that stated in part:
A 56-year-old male was admitted to our hospital on August 
28, 1981 with a 4-day history of anorexia, nausea, vomiting 
and shaking chills. Three weeks before admission, he had 
injured his left elbow and on two occasions he had 
expressed pus from it. He had undergone surgery for 
peptic ulcer disease, a history of ethanol abuse and 
syncopal attacks. In May 1975 a Medtronic bipolar 
transvenous pacemaker had been inserted when 
investigation of his syncopal attacks revealed prolongation 
of conduction through the atrioventricular node. Physical 
examination revealed a temperature of 39.2°C, a resolving 
indurated lesion on his left elbow, and tenderness in his 
9right upper quadrant. Blood cultures grew S. aureus. He 
was treated with cloxacillin, 12 g/day i.v. for 4 weeks. 
During the third week in the hospital, his gall bladder was 
removed. One week after discharge he developed nausea,
vomiting, fever and sweating. Blood cultures again grew S.
aureus. He was treated for 6 weeks with cloxacillin, 12 
g/day i.v., and rifampin, 600 mg/day orally. No signs of 
endocarditis were evident. There was no infection of the 
pacemaker pocket and serial echocardiograms showed 
normal cardiac values. He promptly responded to the 
antibiotic therapy, but was readmitted a third time 9 days 
after discharge with the same symptoms. Again, blood 
cultures grew S. aureus. On this occasion the entire pacing 
system was removed and replaced by an epicardial 
pacemaker. Intravenous cloxacillin was continued for 4 
weeks after removal of the infected pacemaker lead. He 
has since remained well.17
As part of their investigation, Marrie et al. cut the distal 10 cm of the explanted 
pacemaker lead and confirmed the presence of bacteria residing in a biofilm on the 
surface of the lead using culture techniques and scanning electron microscopy (SEM).  
Their conclusion was that Staphylococcus aureus cells had contaminated the laceration 
on the elbow of the patient and hematogenously spread to the pacemaker lead.  Once they 
colonized the lead, the cells developed a biofilm that served as a reservoir of infection in 
the patient. Thus, although antibiotics were able to eradicate septic bacteria residing in 
the planktonic state, the antibiotics were unable to completely eradicate those cells 
residing in the biofilm phenotype on the surface of the lead.
This early report of a biofilm implant-related infection represents a hallmark of
biofilm implant-related infections.  More specifically, multiple physicians began to 
document instances wherein patients, who had a biomaterial(s) either implanted long 
term or in transient use, would recover from infection with antibiotic treatment, but 
would then suffer from a recurring infection once the antibiotic treatment was removed.16
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1.4 The Biofilm Theory Applied to Orthopaedics
One of the earliest reported instances of this sinusoidal recurrence of infection as 
it relates to orthopaedic implants occurred in 1984.16 Once again in collaboration with 
Dr. Costerton, Anthony Gristina, MD, observed that two of his patients, one with a total 
hip replacement device and one with an intramedullary rod in the femoral canal, suffered 
from recurring infection that developed into osteomyelitis.  The patient with the 
intramedullary rod received chronic antibiotic treatment for an astounding 7-year period 
until it was finally decided to remove the implant.  Following explantation and a final 
long-term regimen of cephalothin, the patient no longer suffered.
In both case reports presented by Gristina and Costerton, biofilms were observed 
on the surface of the implants by SEM.  In concluding their observations, they 
highlighted an important aspect of the clinical diagnosis of biofilm implant-related 
infection.  Specifically, they stated that "Adherent bacteria can be efficiently recovered 
from tissues by homogenization and plating." In addition, "Direct observation of the 
colonized biomaterials and tissues, rather than standard sampling techniques, may also 
show morphological types compatible with the true pathogens."16
Many hundreds of clinical investigations have since confirmed these findings as 
well as observed that many pathogenic organisms in the biofilm phenotype, in particular 
those that colonize orthopaedic implants, are unculturable; meaning that these organisms
will not grow on agar using standard plating techniques.  Therefore, current data are now 
strongly suggesting that in addition to direct observation and culture techniques,
molecular analysis of tissue samples may be required to give a proper clinical diagnosis.
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1.5 Characteristics of Biofilms and Antibiotic Resistance
Despite the early indications that bacterial biofilms had a tremendous negative 
impact on the success of implanted devices, many of the defining characteristics that 
made biofilm infections difficult to treat were not well known until the mid-1980s and 
1990s.  For example, although there were clinical observations that biofilms appeared to 
have increased resistance to antibiotic therapy in patients suffering from biofilm-related 
infection, the degree and basis of that resistance was not well known.
1.5.1 Biofilms Can Be 1000x More Resistant to Antibiotics
Than Planktonic Bacteria
Following what would become a lifelong pattern of being involved in every major 
advance of biofilm discovery and research, but also following a pattern of enthusiastic 
recognition for the contributions of others in this important field of research, in 1984 Dr. 
Costerton was the senior investigator of the research team of J. Curtis Nickel, MD to 
elucidate the concentration of antibiotic required to eradicate bacterial cells in the 
planktonic versus the biofilm phenotype. Their work began by growing biofilms of 
Pseudomonas aeruginosa in a modified Robbins Device.18
Nickel et al. used this device to grow biofilms on individual latex sections that
modeled an artificial bladder/catheter system.  After growing biofilms on the surfaces of 
the latex sections, they flowed broth that contained differing concentrations of 
tobramycin through the device.  At various time points, they removed latex sections from 
the device to observe the biofilms directly with SEM or to quantify the number of 
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bacteria using standard culture techniques.  A similar procedure was performed to test the 
efficacy of tobramycin against planktonic bacteria.  
They published their results in 198518 and ultimately changed the field of biofilm 
research by showing that bacterial cells in the biofilm phenotype could be 1000x more 
resistant to tobramycin compared to the same species of bacteria in the planktonic 
phenotype.  Since that time, numerous studies with many strains of bacteria and as many 
antibiotics have been performed with similar results	
 
 ide in biofilms are 
typically more resistant to antibiotics than their planktonic counterparts.
Taken together, these data provided a strong rationale for why patients who 
suffered from biofilm implant-related infections may not have been effectively treated 
with antibiotic therapies: the infectious biofilms were likely more resistant to antibiotic 
treatment than planktonic bacteria that may have been present. But not only did Nickel et 
al., and additional investigators afterward,19-22 show that biofilms have increased 
resistance to antibiotic therapy, their work also suggested that the concentration of 
antibiotic that would be required to eradicate biofilms in a patient would likely be an 
amount that could lead to toxicity in the body.
1.5.2 Biofilms Can Be Removed From Surfaces With Debridement
The fact that antibiotics may have reduced efficacy against bacterial biofilms has 
led to two important developments in recent years.  1) There is an ever growing need for 
investigators and clinicians to discover and employ novel antimicrobial compounds for 
the treatment of biofilm-related infections.  This will be further discussed in Chapter 2.
2) Due to the limitations of antibiotics, physicians, such as Randy Wolcott, MD, who 
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specialize in treating patients with biofilm-related infections typically use a polytherapy 
approach including intense antimicrobial treatment in conjunction with surgical 
debridement.20,21 Of these treatment methods, Wolcott et al. have suggested that 
debridement is a pivotal method of eradicating biofilms.21 Debridement serves two 
purposes: it can immediately reduce the number of bacteria in a biofilm by several logs, 
which increases the potential for antibiotics to function more effectively, and it readily 
removes bacteria from the surfaces of a patient's skin, bone and/or implant surface if an 
implant is present.  
1.5.3 Bacteria in Biofilms Have Strength in Numbers
In 1975, Gibbons et al. wrote a review article outlining the data that were
available regarding the number and species of bacteria in the human mouth.23 In their 
review, they reported that there were roughly 100 bacterial cells firmly attached to each
epithelial cell on a human tongue. They further discussed that scrapings of human teeth 
contained ~1011 bacterial cells per gram of wet weight.  Other work reviewed showed 
that the amount of bacteria in saliva fluctuated significantly throughout the day.  Yet on
average there were 109 bacterial cells per mL of saliva.
From these data, two points of interest can be made.  1) When Antony van 
Leeuwenhoek viewed scrapings from his own teeth, he arguably analyzed the best 
possible sample that was available to him for the detection of microbial cells.  2) It can
easily be understood why bacterial biofilms need to be debrided on a regular basis from
the surface of human teeth.  If they aren't, they have greater potential to lead to gingivitis 
or dental carry formation.
14
Note that the data presented by Gibbons et al.23 were collected and analyzed prior 
to the formalization of the biofilm theory by Costerton et al.7 However, like Dr. Zobell, 
the investigators that pioneered these discoveries made similar observations about 
bacteria: they tended to adhere to solid surfaces, including those that exist in the human 
body, and they did so in incredibly large numbers. These and other early illustrations that 
billions of cells may be present in biofilms that contaminate human tissues and/or implant 
surfaces provided an important insight into why bacteria in biofilms have increased 
resistance to antibiotics; they have strength in numbers.
1.5.4 Biofilms Develop Into Three-Dimensional Structures
By 1991, another characteristic of biofilms was discovered that provided even 
deeper understanding into the architecture of biofilms, and once again, this discovery 
gave researchers and clinicians another rationale as to why biofilms have increased 
resistance to antibiotics.
Utilizing scanning confocal laser microscopy (SCLM), Lawrence et al. were the 
first group to observe that bacterial biofilms had the potential to develop into three-
dimensional, polymicrobial communities that contained a variety of components (Figure 
1.3).24 More specifically, they observed that in addition to growing into vertical pillar-
like formations upward of 100 μm in height, throughout the biofilm communities they 
observed many spaces, which created open channels (see Figure 1.3). Based on their 
observations of these channels, they were led to hypothesize that the biofilm architecture 
was not a random organization of cells, but rather an "optimal arrangement for influx of 
nutrients, transfer of wastes, and establishment of microenvironmental conditions, etc., 
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subject to change as the biofilm progresses from initial to more established stages."24
The work of Paul Stoodley, PhD, later supported this hypothesis by demonstrating, with 
real time videography, that these channels in biofilms were filled with water and thus 
could shuttle antibiotics throughout their community with limited interaction with 
cells.25,26 Lawrence et al. also documented the presence of extracellular matrix 
components that appeared to act as a scaffold to which bacterial cells could attach within 
the biofilm, ultimately contributing to its three-dimensional architecture.
One of the most enlightening aspects of their work was the fact that by using 
SCLM, Lawrence et al. were able to circumvent the limitations that accompanied the use 
of SEM, which was the most common method of imaging biofilms up to that point.  In 
short, SEM imaging always carried, and still carries, the limitation that it was performed 
under very high vacuum conditions, which had the potential of causing cells and the 
hydrated polysaccharide extracellular matrix (ECM) to collapse.  Fixation protocols to 
prepare biofilms for SEM were also limited as they often failed to cross-link ECM 
components to the surface of a cell, which prevented investigators from observing the 
ECM components with SEM.  Promisingly, Erlandsen et al.27 and Williams et al.28 have 
recently demonstrated how modified fixation and treatment protocols can cross-link ECM 
components more readily to cellular surfaces, thus providing a way to overcome one 
aspect of these previous limitations of imaging biofilm and their matrices with high 
resolution SEM.
Finally, in their conclusion, Lawrence et al. commented on the ability of small 
molecules that they used in their study to penetrate deep into the basal layers of a biofilm 





that antibiotics had the ability to reach the deepest portions of a 
biofilm community in a matter of seconds.29 These comments were noteworthy because 
they countered earlier notions that small molecules could not penetrate a biofilm due to 
the presence of ECM components, which were believed to act as a blockade of small 
molecule penetration.
1.5.5 Oxygen Gradients Discovered in Biofilm Communities 
Although Nichols et al. demonstrated that antibiotics could penetrate the deepest 
interstices of a biofilm, they, and other researchers, were still left to wonder why these 
antibiotics had reduced efficacy against biofilms.  Lawrence et al. had provided a partial
answer by finding channels that shuttled antibiotics away from the bulk structure, but it 
was not until researchers discovered that the metabolic state of cells deep within a biofilm 
community was reduced, which contributed to why cells were resistant to antibiotic 
therapy despite the fact that antibiotics were able to come in direct contact with them.
To determine this, for example, Walters et al.30 and Borriello et al.31 examined the 
concentration of oxygen throughout biofilm communities of P. aeruginosa. In their 
studies, levels of oxygen and protein synthesis served as indicators of metabolic activity.
In short, it was found that the concentration of oxygen in a biofilm was reduced as it was 
measured from the outer edges toward the inner most portions of a biofilm, creating an 
oxygen gradient.  Thus, on the outer edges of a biofilm, an aerobic environment was
observed and bacteria were readily killed, whereas there was a predominantly anaerobic
environment in the center of a biofilm. The anaerobic environment resulted in a 
drastically decreased metabolic state of cells, which allowed cells to remain viable 
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despite the ability of antibiotics to completely penetrate the biofilm communities and 
interact with them. Borriello et al. confirmed that these results were similar after 
growing biofilms under anaerobic conditions: in a reduced oxygen environment wherein 
fermentation or denitrification served as metabolic pathways, antibiotics had reduced 
efficacy.
Reduced metabolic activity provided one of the most concrete rationales for why 
antibiotics had reduced efficacy against bacteria in biofilms.  It hinged on the fact that for
antibiotics to function properly, cells must be in a high or active state of metabolism.32,33
In microbiological terms, this state of high metabolic activity is referred to as log phase 
growth.  Thus, because bacterial cells that resided deep in a biofilm community, where 
oxygen was scant and nutrients less available, were found to be in a lower metabolic state
compared to other cells in the community, they were largely immune to antibiotic 
therapy.
Additional work has shown that biofilms also contain persister cells that are 
present in reduced oxygen environments.34,35 These are cells within a biofilm that are 
largely unaffected by antibiotic therapy and thus "persist" in a biofilm community while 
others are killed.
1.5.6 Plasmid Gene Transfer Occurs at a Higher Rate in
Biofilms Than in Planktonic Bacteria
As a final note on biofilms and antibiotic resistance, one more discovery will be 
mentioned in this section.  This discovery was made in 1999 by Martina Hausner, PhD 
and Stefan Wuertz, PhD.36 Prior to their work, it was well known that small segments of 
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deoxyribonucleicacid (DNA), called plasmids, could be transferred from one bacterium 
to another via pili appendages.37,38 More specifically, it was known that plasmids carried 
genetic coding that could ultimately result in the translation of protein(s) that specifically 
interact with, and even quench the activity of antibiotic compounds.  In addition to 
random genetic mutation, plasmid transfer was an important method by which planktonic 
bacterial cells could obtain resistance to antibiotics.37
However, the rate of genetic transfer was not well known within bacterial 
biofilms.  Thus, using quantitative in situ fluorescence methods in conjunction with 
SCLM, Hausner and Wuertz were able to show that in biofilms of P. aeruginosa,
plasmids could be transferred at a rate 1,000 times faster than in cultures of planktonic 
bacteria.  They concluded that the high rates of genetic transfer were likely due to the 
biofilm structure, the proximity of cells to one another as well as the presence of water 
channels that could shuttle molecules from one area of a biofilm to another.
1.5.7 Summary of Biofilm Characteristics
In summary, four major characteristics of biofilms have been outlined in this 
section, which specifically suggest why they have increased resistance to antibiotic 
therapy.  First, bacterial biofilms may have millions or billions of cells that are packed 
into an extremely small volume; thus, they have strength in numbers and an extremely 
high local dose of antimicrobial may be necessary to have any significant effect on them.  
Importantly, there is no environmental or physiological requirement that bacterial 
biofilms must be comprised of millions or billions of cells.  In fact, direct observations of 
biofilms from human skin have suggested that biofilms may consist of as few as 100 or 
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1,000 cells.39 Yet to date, there has not been antibiotic resistance data obtained on 
biofilms that have less than a few million cells and this is one area that needs future 
investigation in order to understand the effect of small number biofilms on human health,
particularly in the field of aseptic surgery (this will be discussed in more detail in Chapter 
3).
Second, biofilm structure itself provides an ability to shuttle antibiotic or other 
antimicrobial compounds away from the bulk structure as well as individual cells within 
its community. This is done via water channels that develop within a biofilm.  Notably, 
water channel formation in biofilm forming species of bacteria was likely a beneficial 
result of natural selection during the evolutionary process because not only can water 
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toxic waste products and nutrients can 
also be diffused throughout the system.  Similarly, natural selection likely also had a
beneficial role for biofilms that produced ECM material, as the ECM has been shown to 
store nutrients that can be made available when nutrients become less available in the 
environment.8
Third, a gradient of oxygen, which goes from higher to lower levels as a function 
of biofilm depth, appears to influence the metabolic state of cells within a biofilm 
community.  As a result, bacterial cells that reside on the outer edges of a biofilm, where 
oxygen and nutrients are readily available, may be much more susceptible to antibiotics 
than those residing in the inner most portions of a biofilm where oxygen and nutrients 
may be less available.
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Fourth, bacteria in a biofilm have been shown to transfer plasmids at a much 
higher rate than their planktonic counterparts.  In effect, this may provide cells in a 
biofilm the ability to upregulate their defense mechanisms at a much faster pace when 
exposed to antibiotic perturbations compared to cells in a broth culture.  Similar to what 
was said about water channel formation, this aspect of genetic transfer in biofilms was 
likely also a beneficial outcome of natural selection during the evolutionary process, as 
was the biofilm structure as a whole.
In Figure 1.4, several diagrams and two SEM images are provided to present a
visual understanding of each of the four major structural characteristics outlined above.
These diagrams demonstrate what mature biofilms look like, the three-dimensional 
conformations they may take on as they mature, their life cycle and the extensive ECM 
products that they produce. The original diagrams shown in Figure 1.4 are used with 
permission from the Center for Biofilm Engineering at Montana State University 
(http://www.biofilm.montana.edu/resources/images?page=5), as well as in the published 
manuscripts of the author.28,40
Other aspects of bacteria that provide them with antibiotic resistance, including 
protein pumps in a bacterium's cell membrane that can quickly remove antibiotics from 
its cytoplasm,41 cell wall thickness,42 cell-to-cell (quorum sensing) communication,43
geographical/anatomical location and an ability to grow in extreme environments,44 have 
not been discussed in this dissertation, but each of these also has the potential to 
contribute to bacterial cells' resistance to environmental perturbations, including 
antibiotic therapies.  Instead, this section has focused on just a few of the major aspects of 
antibiotic resistance as they apply to biofilms in clinical settings, specifically those that 
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apply to biofilm implant-related infections that are treated with antibiotics.  Nevertheless, 
the fact that biofilms continue to develop resistance to all known types of antibiotics and
other antimicrobials, and with recent data suggesting that bacteria can metabolize
antibiotics as an energy source,45 the astounding pace of development has led to what the
author considers to be an antibiotic resistance era.
1.6 The Rise of an Antibiotic Resistance Era
Within months after discovering penicillin in 1928,46 Alexander Fleming noted, 
perhaps with a measurable amount of concern, that S. aureus cells in laboratory cultures 
were already showing signs of resistance to the compound.47 Specifically, he found that 
when penicillin was used in too low of concentrations, or when it was not used long 
enough, S. aureus could become resistant to it.  Notably, this finding highlights the fact 
that bacteria in the planktonic phenotype can also develop resistance against antibiotics, 
albeit at a slower pace than cells that reside in the biofilm phenotype.  Nevertheless, as
Fleming spoke to audiences across the world, he warned, along with Almroth Wright, 
that the overuse of the penicillin antibiotic could lead to resistance and thus lose its 
efficacy.48
Despite these warnings, once it was put into mass production in the Spring of 
1944, penicillin was heavily overused throughout the world, particularly during World 
War II.  Although hindsight has perfect vision, it was likely difficult for those who 
overused penicillin to limit its use as it saved many thousands of soldiers' lives during the 
war and millions of civilian patients thereafter.  In fact, there are currently a number of 
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strep throat and sinus infections.
Nevertheless, antibiotic resistance is now one of the greatest concerns among 
healthcare officials in civilian and military settings across the world.49-51 As stated by 
Clinton Murray, MD, "One of the most disconcerting facts about the bacteria 
complicating combat casualties is their increasing antimicrobial resistance."50 Similarly,
greater than 90% of clinical S. aureus isolates in the U.S. are now resistant to penicillin 
and 40% of S. aureus isolates cultured from hospitals are resistant to methicillin.52 The 
concern of resistant organisms is now also becoming commonplace in national headlines.  
For example, TIME magazine recently ran a headline that stated, "Drug-Resistant 
Superbug Shows Up in Three U.S. States."53 Fox News recently reported, "Europe in the 
Grip of Drug-Resistant Superbugs."54 Alas, studies have suggested that the trend of 
emerging antibiotic resistance has not yet been addressed effectively.55,56
With an era of antibiotic resistance that appears to threaten healthcare systems 
across the world, in combination with the fact that bacterial biofilms are known to thrive 
on hard surfaces,6,7 there are ever increasing rates and concerns of biofilm implant-related 
infections that accompany the use of biomedical devices.  Government agencies and 
healthcare facilities across the world have also come to recognize this problem.57,58 Thus, 
aside from the exponential growth of regulations that affect medical device development,
biofilm implant-related infections threaten to make the future of development a difficult 
and complex challenge.10,16,59
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1.7 The Current Impact of Biofilms on Biomedical Devices
As has been alluded to in this chapter and as will be evident throughout the 
remainder of this dissertation, the literature regarding biofilm-related infections and their 
adverse effects on human health, particularly in instances of biomedical device 
implantation, is growing at a steady pace.  All reports of biofilm-related infections and 
studies that the author has read to date carry a similar theme: biofilm implant-related 
infections are becoming a tremendous concern to researchers and clinicians, these 
infections cost healthcare systems across the world billions of dollars each year, 
antibiotic resistance is the most disconcerting aspect of biofilm-related infections and the 
number of effective antimicrobial agents against biofilms are becoming less and less each 
year.10,16,50,59,60 Yet companies are currently hesitant to produce novel agents due to the 
high cost of development, regulatory requirements and the rapid development of bacterial 
resistance.
According to a review by Rabih Darouiche, MD,10 each year more than $3 billion 
dollars are spent in the U.S. to treat nine of the most frequent implant-related infections
(see Table 1.1). Notably, the numbers he provided did not include infections that develop 
as a result of revision surgeries, which are accompanied by higher rates of infection.
In outlining the general principles of treating patients who suffer from biofilm 
implant-related infections, Darouiche noted that "The essential factor in the evolution and 
persistence of infection is the formation of biofilm around implanted devices.  Soon after 
insertion, a conditioning layer composed of host-derived adhesins (including fibrinogen, 
fibronectin, and collagen) forms on the surface of the implant and invites adherence of" 
organisms, which ultimately leads to "A three-dimensional structure of biofilm . . . that 
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contains complex communities of tightly attached (sessile) bacteria.  These bacteria 
display cell-to-cell signaling and exist within a polymer matrix containing fluid channels 
that allow for the flow of nutrients and waste."10
Granting agencies are also becoming aware of the adverse impact that biofilms 
have on human health.  In a recent announcement, the National Institutes of Health (NIH) 
stated that over 80% of infections in the human body are biofilm related (see 
announcement PA-07-288).  The Centers for Disease Control (CDC) placed that estimate 
at 65%.58 In the case of implanted devices, Hetrick and Schoenfisch have stated that 
"When considering all indwelling devices, the number of implant-associated infections 
approaches approximately 1 million per year."61 Chronic wounds are now considered by 
many investigators to be the result of acute infection that begins with biofilm 
contamination as opposed to a nonhealing wound that is later contaminated and suffers 
from biofilm formation/infection.57,62-64
From the literature it can be seen that open fracture wounds demonstrate one of 
the wound types that are most susceptible to the development of chronic biofilm-related 
infection.50,65-69 This is due to the fact that open fractures are often contracted in a
traumatic fashion, wherein the risk of contamination with bacteria from natural 
ecosystems is very high. The potential for bacterial contamination in open fractures may
be highlighted by the work of Torsvik et al.70 and Bakken.71 Their work has 
demonstrated, on an independent basis, that tens of millions to tens of billions of bacterial 
cells may reside in a single gram of soil.  In addition, based on the work of Geesey et al.,9
Costerton et al.8 and Wimpenny et al.72 it has been estimated that greater than 99.9% of 
bacteria recovered from natural ecosystems such as dirt, human skin, plants and water 
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sources, reside in the biofilm phenotype.  Thus, it could be argued that open fracture 
wounds that are contaminated with bacteria from natural ecosystems are at significant 
risk of being contaminated with bacteria that reside in the biofilm phenotype as opposed 
to the planktonic phenotype.  This topic of biofilms contaminating wound sites initially as 
opposed to planktonic bacterial cells will be discussed in detail in Chapter 3.
Based on the fact that open fracture wounds have such a significant risk of being 
contaminated with bacteria that reside in biofilms, and because they result in
unacceptably high rates of biofilm implant-related infection, with minimally efficacious 
methods of treatment to date, a model of a highly contaminated open fracture wound was
the basis for this dissertation with the understanding that if a novel antimicrobial 
treatment could reduce rates of biofilm implant-related infection in this model, the 
antimicrobial strategy could then be applied to additional models in the future.  To
demonstrate just how high the rates of open fracture infections are as well as outline the 
prevalence of open fracture formation, the next section will focus on these data.
1.8 Prevalence of Open Fractures and Rates of Infection
According to the CDC, fractures are the leading cause of injury hospitalization in 
the United States.73 Each year in America, there are between 3 and 6 million patients 
who suffer from bone fractures.69,73,74 Of those patients, 3%-4% have open fractures.69,75
Rates of infection that accompany these open fractures range between 5% and 
50%.50,65,66,75-78 This range of infection corresponds to the severity of an open fracture 
type. The most common classification system of open fracture severity, and correlatively 
the rates of associated infection, was first developed by Gustilo and Anderson in 1976.78
26
Using a retrospective analysis of long bone open fractures treated from 1955 to 
1968 at the Hennepin County Medical Center, Minneapolis, Minnesota, Gustilo and 
Anderson classified fractures into three levels of severity.  A Type I fracture was defined 
as an open fracture with a wound that was less than 1 cm and clean. A Type II fracture 
was one that had a laceration that was larger than 1 cm long without extensive soft-tissue 
damage, flaps, or avulsions.  A Type III fracture was either an open segmental fracture, 
an open fracture with extensive soft-tissue damage, or a traumatic amputation.  Special 
categories in Type III were gunshot injuries, any open fracture caused by a farm injury, 
and any open fracture with accompanying vascular injury requiring repair.
By 1984, Gustilo et al. once again performed retrospective analysis on open 
fractures that were treated from 1976-1979 and recognized that due to "Varied severity 
and prognosis . . . the current designation of Type III open fracture is too inclusive."66
Therefore, they recommended "That Type III open fractures be divided, in order of 
worsening prognosis, into three subtypes."66 They then defined these three subtypes as
Type IIIA, Type IIIB, and Type IIIC.  Specifically, these were defined as:
Type IIIA
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erial injury requiring repair.
Gustilo et al. also provided the infection data that accompanied each of the Type 
III fractures.  In doing so, they noted that Type IIIB open fractures had the highest rates 
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of infection, which were reported to be 52%.  They also showed the amputation rates 
among patients with Type III fractures.  Of those with Type IIIA fractures, 0% were 
amputated.  Of those with Type IIIB fractures, 16% were amputated and of those with 
Type IIIC open factures, 42% were amputated.  Amputations were primarily the result of
the complications of infection and non-union.
Notably, these data were consistent with the personal experience of J. Peter Beck, 
MD, a collaborator on this project, who is a board certified orthopaedic surgeon with 40 
years of clinical experience.  In a personal conversation with Dr. Beck, he noted that in 
his clinical experience, the reason that it is common to see Type IIIC open fractures 
treated with amputation is due to the tremendous damage that has occurred to a patient's 
limb and the limited ability for their tissues to heal.
In the military theater, rates of open fracture formation are much higher compared 
to the civilian population.  In a recent report by Owens et al.,51 wherein all injuries in 
soldiers from October 2001 through January 2005 were considered, data from the Joint 
Theater Trauma Registry were obtained for U.S. soldiers who were being treated for 
wounds sustained in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom 
(OEF).  This report indicated that 26% of all injuries (915 out of 3,575) in soldiers were 
fractures.  Of those fractures, 82% were open with rates of infection that reached as high 
as 60% in at least one instance.79 Additional data collected from Brook Army Medical 
Center showed that 40% of injured soldiers treated, 26% of which had orthopaedic 
trauma, from January to June of 2006 received courses of antibiotics.50
Data that have been collected from military and civilian populations have
suggested that Type IIIB open fractures of the tibia are extremely susceptible to bacterial 
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contamination, which leads to high rates of non-unions.50 Johnson et al.67 found that in a 
group of 35 soldiers who suffered from Type IIIB open fractures of the tibia, 77% of their 
wounds had bacteria present.  Thirteen of these soldiers had non-unions after >9 months 
of treatment, which was the result of infection.  Due to complications of infection, four of 
these were amputated. As was shown in the work of Gustilo et al., similar results have 
been seen in the civilian population and high rates of infection with Type IIIB open 
fractures continue to be reported today.65,66,75,77,78
1.9 Rationale for Study Design and Dissertation Outline
Taken together, the infection data surrounding Type IIIB open fractures represent 
a class of fracture, and injuries in general, that are difficult to treat due to massive
amounts of contamination with rates of infection that reach as high as 50% even after 
prophylactic antibiotic treatment and surgical reduction with fracture fixation devices.
These high rates of infections have led to three major concerns. The first is due to the 
limited efficacy of current antibiotic therapies.  Infections that accompany highly 
contaminated Type IIIB open fractures have the potential to develop into chronic 
osteomyelitis despite antibiotic therapy. The second concern is that there are currently a
limited number of alternative antimicrobial strategies in clinical use that have been shown 
to effectively circumvent the problem of antibiotic resistance. The third concern is based 
on the fact that all animal models of infection that have been developed to date have 
utilized planktonic bacterial cells as opposed to bacteria that reside in well-established 
biofilms.80-102 This is a concern since 99.9% of bacteria in natural ecosystems appear to 
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reside in the biofilm phenotype,7,9,72 in addition to the fact that planktonic bacteria are 
much more susceptible to antibiotics than bacteria in a biofilm.18,21
Thus, the overall goal of the work presented in this dissertation was to employ a 
novel antimicrobial compound, known as cationic steroid antimicrobial-13 (CSA-13), 
which has been shown to be a very promising antimicrobial compound with broad 
spectrum activity against both Gram negative and Gram positive bacteria in the 
planktonic and biofilm phenotype,103-109 as an alternative to traditional antibiotics to 
prevent biofilm implant-related osteomyelitis. 
To demonstrate the exact method of how this work was performed, Chapter 2 of 
this dissertation will first outline a few of the most recent developments in alternative 
antimicrobial compounds and strategies to treat biofilm-related infections with a specific 
emphasis on why CSA-13 was chosen for this project.  Chapter 3 will then outline the 
current limitations of animal models of biofilm-related infections in general.  
Specifically, this chapter will address the issue of using planktonic bacterial cells as 
opposed to bacterial biofilms as initial inocula in animal models of infection.  
Importantly, the concept of using biofilms as initial inocula in Chapter 3 cannot be 
overstated since, after a careful literature review, it provided the first proposal in the 
literature to use bacteria as they exist in natural ecosystems, i.e., biofilms, as initial 
inocula in animal models as opposed to planktonic bacteria.57 Chapter 4 will outline the 
development of a membrane biofilm reactor that was machined with 
ultrahighmolecularweightpolyethylene (UHMWPE).  This reactor was developed for this 
study to grow well-established biofilms of methicillin-resistant Staphylococcus aureus 
(MRSA) such that they could be used as initial inocula for in vitro and in vivo 
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testing.40,110 The criterion for the successful development of this reactor was that it 
needed to grow biofilms with similar cellular number on the surface of polymeric 
membranes over various runs.  If this reactor could not grow biofilms in a repeatable,
consistent fashion, then the in vitro results would have been untrustworthy and the initial 
inoculum of bacteria in the in vivo portion of the study would have been inconsistent.  
Chapter 5 is then aimed at demonstrating how CSA-13 was used as an active release 
agent from a device coating against MRSA biofilms in an in vitro system.  Chapter 6 will 
then add onto the work outlined in Chapter 5 by providing a specific characterization of 
the active release coating that was developed to elute CSA-13 away from its surface.
Chapter 7 provides data obtained from pilot work that was performed in sheep in order to 
establish the experimental animal model of osteomyelitis using biofilms as initial inocula.  
The importance of this chapter, and the publication of this work, lies in the fact that this 
animal model demonstrated, for the first time, that when bacteria residing in a well-
established biofilms grown under fluid sheer forces are used as initial inocula in an 
animal model, they have the potential to lead to a persistent, chronic and slow-developing 
osteomyelitis infection.  Chapter 8 will then focus on the definitive animal study that was 
undertaken to test the efficacy of CSA-13 against biofilms in the animal model that was 
established in Chapter 7.  Chapter 9 will then summarize the results, provide a discussion 
and outline the direction for future work that can be performed to validate the results of 
the work performed in this dissertation.
At the end of this dissertation, five appendices--Appendix A, Appendix B,
Appendix C, Appendix D and Appendix E--will also be attached to provide the reader 
with a copy of the manuscripts that were published  prior to the completion of this 
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dissertation work.28,57,110 Three additional manuscripts will also be published as a result 
of this work and will be based on the work presented in Chapters 5, 6, and 8. 
Taken together, this work, in addition to future work that will be performed, will 
be used to establish the principles for developing combination products for Food and 
Drug Administration (FDA) submission.  The ultimate goal is to have CSA-13 approved 
as an active release agent of biomaterial device coating(s) that can be used clinically to 
prevent biofilm implant-related infections in human patients.
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Figure 1.1: Hand drawn pictures of the "animalcules" that Antony van Leeuwenhoek 
observed as he analyzed the scrapings from his own teeth.  These drawings are now 
known to represent the various shapes of bacterial cells including rods (fig: A and F), 
cocci (fig: E) and spirochetes (fig: G).  It is important to note that van Leeuwenhoek 
observed organisms move as indicated in fig: B, which further suggested to him that 
these were viable, functioning organisms. Figure is available for use by the general 
public.
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Figure 1.2: Hand drawn pictures of the flasks that Louis Pasteur used to disprove the 
theory of spontaneous generation.  Note the p-trap appearance of the necks which led 
without blockage to the bulb portion of the flasks that held growth media. Figure is 
available for use by the general public.
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Figure 1.3: The first three-dimensional reconstruction of a biofilm using SCLM.  This 
image was created from a biofilm of Vibrio parahaemolyticus and was published by 
Lawrence et al.24 Figure used with permission.
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Figure 1.4: The various cartoons and images in the following figure provide an indication 
of the morphology, functionality and life cycle of bacterial biofilms.  (A) Diagram 
outlining at least two conformations that a mature biofilm may take on as it grows to 
maturity.  These conformations include mushroom-like formations or pillar-like 
structures.  This diagram also shows that as a bulk fluid flows across a biofilm, it may 
pass through channels, similar to those that Lawrence et al. discovered.  It is not 
uncommon for portions, or streamers, of a biofilm to detach from the main body of the 
biofilm as shown here.  In a clinical setting, these streamers may detach and relocate to a 
distal site, causing additional biofilms to form in multiple areas of a patient's body.  (B) 
As shown in this diagram, biofilm structures are dynamic.  Their structure may be 
influenced by flow rates and a variety of other factors. Biofilms may even roll along a 
surface if turbulent flow is present. (C) Streamers that detach from the main body of a 
biofilm, as indicated in (A) and (B), may contain planktonic bacteria.  The natural 
tendency of planktonic bacteria, as was outlined by Zobell, is to attach to a surface and 
subsequently colonize that surface by developing into a biofilm.  This diagram provides a 
schematic of the life cycle of a biofilm showing how planktonic bacteria may colonize a
surface, develop into a biofilm, and then planktonic bacteria detach again to colonize a 
distal location.  This cycle has been followed using live imaging techniques and this is 
shown below the diagram. (D) SEM image of a biofilm of Staphylococcus epidermidis 
that was grown on the surface of titanium.  Note that the biofilm structure has a 
mushroom-like appearance with the top of the mushroom extending toward the reader.  
(E) SEM image of a biofilm of S. aureus that was grown on a polymeric membrane.  This 
biofilm demonstrated that an extensive ECM network can develop in a mature biofilm.
(A), (B) and (C) used with permission from the Center for Biofilm Engineering at 
Montana State University (http://www.biofilm.montana.edu/resources/images?page=5). 
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Table 1.1: Estimated occurrences and rates of infections in the U.S. population that 
accompany a select number of implanted devices.  The associated cost to treat each 
infection type is also given.  Table used with permission and previously published by 
Darouiche.10
CHAPTER 2
PREANTIBIOTIC THERAPIES, THE DEVELOPMENT OF
NOVEL ANTIMICROBIAL COMPOUNDS,
AND ACTIVE RELEASE COATINGS
2.1 Methods of Treating Infection Prior to the Discovery of Antibiotics
By no means will this chapter have the capacity or necessity to cover all of the 
antimicrobial strategies that existed prior to the development of antibiotics.  It will
hopefully, however, provide information regarding a few of the most prominent 
advancements that have been made in antimicrobial treatments.
Prior to the mass production and optimization of antibiotic therapy(ies), the word 
"surgery" was synonymous with death.  Indeed, surgical procedures, which were largely 
optimized on the battlefield, were often accompanied by mortality rates of 80% to 90%
largely in part because of infection.111 From the 1300s to the 1800s, the most widely 
adopted treatment to prevent infection of a wounded limb was amputation.  A particular 
advocate of early amputation was Napoleon's physician, Baron Dominique Jean Larrey.  
In 1812, during the Battle of Borodino, Larrey was documented to have performed more 
than 300 amputations in a 24-hour period.  The basis by which he amputated so readily 
was founded in the fact that early amputation "Reduced morbidity, mortality, the 
likelihood of tetanus, and the suffering of the soldier."111
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Similarly, during those preantibiotic years, the general public was wary of 
maternity wards, wherein physicians such as Ignaz Semmelweis delivered babies in the 
mid-19th century.112 Prior to the controversial implementation of hand washing by 
Semmelweis in 1847, which he did with an antiseptic chlorinated lime solution, mortality 
rates of childbirth ranged between 5% and 30% due mostly to infection.  Though 
Semmelweis' hand washing procedure reduced rates of mortality to less than 2%, his 
work was not widely accepted and hospitals continued to perform surgeries using 
unsterile conditions, believing instead that a poisonous miasma in the air was the cause of 
infection.112-114 However, adding onto the findings that were part of the Golden Age of 
Microbiology, the work of Joseph Lister, whom many consider to be the father of modern 
surgery, fundamentally changed this mentality after he demonstrated in 1865 that by 
washing surgical instruments and wounds with carbolic acid (also known as phenol), 
rates of surgical site infections could be drastically reduced.115
By World War I, Henry Drysdale Dakin had collaborated with Alexis Carrel to 
produce an irrigating solution, which consisted of 0.4% - 0.5% sodium hypochlorite and 
4% boric acid.116-118 This "Dakin's solution," as it came to be called, was used to irrigate 
the wounds of soldiers, and drastically reduced rates of battle wound infections. There 
are indications to suggest that Dakin's solution is toxic, but it appears that when used in 
applications wherein necrotic tissue is present and in concentrations at or lower than 
0.025% sodium hypochlorite, toxicity may be limited.116-120 From personal conversations 
of the author with practicing physicians, it appears that Dakin's solution is still in clinical 
use to either soak gauze and apply to the surface of an incision site or wound bed, or as 
an irrigating solution.
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Notably, in the late-19th century, another method of treating infections had been 
discovered.  In 1896, Ernest Hanbury Hankin noted that water from the Ganges and 
Yamuna rivers in India had antibacterial properties against cholera.121 By 1915 Frederick 
Twort had discovered a small agent in these waters that he believed could be a virus. His 
belief became reality when, in 1917, Félix d'Hérelle, who worked at the Pasteur Institute 
in Paris, discovered an invisible, antagonistic microbe of the dysentery bacillus. He 
"knew" that it was a parasitic virus, and in 1923 the Eliava Institute was opened in Tblisi, 
Georgia to research this newly discovered organism and put it into practice.121 These 
organisms are now well documented as bacteriophages, i.e., small viruses that have the 
potential to specifically infiltrate and kill bacterial cells (Figure 2.1).  To date, many 
thousands of these organisms have been sequenced, characterized, documented and put 
into bacteriophage libraries across the world. In the mid-1940s bacteriophage research
took a backseat to the much more reliable and potent action of antibiotics.121
Other inorganic compounds have also been used for many centuries.  These 
include silver, copper, gold and platinum.122-125 The Phoenicians were known to store 
water, wine and vinegar in silver bottles because it helped prevent spoilage.126 During 
the 1800s, Western Pioneers placed coins such as pennies in their drinking water to help 
reduce spoilage.127,128 Galen was the first to make reference to sutures made of gold129
and physicians in the 1800s used sutures made of silver because they were known to have 
a reduced risk of infection.130,131 As will be discussed below, many investigators today 
continue to apply these metallic molecules in device coatings.
Also deserving of mention are natural products, such as plants, herbs, spices and 
food, that have been used for centuries to fight infections in rural settings, Native 
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American tribes, amongst the pilgrims, aborigines, pioneers, and those who currently 
practice and advocate holistic medicine.132,133 For example, honey has been used to treat 
wounds throughout the ages, but until recently its antimicrobial properties were not well 
known.134 Traditional Chinese medicine has also been in use for centuries, but has had 
variable strength in clinical settings.135 The antimicrobial activity of cinnamon, clove and 
cumin have also been tested recently136 and the author has likewise tested the 
antimicrobial efficacy of cinnamon, plant leaf extracts, garlic, sugar and a variety of other 
natural compounds. In short, natural compounds and holistic therapies may display 
antimicrobial activity, but they have not been widely accepted as being clinically 
efficacious.
Importantly, there are several reasons why antiseptics, bacteriophages and holistic 
medicines have been limited in their ability to fight infections within the human body.
First, the majority of antiseptic solutions cannot be taken orally due to their toxic nature.  
This toxicity further extends to use on human skin, where it may result in adverse side 
effects such as rashes, blisters, or irritation.  For example, sodium hypochlorite (bleach) 
has remarkable antimicrobial potential,137 yet it is well known to burn and irritate the skin 
and tissues of humans when used at high concentrations. As is commonly the case with
antiseptics and virtually every other form of medicine, these adverse reactions are 
concentration dependent and vary from patient to patient.  Similarly, chlorhexidine 
gluconate, a common skin prep agent for surgical procedures, was shown to cause
anaphylactic shock in a select number of patients when it was used topically138 or as part 
of a device coating.139 Typically, the fact that antiseptics are limited in their ability to be 
taken orally limits their usefulness to skin prep solutions and small wound treatments.
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With respect to bacteriophages, aside from the difficulty of convincing the FDA 
to approve the use of a biological agent, i.e., a virus, in human patients to treat wound 
and/or other infections, bacteriophages have been significantly limited in that the 
administration of a single bacteriophage or a cocktail of bacteriophages has been shown 
to be extremely delicate and dependent on the time of bacterial contamination as well as 
the stage of infection in a patient.140 In addition, there is concern with the fact that 
bacteriophages can have one of two forms: they can be lytic, meaning after they replicate 
in a bacterial cell, they can cause it to lyse; or they can become lysogenic, which means 
the DNA of a bacteriophage can incorporate itself into the DNA of the host bacterium.  
This is a concern for human patients since the DNA of a virus may potentially 
incorporate itself into the DNA of the patient, leading to unknown, perhaps adverse 
results.  At this time it appears that the main role of bacteriophages in nature is to keep 
bacterial numbers "in check," meaning as opposed to completely eliminating all bacteria 
with which they come in contact, they eradicate only a portion of them.  After bacterial 
numbers decrease, the amount of bacteriophage decreases as well, resulting in a cyclical 
pattern of existence for bacteriophages and the bacteria they affect in nature.
Traditional Chinese medicines, holistic therapies, natural compounds and  
inorganic metals have all had variable clinical results.135,138,139,141 Metal ions in particular 
have been hampered by their ability to elicit allergic reactions,142 the lack of infection 
prevention in clinical trials in patients and their reduced efficacy against bacteria residing 
in the biofilm phenotype.137,141,143 The variable clinical results that have been seen with 
holistic medicines may be due to a lack of regulated extraction protocols, varying 
concentrations of active compounds in plant products, unknown dosages that should be 
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given, and so forth.  Nevertheless, as a result of the variable outcomes, these medicines 
have been viewed with at least some skepticism by western academic medicine and will 
require hypothesis driven, scientific testing and evidence-based clinical studies before 
they can be deemed as efficacious.  At this time, they are considered alternative or 
complementary medicines.
As a result of the discoveries that have been made and the research that has been 
performed over the centuries, in clinical settings today and within the general public, the 
most efficacious method of fighting infection is to prevent infection.  This is primarily 
done in hospitals and in the home by combining the power of antiseptics with antibiotics, 
i.e., using a polytherapy approach to kill microorganisms.  For example, this is done by 
wiping surfaces with disinfectants or antiseptics, using scrupulous methods of cleaning 
clothing, bedding and other materials, along with frequent hand washing.  Although there 
are concerns that the overuse of disinfectant solutions and the overuse of triclosan 
antibiotic in hand soaps run the risk of engendering bacterial resistance and weakening 
the human immune system,144 these methods are still largely effective in reducing rates of 
infection and illness in general.  Moreover, in surgical settings today, prepping a patient's 
skin with antiseptics, such as betadine, isopropanol or chlorhexidine solution, prior to 
surgery is common practice.  Similarly, patients in America who undergo surgery are
given prophylactic doses of antibiotic before surgery, after surgery or both, depending on 
the physician.
In summary, antibiotics have largely overcome the limitations of antiseptics,
metals and bacteriophages due to the fact that they have lower toxicity comparatively, 
they can be administered orally and are well tolerated by the majority of patients, and 
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their obvious success to treat infections has been overwhelming for more than 50 years.  
Yet, as discussed in Chapter 1, the most concerning limitation of antibiotics is that many 
bacteria themselves produce them, and they can quickly "learn," evolutionarily and via 
mutation, how to refuse them.  This makes the outlook for antibiotic use grim and 
strongly suggests that alternative molecules need to be developed and/or discovered to 
address the current trends of antibiotic resistance.
2.2 A Novel Class of Antimicrobial Compounds Discovered
In 1981, Michael Zasloff, MD PhD, discovered, somewhat serendipitously, a 
unique class of antimicrobial compounds that showed tremendous promise to overcome 
the limitations of antiseptics, bacteriophages and antibiotics.145 While working for the 
National Institutes of Health in the field of molecular biology, Dr. Zasloff noted that after 
performing surgeries on African clawed frogs (Xenopus laevis), their suture sites healed 
without infection, inflammation or scarring despite the fact that the frogs were placed into 
tanks of water that contained high quantities of bacteria.  Curious as to why that was the 
case, he extracted peptides from the skin of these frogs, which he found to have 
significant antimicrobial activity against Gram negative and Gram positive bacteria, 
protozoa, fungi and viruses. He classified these compounds as antimicrobial peptides
(AMPs), and called the AMPs from African frogs magainins (magainin means "shield" in 
Hebrew). It was found that magainins were part of the innate immune system of the
African frogs.
Since Dr. Zasloff's initial discovery, thousands of AMPs have been discovered as 
part of the innate immune system in nearly all life forms including plants, insects, 
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mammals and amphibians.146-148 Over time, it has been found that nearly all AMPs that 
display antimicrobial activity have very similar characteristics.146-150 Typically, AMPs
have a predominantly net positive charge due to significant amounts of arginine and/or 
lysine residues, they commonly contain multiple cysteine bonds and they also commonly 
comprise an @-helical structure with amphipathic properties, meaning that one face of the 
alpha helix is charged and the other is hydrophobic.147,151 The fact that these peptides 
carry a net positive charge makes them prime candidates to adhere to the negatively
charged components of bacterial cell membranes. As a side note, eukaryotic cells are 
largely unaffected by antimicrobial peptides due to the fact that they are predominantly 
zwitterionic, or have a net positive charge and they contain cholesterols.147 Nevertheless,
because erythrocytes typically have a net negative charge, hemolysis is a known effect of 
AMPs.147
When AMPs were first discovered, one of their most promising aspects was
immediately apparent: they had an inherently reduced risk of engendering resistance in 
bacteria.  There are three main reasons why this is so. The first reason relates to the fact 
that AMPs have been in existence for millions of years and continue to display significant 
antimicrobial activity against bacteria.146 The second reason has recently been 
highlighted by the work of Fantner et al.152
Using novel high-speed, high-resolution atomic force microscopy (AFM) in 
conjunction with live/dead staining and fluorescence microscopy, this group tested a
naturally occurring AMP, called CM15, against cells of Escherichia coli. The purpose of 
their work was to determine the rate at which an AMP might have a bactericidal effect 
against individual bacterial cells as well as determine the morphological changes that 
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occur in a cell after it has been exposed to an AMP.  The AFM results showed that CM15 
caused cells to display a corrugated surface within ~80 seconds of exposure.
Fluorescence imaging results indicated that the corrugation was related to cell death.
Thus, Fantner et al. were able to demonstrate that the second reason AMPs carry reduced 
risk of engendering bacterial resistance is due to the rapidity with which they act on 
bacterial cells.
The third reason relates to the nonspecific method of action that these molecules 
use to attack a bacterial cell.151 More specifically, in a manner that is still not well 
known, many thousands of AMP molecules adhere to the cell membrane of a bacterium.  
In doing so, the molecules can cause the membrane to depolarize.151 This depolarization 
is believed to lead to the formation of nanosized holes in the cell membrane, which 
subsequently leads to the corrugated appearance of the cell, as demonstrated by Fantner 
et al. In the end, membrane depolarization and corrugation lead to full or partial lysis of 
a bacterium, which equates to cellular death.
Notably, this nonspecific method of attack by AMPs is in stark contrast to the 
method of action of antibiotics.  The method of action of antibiotics was alluded to in 
Chapter 1, section 1.5 above.  However, to reiterate, the large majority of antibiotics that 
are clinically approved have a very specific method of action against a single type of 
molecule, protein or enzyme in a metabolic pathway of bacteria.  For example, penicillin 
specifically targets DD-transpeptidase enzymes, which play an integral role in the cross-
linkage of peptidoglycan units in the cell wall of bacteria.153 The speed of function, then, 
of penicillin correlates with the speed of the components that are deployed to build the 



















 -lactamase enzymes to break down penicillin enzymatically.154
This is one example of how bacteria have evolved in the presence of antibiotics and 
antibiotic-like compounds and have "learned" how to circumvent their specific method of 
action.  Thus, antibacterial molecules such as AMPs that have a nonspecific method of 
action and which act quickly on bacteria prevent them from being able to upregulate their 
defense mechanisms.146-148
Several models have been proposed for how AMPs act on a bacterium's cell 
membrane.  These have been well reviewed by van 't Hof et al.151 In short, there are 






@-helix "Face the hydrophobic fatty acid tails at the inside 
of the phospholipid bilayer and the hydrophilic side-chains are pointed inward into the 
water-filled pore.  Progressive recruitment of additional peptide monomers leads to a 
steadily increasing pore size."151 A diagram of this model, as published in van 't Hof's 
review, can be seen in Figure 2.2A.  The second model is the carpet model.  In this 
model, "The microbial cell membrane is fully covered by a carpet-like cluster of peptides.  
When a critical concentration is reached, the membrane collapses, and in a short span of 
time, worm holes are formed all over the membrane, leading to lysis of the microbial 
cell."151 A diagram of this model is shown in Figure 2.2B.  Notably, this model was 
specifically developed to describe what was believed to be the function of magainins.  
Finally, the third model is the aggregate model.  In this model, "The peptides insert into 
the membrane and then cluster into unstructured aggregates that span the membrane.  The 
water molecules associated with the aggregated peptides would provide channels through 
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which ions and larger molecules could leak."151 Again, a diagram of this model is shown 
in Figure 2.2C.
Although AMPs entail a very promising class of alternative compounds to 
antibiotics, there are three major limitations that have prevented them from being put into 
clinical use.147 First, AMPs are prohibitively expensive to manufacture on a commercial 
scale.  According to a personal conversation of the author with one of the world leaders 
in the field of AMP research, Bob Hancock, PhD, it costs several thousand dollars to 
produce a few milligrams (mg) of AMPs using recombinant DNA technology. Since 
hundreds of mg of compound may be required clinically to have bactericidal effects, 
these costs are currently not feasible for clinical use.  Second, because they are natural 
peptide products, AMPs are direct targets for proteases in the human body.  As such, 
multiple doses have been needed in in vivo studies to have even minimal effects against 
infection.  Third, AMPs have limited stability outside of their natural environments.  
Thus, their shelf life and ability to be sterilized are not always conducive to the clinical 
requirements of an antimicrobial product.
For these reasons, multiple investigators have engaged in the development of
antimicrobial peptoid oligomers,155 peptide mimetics156 and synthetic analogs of 
AMPs.109 Of these, there is a particularly promising class of compounds.  These 
compounds have been shown to have significant, broad spectrum antimicrobial activity 
against Gram positive and Gram negative bacteria in the planktonic and biofilm 
phenotype, they are stable in vivo since they are not targets for proteases, they can be 
sterilized by gamma radiation, autoclaving and ethylene oxide treatment, they can be
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manufactured on the kilogram scale for hundreds of dollars, and many of them have a 
shelf life of several years.  These compounds are called ceragenins.
2.3 CSA-13 Ceragenin: A Novel Synthetic Analog of AMPs
Ceragenins are synthetic analogs of AMPs.  They were developed in the late 
1990s by Paul Savage, PhD.109 Using cholic acid (Figure 2.3), a bile salt from humans, 
as the backbone molecule, Dr. Savage developed a method of attaching alkane chains 
with varying lengths to hydroxide groups that are an integral part of cholic acid's sterol 
backbone.107 These alkane chains can be further modified to contain positively charged 
primary or secondary ammonium salts.  These positively charged salts, in combination 
with the hydrophobic sterol backbone, result in the formation of a facially amphipathic 
molecule, one that has a positively charged face and a hydrophobic backbone.109 In this 
study, of the many ceragenin compounds that could have been used, CSA-13 (Figure 2.4)
was chosen due to the fact that it has displayed significant activity against prokaryotes, 
fungi, and viruses with limited toxic effects to human eukaryotic cells.  CSA-13 has also 
been shown to have superior activity compared to other CSA molecules and AMPs.106 In 
addition, CSA-13 is highly stable in a variety of environments including in vivo 
environments, broth solutions, aqueous solutions and organic solvents.
To date, Dr. Savage and others have published several dozen papers outlining 
the broad spectrum efficacy of CSA-13.103,104,106-108,157-161 As will be seen in Chapters 5
and 8 of this dissertation, the author will also show that CSA-13 has the ability to kill 
very high inocula of bacteria residing in the biofilm phenotype in in vitro and in vivo
settings. From Dr. Savage's lab it has been shown that in head to head comparisons with
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antibiotics, CSA-13 has superior antimicrobial activity.104 Furthermore, CSA-13 was
shown to act synergistically with antibiotics,160 suggesting that the minimum inhibitory 
concentration (MIC) of an antibiotic can be reduced with the help of CSA-13 (a more 
detailed discussion of what an MIC is will be provided in Chapter 3).  Epand et al.106 also 
recently published a manuscript that elucidated, at least in part, the method of action of 
CSA-13.
This method of action was elucidated by analyzing the ability of several ceragenin 
molecules (CSA-8, CSA-13 and CSA-54) to permeabilize the outer and inner membranes 
of Gram negative E. coli cells as well as the membrane of Gram positive cells.
Permeabilization of E. coli was monitored through the use of two chromogenic reporter 
molecules, nitrocefin and o-nitrophenyl-3-D-galactoside, that were cleaved once they 
crossed the outer and inner membrane, respectively.  Permeabilization of Gram positive 
membranes was monitored with 3,3'-diethylthiadicarbocyanine iodide. Once cleaved, 
each molecule had a color change that was detected spectrophotometrically. Importantly, 
the E. coli isolate used in this study was genetically tailored to cleave these molecules 
only after they traversed a permeabilized membrane.  Results indicated that CSA-13 was 
the only ceragenin to permeabilize both the outer and inner membrane of E. coli. CSA-
13 was also shown to permeabilize the membrane of all Gram positives that were tested.  
(S. aureus, Enterococcus faecalis, Bacillus cereus) within minutes after being added to a 
solution. CSA-8 and CSA-54 permeabilized the outer membrane, but they failed to 
permeabilize the inner membrane of E. coli. As such, this study not only indicated that 
CSA-13 had greater antimicrobial potential than CSA-8 and CSA-54, but that the method 
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of antimicrobial action of CSA-13 was based on its ability to permeabilize the cell 
membranes of bacteria.
To corroborate these findings, Bucki et al.103 compared the efficacy of naturally 
occurring AMPs to CSA-13 and showed that CSA-13 was more effective in killing 
bacteria.  They also showed by AFM, similar to Fantner et al.,152 that CSA-13 caused 
bacterial cells to become corrugated after they had been exposed to CSA-13.  Taken 
together, the studies undertaken by Epand et al. and Bucki et al. have indicated that CSA-
13 has a similar, if not equivalent method of action against bacteria as naturally occurring 
AMPs. In clear terms, the method of action of CSA-13 is to adhere nonspecifically to the 
negatively charged cell membrane of bacteria, cause the membrane to depolarize, then 
take on a corrugated appearance, which provides an indication that its cytoplasmic 
components have leaked out and the cell has died or soon will die.
One of the most important aspects of all the work that has been done with CSA-
13 is that the MIC levels of CSA-13 have ranged from 0.4 μg/mL to 3 μg/mL for Gram 
positive cells and 2 μg/mL to 3 μg/mL for Gram negatives.104,107 Furthermore, minimum 
bactericidal concentrations (MBC) have been shown to range between 1 μg/mL  - 5.5
μg/mL.106 This is significant in the context of the MICs and MBCs of traditional 
antibiotics, which can be one or two orders of magnitude greater.104
2.4 General Hypothesis of Dissertation and Specific Aims
In 2005, the author was hired by a company specifically to investigate alternative 
antimicrobial therapies to prevent infections that have the potential to accompany the use 
of a novel orthopaedic implant known as an osseointegrated implant.  This work was
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headed by Roy Bloebaum, PhD.  As that work was taking place, the author came across a 
Press Release indicating that Ceragenix, a company that previously licensed CSA-13, had 
received permission from the FDA for an expedited review of CSA-13 for medical device 
applications.  Following the reading of this Press Release, the author emailed Dr. Savage 
and a collaboration ensued to test its efficacy independently.  Following a series of pilot
experiments, CSA-13 showed tremendous efficacy against a variety of bacteria in broth 
solutions including when it was used as the active release agent of an antimicrobial 
coating on metal implants.
Three years later, the author and Dr. Roy Bloebaum gathered together a team of 
researchers and collaborators, including Dr. Paul Savage and Dr. Bill Costerton, to test 
the efficacy of CSA-13 in an animal model that had never before been established.
Together, this team, with the current author being the lead author, wrote a NIH R01 
grant.  The general hypothesis of the grant was that when CSA-13 was used as an 
active release agent of a medical device coating, it would prevent biofilm implant-
related infection in an in vivo animal model of Type IIIB open fractures.  Three 
Specific Aims were used to test this hypothesis:
Aim 1: Develop a membrane biofilm reactor to grow biofilms of MRSA on the 
surface of polymeric membranes in a repeatable fashion.
Aim 2a: Confirm the efficacy of CSA-13 to eradicate biofilms of MRSA in vitro.
Aim 2b: Determine the elution profile of CSA-13 out of the device coating.
Aim 2c: Characterize the novel active release coating.
Aim 3: Confirm the efficacy of CSA-13 to prevent biofilm implant-related 
infection in an in vivo animal model of Type IIIB open fractures.
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The grant outlining this work was funded in April of 2009 and the work presented 
herein shows the results of each Specific Aim as well as how these results helped to 
support the general hypothesis. More specifically, Chapter 4 addresses Aim 1, Chapters 
5 and 6 address Aim 2 and Chapters 7 and 8 address Aim 3.
Importantly, the method of delivering CSA-13 in this work was to use it as an 
active release agent in a device coating.  The development and method of producing this 
coating is outlined in detail in Chapters 5 and 6 of this dissertation, but it is important to 
understand the rationale for why CSA-13 was delivered as a local, active release agent in 
a coating as opposed to being administered systemically as is the common method of 
administering antibiotics to a patient in the clinic.  It is also important to address the 
rationale for why silicone was chosen as the carrier polymer in this work over other 
polymer types.  Thus, the next section (2.5) will provide a review of active release 
coatings, their advantages and disadvantages, and the advantages and disadvantages of 
systemic antimicrobial therapy.  Section 2.6 will then provide the rationale for why 
silicone was chosen for this work.
2.5 A Practical Approach to Delivering Antimicrobials:
Active Release Coatings
2.5.1 Advantages of Active Release Coatings
In 2005, Dr. Bill Costerton suggested in a review article of the biofilm theory that 
"One of the most practical strategies for the prevention of colonization and consequent 
biofilm formation on biomaterials is the use of materials and coatings that release 
conventional antibiotics into the surrounding tissues and fluids."60 Coatings on 
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biomedical devices that are specifically designed to incorporate and release agents into 
the surrounding tissues and fluids are known as active release coatings.  
As suggested by Hetrick and Schoenfisch, "The primary advantage of delivering 
antibiotics directly at the site of implantation is that high local doses can be administered 
without exceeding the systemic toxicity level of the drug.  In this fashion, enhanced 
efficacy can be achieved at the implant site.  Localized administration also allows for the 
tailored selection of antibiotics toward specific pathogens associated with implant 
infections, circumventing potentially harmful side reactions in other parts of the body.  
Such delivery also enables long-term antibiotic administration and presumably avoids 
fostering resistance."61
Although Costerton, and Hetrick and Schoenfisch suggested that antibiotics can 
be used as active release agents, it will be clear to the reader after Chapter 1 of this 
dissertation that antibiotics may not always be the most effective agent to use.  
Nevertheless, the most common method found in the literature and which is used 
clinically for delivering active release agents as part of a device coating is to incorporate 
them with carrier polymers.  To do so, an antimicrobial agent is typically mixed with a 
prepolymerized solution or dispersion at a particular concentration that is determined by 
the investigator or clinician. This solution is then used, for example, to dip coat, spray 
coat, electrospin or brush coat onto a device.
2.5.2 Active Release Strategies Apply to Multiple Material Types 
As a brief side note, there are active release systems that may not be used as 
coatings.  For example, the addition of antibiotics into bone cement in the 1970s was in 
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fact the first documented instance of eluting antibiotics out of a polymer carrier system 
into the surrounding tissues and fluids of a patient.162,163 Bone cements are 
methylmethacrylate based and were developed clinically to increase the stability of total 
joint replacement devices when they are inserted into the body.  In this instance, an 
antibiotic is mixed with a bone cement that is not yet polymerized and placed by a 
surgeon into the medullary canal of a long bone prior to the insertion of a replacement 
device with the intent to prevent perioperative infection. As the methylmethacrylate 
polymerizes, it hardens and holds the device in place while also providing the ability to 
elute antibiotic based on diffusion out of the polymer as the fluids of a patient penetrate 
the polymerized polymer.
By the 1980s, this technique of incorporating antibiotics into a polymer system 
was adopted and applied to device coatings.164 Since that time, investigators and 
clinicians have tested a variety of polymer types.  These have included, but are not 
limited to, polyurethanes (PUs),165 polymethylmethacrylates (PMMAs),166-168
polyhydroxyethylmethacrylates (PHEMAs),169 hydroxyapatite (HA),170,171 silicones
(which are also known as polydimethylsiloxane, or PDMS),164,172 polylactic acids
(PLLAs),94,173,174 polylactide-co-glycolide acids (PLGAs),175 etc.  As will be discussed in
section 2.5, the choice of polymer is application dependent.
2.5.3 Limitations of Previous Active Coating Investigations
As a preface to discussing the development of active release coatings, the author 
would like the reader to keep in mind three limiting factors that almost all investigators, 
companies and clinicians have failed to address during the development of active release 
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coatings that have been intended for medical devices. It is believed by the author that 
these three limitations are the primary contributing factors that have prevented the
development of a greater number of effective active release coatings on medical devices 
for clinical use.  Indeed, as a result of these limitations, which are evident from a careful
literature review, at this time there are only a handful of approved medical devices that 
contain active release agents.141,143,176-185 These include triclosan coated vicryl sutures
(for example the Coated Vicryl Plus suture by Ethicon)176,177 and silver/platinum coated 
catheters (for example the Vantex Central Venous Catheter by Edwards 
Lifesciences).141,143,178,180,186 Synthes has also recently undertaken the development of an 
intramedullary nail (the Expert Tibial Nail PROtect) for fracture fixation of the tibia.187
To address the three limitations that are found in the literature, the first limiting 
factor, which will be discussed in more detail in Chapter 3, is that investigators have 
often trusted in MIC values of an antibiotic, which are completely based on the efficacy 
of an antibiotic against planktonic bacteria, without considering that higher 
concentrations of antibiotic may be needed to prevent or treat biofilm implant-related 
infection.84,173 As such, antibiotic coatings have been designed to release just enough 
antibiotic to kill bacteria residing in the planktonic phenotype, which carries the risk of 
making a coating that is ineffective against bacteria in the biofilm phenotype.  The 
second limitation has been the lack of translatability of experiments from in vitro testing 
to the in vivo paradigm.57,165,174,175,188 Specifically, essentially all of the in vitro testing 
that has been performed with active release coatings has employed with the use of 
stagnant broth solutions and/or Kirby-Bauer-like agar diffusion testing to monitor zones 
of bacterial inhibition that develop when a coated device is placed on top of a "lawn" of 
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bacteria.  The problem with these tests is that in the body, physiological fluids have flow.
Stagnant broth solutions and agar surfaces do not model the flow of fluids in a body and 
the efficacy of these tests may not necessarily correlate with the efficacy of an antibiotic 
in vivo. If an antimicrobial coated device is placed into a stagnant broth solution, the 
active release agent will be released into the surrounding broth solution and ultimately 
reach concentrations that may be well above those that would be reached physiologically.
Thus, if stagnant broth or hard surface agar systems are used to test the antimicrobial 
efficacy of a coated device, data interpretation may be severely skewed.  Finally, the third 
limitation of testing antimicrobial coated devices is the common use of planktonic 
bacteria in in vitro and in vivo settings.80-102 Once again, this problem of using planktonic 
bacteria as initial inocula will be discussed in detail in Chapter 3.
As will be seen in Chapters 5, 7, and 8, the work in this dissertation addressed
each of these limitations by developing a flow cell system that could be used for in vitro 
testing to model the flow of fluid in a physiological environment instead of trusting in 
MIC values that are obtained with stagnant broth, and by using well-established biofilms 
as initial inocula for the in vivo work to model the phenotype of bacteria as they exist in 
natural ecosystems.
2.5.4 Earliest Use and More Recent Developments of
Active Release Coatings
To provide an example of the earliest use of a device coating as well as more 
recent investigations that have been undertaken, in the early-1980s, Rushton et al.164
performed work showing the efficacy of incorporating fusidic acid and gentamicin into a 
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one part room temperature vulcanizing (RTV-1) PDMS dispersion, then brush coating the 
surface of electrical stimulator devices. The PDMS was allowed to cure for a several day 
period and sterilized by ethylene oxide (ETO) treatment.  These devices were tested in 
vitro on hard agar surfaces and then in vivo in human patients.  Using their active release 
coating, they reported that they were able to reduce rates of infection that typically 
accompanied these devices, to less than 1%.  This rate of infection was more than 10-fold 
less than patients who received the same implant without an antibiotic coating, but who 
received systemic antibiotic treatment instead.  Thus, this provided one of the first 
indications that an antibiotic-loaded polymer system could reduce rates of implant-related 
infection.
As will be seen in the following paragraphs, not all coatings have had the in vivo 
success that Rushton et al. had, but the work of Rushton et al. may be criticized for four
reasons.  First, their in vitro work was performed by placing their device on a "lawn" of 
bacteria on hard agar surface.  Second, their work did not display strong scientific, 
hypothesis driven research.  Many patients that received one of their coated devices also 
received postsurgical antibiotics and some on multiple occasions confusing the 
interpretations of the findings.  In doing so, their work was not randomized, and it is
difficult to know whether the active components of the coating itself prevented infection 
or if the systemic antibiotics did so.  The possibility existed that the systemic antibiotics 
worked in a synergistic fashion with the coating. Nevertheless, a careful review leaves 
one to wonder what the effect of the coating alone would have been.  This might have 
been elucidated in a hypothesis-driven, scientific, randomized animal study prior to 
human testing.  Third, when Rushton et al. performed their work nearly 20 years ago,
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they were specifically concerned about S. aureus bacteria and they used two active 
release agents, fusidic acid and gentamicin, that are now well known to develop bacterial 
resistance and their coating may not have the same efficacy today as it had then. In 
addition, they had limited if any knowledge of the pending problems with S. aureus 
biofilm formation on implanted devices. Fourth, the amount of antibiotic they used 
(~40mg/implant) may have been in a toxic range, and is likely the reason their coating 
did show efficacy, yet at such high amounts the mechanical stability of their PDMS likely 
suffered and there may have been unreported issues of toxicity. Unfortunately, they did 
not publish any results of mechanical testing, histology of interface or regional tissues 
near the coated device, and they put these into humans without any mention of what 
regulatory guidance they had to perform the study. Granted, the development of active 
release coatings was in its infancy at the time and these issues are apparent in hindsight.
Since the work of Rushton et al. was undertaken, there have been relatively few 
human studies performed with active release coatings.  In at least one human study that 
has been performed to test the efficacy of a pseudo antibiotic coating on penile 
prostheses, the number of patients in the two study groups was variable (there were more 
than 2,200 patients in the group that received a coated implant and 400 in the other), and
although there was statistical significance between the two groups (1.06% vs. 2.07% 
infection), it is difficult to know if this difference would have remained significant with 
equal numbers of patients.189
Due to the fact that human studies with coated devices have often not been able to 
be performed in a randomized, blinded fashion, in addition to the variable outcomes that 
have been seen, and because of the concerns of bacterial resistance to antibiotics, the 
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FDA has pushed investigators toward generating more translatable data with greater 
emphasis on performing in vitro work first, then in vivo animal model studies prior to 
testing in humans.  As a result, there is now a plethora of in vitro experiments and in vivo 
animal studies in the literature that have undertaken to develop antimicrobial coated 
devices. But once again, as was mentioned, these studies are limited in three main areas 
of testing.
To provide a few examples of what is currently found in the literature with regard 
to the development of antimicrobial coated devices, particularly for orthopaedic 
applications, and how they have failed in the three aforementioned areas, the work of 
Darouiche et al. will be examined first.
Dr. Rabih Darouiche has been involved with more than a dozen published papers 
investigating the efficacy of various antimicrobial coated devices with a variety of 
antiseptics and antibiotics as active release agents.83-85,172,188,190-192 For example, in the 
late 1990s, he and his group coated simulated intramedullary nails with chlorhexidine and 
chloroxylenol using a proprietary dip coat method.83,188 These nails were used in rabbits 
to test their efficacy to prevent biofilm implant-related infection. After creating an 
osteotomized tibial fracture, the medullary canals of rabbits were inoculated with 106
planktonic bacteria followed by reduction with a coated or uncoated nail, depending on 
the rabbit group.
Notably, in their study design, they administered antibiotics prophylactically in a 
systemic fashion, which is consistent with what would be used in a clinical setting, but 
the use of prophylactic antibiotics has the potential to compromise an experiment to 
determine the ability of an active release coating alone to prevent localized infection.  
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Nevertheless, their outcomes showed that 9% of rabbits became infected despite 
receiving an implant that was coated, whereas 62% of rabbits became infected that 
received implants that were not coated.  These results suggested that in their particular 
animal model, systemic antibiotics were able to reduce rates of infection by roughly 40%, 
but systemic antibiotics in combination with a coated device reduced infection to 9%. It 
may be considered by some that a 9% rate of infection would be clinically unacceptable,
making these results promising, but potentially unsatisfactory.
Importantly, Darouiche et al. did test the efficacy of chlorhexidine and 
chloroxylenol coated devices in vitro prior to using them in vivo and they published this 
work separately.83 However, in accordance with the limitations outlined above, their in 
vitro tests were performed against planktonic bacteria using zones of inhibition on agar 
surfaces, which, in the case of a coated device, has limited ability to translate to clinical 
applications.
Price et al.175 was another group to perform in vitro work that was potentially 
limited in two areas. In their study, they incorporated gentamicin antibiotic with PLGA 
polymer and coated sections of narrow fracture fixation plates using a coating method 
that they failed to outline in their paper.  The coated sections were placed in 10 mL of 
stagnant broth that contained 106 S. aureus cells in order to test the ability of gentamicin
to eradicate the bacteria as it was released over a 24-hour period. Their results indicated 
that they were able to reduce the number of cells to less than 101/mL of broth. However, 
their data interpretation may have been skewed by two factors.  First, they used stagnant 
broth solution for their testing, which allowed the concentrations of antibiotic to reach 
levels that likely would not be present in the body.  Second, they suggested that because 
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the levels of gentamicin in the broth were above its MIC value, such was an indicator that 
their coating would be effective against biofilm implant-related infection.  
In another study published in 2006, Kalicke et al.174 tested the efficacy of
antibiotic compounds and antiseptics incorporated into bioresorbable PLLA coatings.  In 
this study, using a solvent casting technique, pieces of manufactured fracture fixation 
plates were coated with either Rifampicin and fusidic acid antibiotics, or Octinidin and 
Irgasan antiseptics.   These coatings were tested in vitro using stagnant broth solution 
against planktonic bacteria prior to being tested in vivo.  For the animal model portion of 
their study, they used four groups of animals with n=12 animals per group.  The groups 
were arranged in this manner: 
Group I: Six-hole AO DC minifragment titanium plate without PLLA
Group II: Six-hole AO DC minifragment titanium plate with PLLA without 
antibiotics/antiseptics
Group III: Six-hole AO DC minifragment titanium plate with PLLA + 3% 
Rifampicin and 7% fusidic acid
Group IV: Six-hole AO DC minifragment titanium plate with PLLA + 2% 
Octenidin and 8% Irgasan.
In contrast to the work of Dariouche et al., Kalicke et al. did not administer 
prophylactic antibiotics to their rabbits and they also did not create an osteotomized 
fracture in rabbit tibiae. To perform their surgeries, they created an incision in the 
anteromedial margin of the left tibia, secured a minifragment plate (coated with 
antibiotics or antiseptics as outlined above) to the bone, inserted a sterile puncture needle 
at the proximal margin of the plate, closed the wound and lastly inoculated the plate bed
through the opening that was made with the puncture needle using a range of S. aureus 
bacteria from 2 x 105 to 2 x 108 per 100 μL. Results from their work indicated that in 
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both of the rabbit groups that received a coated device (Groups III and IV), 17% became 
infected, whereas 83% of rabbits without a coated device (Groups I and II) became 
infected.  Similar to the outcomes of Darouiche et al., a 17% rate of infection may be 
considered clinically unacceptable and once again, although these coating types were 
promising, they may be unsatisfactory in the end.  Notably, neither Darouiche et al. nor 
Kalicke et al. used negative control groups (i.e., an implant only and no bacteria) in their 
studies.
Another important observation can be made from the work of Kalicke et al. and 
that is without systemic antibiotic treatment, they were only able to cause infection in
83% of the animals in their positive control groups (Group I and II). The fact that they 
did not infect 100% of animals foreshadows the discussion and the work that will be 
shown in Chapters 3, 7 and 8 of this dissertation. As a preface, the use of planktonic 
bacteria in animal models of biofilm implant-related infection has been limiting in that 
there are times when investigators have seen 40% of positive control animals become 
infected and there are times when investigators have seen 100% of animals become 
infected.  Gaudin et al.193 have noted that this variability in infection outcomes is one of 
the most difficult aspects of developing animal models of infection.  Based on this 
understanding, the goal of the work in this dissertation was to develop an animal model 
of infection wherein 100% of positive control animals would become infected and 0% of 
animals treated with an antimicrobial coated implant would become infected, thus 
providing strong evidence that infection could be developed in positive controls and 
prevented in treated animals.
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Similar to the studies outlined above, the trends and principles of trusting in MIC 
values, using stagnant broth solutions and/or hard agar surfaces, and the use of planktonic 
bacteria for all in vitro and in vivo predominate in the literature. It is proposed that these 
limitations are what have led to a paucity of antimicrobial coatings that have shown in 
vivo and clinical efficacy. Promisingly, researchers, including the current author, have 
begun to incorporate the use of flow cell systems to model the flow of physiological 
fluids in an application dependent manner with the intent to more closely model the 
clinical use of biomedical devices and antimicrobial therapies.194
2.5.5 Potential Limitations of Active Release Coatings
Although active release coatings provide a promising method of fighting local 
biofilm implant-related infections, there are at least three major limitations that may 
accompany the use of these coatings. First, due to the fact that there are classes of 
antibiotics that are effective against Gram positive bacteria and classes of antibiotics that 
are active against Gram negatives, the incorporation of two antibiotics may be necessary 
in a coating if antibiotics are the active agent of choice in order for the coating to have 
broad-spectrum capacity. Some of the difficulties that may be associated with using 
more than one active release agent include a difference in solubility between two 
molecules, toxicity, poor mechanical properties of a polymer, if the molecules are 
incorporated as particles their particle size may differ, which may affect pore size in the 
polymer system and elution kinetics. As such, the use of a single, broad spectrum 
antimicrobial agent may reduce these complexities.
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Second, active release coatings tend to release active agents for a temporary
period of time, typically meaning days or weeks.162 Thus, after the active agent in a 
coating is completely released away from an implant surface, an implant that is intended 
to be present in the body for an extended period of time may be colonized by bacteria that 
are hematogenously spread in the body. The risk of infection is significantly decreased, 
however, if bacteria are eliminated at the time of implantation. There are also concerns 
with developing a coating that releases or is comprised of an agent that is constantly 
present.  For example, the long-term presence of an active agent may result in toxicity or 
may be carcinogenic.  Thus, the use of a transient or long-term coating is application 
dependent.  In the context of this dissertation, the goal was to develop a transient release 
coating that could release CSA-13 for greater than 10 days, but less than 30 days to 
prevent perioperative device-related infection from developing when high inocula of 
bacteria are known to have contaminated a wound site.
Third, since it is the inherent nature of an active release agent to kill bacteria in 
the surrounding tissues and fluids of a patient, bacteria that are killed carry the risk of 
releasing toxic byproducts into the surrounding tissues and fluids.195,196
Other considerations that should be taken into account by investigators or 
clinicians who are undertaking to develop active release coating(s) include, but are not 
limited to, the rate at which an active agent is released; the amount of agent that needs to 
be released so as to kill bacteria without engendering bacterial resistance; the rapidity 
with which bacteria develop resistance to a compound; the duration of active agent 
release; the toxicity of an active release agent; the thickness of a coating and how that 
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may affect clinical applications; the mechanical and chemical stability of a coating after 
the agent, or additive, is incorporated.
2.5.6 Passive Coatings
The most obvious alternative to active release coatings are coatings that consist 
of molecules that are covalently bound to an implant surface.61,162,197 These types of 
coatings do not release an active agent into the surrounding tissues and fluids of a patient 
and they are referred to as passive coatings.  The intent of these coatings is to achieve one 
of two things: to either prevent the adhesion of bacteria to the surface of an implant, as is 
the case with polyethyleneglycol (PEG),198 or to kill bacteria that come in contact with 
the surface of an implant, as is the case with covalently bound antibiotics such as 
vancomycin.199
Although passive coatings may last on the surface of an implant for an extended, 
if not life-long period of time, there are several drawbacks to using them.  For instance, if 
bacteria reside even a few millimeters (mm) away from the surface of an implant that has 
a covalent coating, the antimicrobial agent will not kill the bacteria.  In addition, within 
seconds after a medical device is implanted into the body, a conditioning film of lipids, 
proteins, electrolytes, nucleic acids and carbohydrates forms on its surface.200,201 This 
conditioning film has the potential to mask and prevent the interaction of covalently 
bonded antimicrobial molecules with bacteria that may come in contact with the implant.  
Taken together, although passive coatings may have the ability to prevent biofilm 
growth/formation on the surface of an implant, they do not have the ability to kill bacteria 
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that may be in the surrounding tissue regions and even this ability may be drastically 
reduced by the formation of a conditioning film on an implant.
2.5.7 Advantages and Disadvantages of Systemic
Antibiotic Treatment
At this time, the most common (and FDA approved) method of administering 
antibiotics to a patient is to administer them systemically.  This can be done by 
administering antibiotics orally or by injection.  The intent of systemic delivery is to have 
the antibiotics circulate throughout the organs/tissues of a patient's body.  The advantage 
in doing so is that they have the potential to interact with bacteria wherever they may be 
located in the body.  This may be beneficial in particular in a patient who may be 
suffering from infections that are present in multiple areas of their body.  The drawback, 
however, in doing so is that in addition to killing unwanted bacteria that are causing 
infection, normal flora bacteria are likewise killed.  The problem with killing normal 
flora bacteria is that they provide protection to the host and they also help maintain 
homeostasis.202 Moreover, systemic therapy also carries the risk of being toxic to a 
patient's organs.203,204 For these reasons, it may be beneficial to deliver antimicrobial 
agents in a local, high dose fashion as is the case with active release antimicrobial 
coatings.  
2.6 The Selection of Polymer for an Active Release Coating
There are several factors that influence the type of polymer that could be used 
for active coating applications.  As mentioned previously, in the literature the most 
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common polymers that are used as carrier polymers for active release coatings include 
PU, PDMS, HA, PMMA and bioresorbable polymers such as PLGA, PLLA and 
polycaprolactone.  There are a variety of others as well, but only a few principles will be 
reviewed. Each polymer type has its advantages and disadvantages.  For example, for 
this dissertation, a bioresorbable polymer was specifically not chosen based on previous 
work published by Uhthoff et al.205 In a study they undertook, they showed that when 
PLA was used on a fracture fixation plate, as the polymer degraded it led to micromotion
of the implant, which subsequently led to implant failure.  Specifically, this was due to 
the fact that as the polymer resorbed, a gap was left between the plate, screws and the 
bone surface, which allowed the implant to move and ultimately come loose resulting in 
implant failure.
2.6.1 Dissolved Material vs. Particles and Particle Aggregates
in Polymer Dispersions
Another important criterion for polymer selection is the solvent in  which a pre-
polymerized dispersion or mixture is suspended.  This is a particularly important aspect 
of polymer selection for CSA-13.  For example, prior to polymerization, PDMS is 
dispersed in organic solvents such as xylene or naphtha that are very hydrophobic and in 
which CSA-13 is minimally dissolved. Because CSA-13 does not dissolve well in these 
organic solvents as it is stirred in them, it remains as particles in the solvent that are 
nanometer (nm) in size or it creates particle aggregates that are micrometer (μm) sized as 
opposed to dissolving to individual molecules as it would in a solvent that was, for 
example, water or alcohol-based.  As a result, when CSA-13 is mixed with a PDMS 
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dispersion, the particles of CSA-13 cause pores to form in the PDMS polymer as it cures 
over time.  These pores allow water to penetrate the PDMS network and release CSA-13 
as an active agent.  Data will be provided in Chapter 6 to demonstrate what these pores 
look like, their size, as well as show that CSA-13 particles are in fact what cause them to 
form.  
It is difficult to overstate the importance of the concept of an antimicrobial 
compound residing in particles or particle aggregates or having it dissolve completely 
into a solvent.  For example, during the developmental phase of CSA-13 as an active 
release agent, the author worked with Dr. Savage's group to incorporate CSA-13 into PU 
polymers.  To do so, CSA-13 was mixed with a solvent that contained methanol.  
Notably, CSA-13 is very soluble in alcohol-based solvents such as methanol.  Thus, in 
this instance, as opposed to residing as particles or particle aggregates, CSA-13 was 
dissolved into the solvent prior to mixing it with a prepolymerized PU mixture.  When 
this mixture was used to dip coat various materials, we found that we had to add CSA-13 
at a concentration of 33% weight-to-weight (w/w) in order to achieve bactericidal levels.  
We also found that only 7% of the total CSA-13 that was added to the coating was 
actually released, which indicated why such a high amount (33% w/w) had to be added 
initially. Furthermore, we were only able to confirm antimicrobial activity of CSA-13 
with a PU coating for 3-4 days as opposed to greater than 10 days with PDMS as will be 
shown in Chapter 7 of this dissertation.
As we examined the PU coatings with SEM, we noted that the PU network was 
largely aporous, which was in stark contrast to the results of CSA-13 being incorporated 
into PDMS polymer wherein the PDMS network was highly porous.  In comparing these 
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results, it was concluded that the reason only 7% of CSA-13 had been released from the
PU network was that the PU crosslinked to such a degree that water was unable to 
penetrate the deep layers of its network and likely only caused  CSA-13 to be released 
from the outer most layers.  Importantly, as will be shown in Chapter 6, we were able to 
confirm that by our detectable limits, all of the detectable CSA-13 added to the PDMS 
product that was used in this dissertation was released by 30 days of exposure to aqueous 
solution.
These findings may help investigators and clinicians understand why it is that in 
many instances, not all of an antibiotic or other antimicrobial product is released from a 
polymer network.  This is particularly apparent for PMMA bone cements wherein it is 
well known that not all of an antibiotic is released when it is incorporated into
PMMA.162,206,207 In short, if an antibiotic or antimicrobial is dissolved completely in a 
solvent or if it resides as particles or particle aggregates, it may have a different effect on 
the physical properties of a crosslinked polymer, such as porosity, and it may also affect
release kinetics.
2.6.2 Additional Factors to Consider
There are many other factors to consider when selecting a polymer for active 
release coating applications.  These include the stability of a polymer in vivo, tensile 
strength, shear strength, adhesive strength, degradability, toxicity, cure time, cure 
temperature, pore size and so forth.  For this particular dissertation, PDMS was selected 
for several reasons.  It was able to release CSA-13 and display antimicrobial activity over 
a minimum of a 10-day period (as will be shown in Chapter 5). Using SEM techniques, 
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all of the detectable CSA-13 was found to be released from the polymer by 30 days of 
elution. PDMS is also well known for its biocompatibility in the human body. The 
particular PDMS selected for this work was found to be compatible, i.e., cross-link well 
in the presence of CSA-13, which has not been the case with PU polymer or other types 
of PDMS polymers. Another advantage was that the PDMS was found to be 
mechanically and thermally stable (see Chapter 6).  Finally, the PDMS used for this
dissertation cured at room temperature, which was an important requirement for CSA-13
to remain as particles or particle aggregates because it has a melt point of approximately 
81° C and begins to oxidize at high temperatures (above ~150° C). Various polymers are 
heat curing polymers that require temperatures greater than 150° C to cure.
Based on the above material, chemical properties and rationale, an active release 
coating which incorporated CSA-13 as the active release agent of a PDMS polymer 
network was developed for this project and applied in a translational manner by testing its 
ability to eradicate biofilms of MRSA in vitro followed by testing its efficacy to prevent 
biofilm implant-related infection in an in vivo animal model of a Type IIIB open fracture.  
This animal model is the first model in the literature to utilize well-established biofilms 
of MRSA that were grown under fluid sheer forces to cause infection.  The importance of 
this model will be discussed in the next chapter.  
Notably, at roughly the same time that the work from this dissertation was being 
performed, Zhao et al.208 had undertaken a study wherein polycarbonate filters were 
placed on the surface of lysogeny broth agar plates that were plated with P. aeruginosa.
Though bacteria grew on the surface of the filters prior to being placed in mice, and thus 
it was assumed that biofilms had formed on them, these biofilms were not well 
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characterized, the method for producing the biofilms was not tested for repeatability and 
they were not grown under fluid sheer conditions.  Nevertheless, the important aspect of 
the work performed by Zhao et al. and the work of this dissertation is that the concept of 
using biofilms as initial inocula is currently being introduced in the fields of biofilm 
research.  The work presented in this dissertation constitutes the first study to use 
biofilms of MRSA that were grown under fluid sheer conditions in a biofilm reactor. 
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Figure 2.1: Schematic of a T4 bacteriophage.  This particular bacteriophage displays 
antimicrobial activity against E. coli cells.  Note the prolate icosahedral head shape, the 
neck, tail fibers and baseplate.  As this bacteriophage "docks" with an E. coli cell via its 
tail fibers and baseplate, it contracts at the neck and injects its DNA into the cell.  In 
doing so, it provides the genetic information required to replicate within the bacterial cell
and ultimately lyse the cell, which leads to its death.  For a detailed description of the 
various numbers associated with the viral components, refer to the review article of 
Miller et al.209 Figure used with permission.
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Figure 2.2: Possible methods of action for AMPs.  (A) Diagram of the barrel-stave model 
of AMP action against a lipid bilayer of a bacterial cell membrane.  (B) Diagram of the 
carpet model of AMP action on a cell membrane.  (C) Diagram of the aggregate model of 
AMPs acting on a bacterial cell membrane. Figure used with permission and originally
published by Hoff et al.151
75
Figure 2.3: Schematic diagram of the chemical composition of cholic acid.  Note the 
hydroxyl groups that are attached to various portions of the steroid backbone.  It is to 
these hydroxyl groups that alkane chains and their accompanying ammonium salts can be 
attached to produce ceragenin molecules.
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Figure 2.4: Schematic diagrams of the CSA-13 molecule.  The top diagram is a depiction 
of CSA-13 in two dimensions.  The bottom diagram is what CSA-13 may look like in 
three dimensions.  In these diagrams, alkane chains can be seen attached to oxygen atoms 
that comprised the hydroxyl groups on the cholic acid sterol backbone.  In addition, 
positively charged ammonium salts can be seen attached to the alkane chains.  The 
steroid group creates a hydrophobic backbone and the ammonium salts create a 
polycationic face, the combination of which results in an amphipathic molecule. 
CHAPTER 3
USING BIOFILMS AS INITIAL INOCULA IN ANIMAL
MODELS OF BIOFILM-RELATED INFECTIONS
3.1 The Use of Planktonic Cells in Animal Models
The information presented in this chapter is based on a review article that was 
written and published by the author and Dr. Bill Costerton.57 For the reader's reference, a 
copy of the published review article is provided as Appendix A at the end of this 
dissertation.
As has been the theme of this dissertation so far, combination biomaterials and 
coatings are being developed for the treatment and prevention of biofilm implant-related 
infections.  The majority of animal studies that are used to model infections related to 
these materials primarily involve the use of an initial inoculum of planktonic bacterial 
cells from batch cultures.80-102 The expectation has been that these planktonic cells would 
attach to the surface of a biomaterial, medical device or surrounding tissue and 
subsequently form a biofilm.  Although valuable, data that have been derived from these 
experiments may not provide clinicians and biomaterials scientists additional clinical 
insight into how bacteria that reside in well-established, mature biofilms impact device-
related and other human infections when they initially contaminate an implant site.    
The history of biofilm discovery was outlined in Chapter 1 and in the context of 
this dissertation the importance of the discoveries that have been made may be 
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summarized to state that bacteria in natural ecosystems preferentially reside in the biofilm 
phenotype on solid surfaces.  Based on this information, it is important to consider that 
when bacteria come in contact with wound sites, biomaterials or portals of entry in 
humans, i.e., inoculate patients, there is strong evidence to suggest that the majority of 
these bacteria are inherently residing in well-established, mature biofilms.  A specific 
example of this scenario was also provided in Chapter 1 and is that of a patient who 
suffers from a Type IIIB open fracture, which is reduced with a fracture fixation device.
To reiterate, these fractures have high rates of infection due the potential that they have to 
be contaminated with many millions or billions of bacteria that are ubiquitous in soil and 
other natural environments.  The biofilms that contaminate these wound sites have the 
potential to colonize and cause infection near a fracture fixation device that has been
implanted.
However, in all animal models of open fracture infections and other device-
related infections to date, planktonic bacteria have been used as initial inocula. The same 
is true for other animal models of biofilm device-related infections. 80-102
3.2 Limitations of Using Planktonic Cells as Initial Inocula
At least three proposed rationales can be given for why the use of planktonic cells 
has potentially limited investigators' abilities to detect clinically relevant outcomes of 
device biofilm-related infections.  1)  Planktonic cells are more readily cleared by the 
immune system than cells residing in a biofilm.210-212 Furthermore, animals typically 
have immune systems that are inherently advantaged compared to those of humans.  
Thus, when planktonic cells are used in in vivo models, it may be that the majority are 
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eradicated before they can form biofilms.  This may contribute to the low reproducibility 
for the induction of osteomyelitis, which has been suggested by Gaudin et al.193 as a
common problem with animal models of osteomyelitis.  2)  It is well documented that 
planktonic bacterial cells are more susceptible to antibiotics than those residing in a 
biofilm.18,213 Therefore, if antibiotics are administered immediately following 
inoculation, they may affect planktonic cells more effectively than they would biofilm 
cells.  3)  When planktonic cells are added to an in vivo system, the possibility exists that 
they may be dispersed rapidly away from the site of initial inoculation, which would 
dilute the concentration of bacteria per given area—potentially making it easier for the 
body to handle the bacterial load214 and prevent attachment to a medical device.
In addition to these limitations that may accompany the use of planktonic cells as 
initial inocula, investigators have depended heavily on MIC values to determine the dose 
of antimicrobial that should be delivered, either from a device coating or intravenously, 
to prevent and/or treat biofilm-related infections.84,173 The limitation of the MIC value in 
this specific instance is that it is based on data derived from planktonic cells from batch 
culture.  Specifically, a MIC is defined by the Clinical and Laboratory Standards Institute 
(CLSI) as the dose of antimicrobial that is needed to result in a three log10 reduction (105
^
 _2) of planktonic bacteria over a 24-hour period (see CLSI standard M26-A).  
Antimicrobial efficacy tests as standardized by the Environmental Protection Agency 
(e.g. standard operating procedure (SOP) Number: MB-09-04 and SOP Number: MB-06-
05) are also based on planktonic bacterial responses.  At least one standard of the 
American Society for Testing and Materials (ASTM E645-07) was found to recommend 
that microbicides be tested against biofilms.  Citing these planktonic cell-based standards, 
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Ceri et al.215 suggest that additional standards must be developed to treat and/or prevent 
recurring and untreatable infections that are the result of biofilm contamination and/or 
subsequent biofilm formation on medical devices.
3.3 Number of Bacteria in a Biofilm That May Be
Used as Initial Inocula
It does not appear that all biofilms carry the same infectious potential and the 
author has proposed that most have minimal pathogenicity.  If the opposite were true, it is 
likely that many more people would suffer from infections including gingivitis, 
periodontitis, sinusitis, conjunctivitis, cellulitis, gastroenteritis, vaginitis and/or colitis.  
Each human being is colonized with billions to trillions of bacteria, the majority of which 
appear to reside in well-established biofilms.216 As such, infection may be considered an 
anomaly that extends beyond the normal host/bacterial relationship.  Infection may also 
occur as humans are exposed to well-known pathogens that reside in biofilms from soil 
samples, on grocery carts, in food, within the human microbiome, on office desks, in 
shower heads, women’s purses, grocery bags, and a plethora of other locations all over 
the world.
The number of bacteria that should be used as initial inocula in animal models is 
application dependent.  Conditions may be considerably different in an animal that is 
intended to model a patient of total joint replacement, or some other elective surgery.  
Elective surgeries are performed under scrupulously aseptic conditions, yet despite these 
efforts, rates of infection still range from 1% - 4% and at times higher.50,51,217-222 If an 
animal model were used to replicate an elective surgery scenario for biomaterial 
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development, it may be more appropriate to use a low number biofilm as the initial 
inoculum than what might be used for a massively contaminated open fracture model.  
Additional consideration would also need to be taken for the inclusion of organisms 
associated with human skin.  Similarly, the use of planktonic or biofilm bacteria is 
application dependent.
When biofilms are grown in the laboratory, it is common to see them reach 
incredibly high numbers—on the order of 107 or 1010 cells/given area.18,21,25,40 Biofilms 
that contain high numbers of cells can also be found in nature.6,7,9,70,71 Similarly, 
bacterial cells that have been directly observed on and in the human body have been 
shown to reside in the biofilm phenotype.216,223 Biopsy punches of human skin have been 
estimated to contain ~106 cells/cm3 and it is well documented that the hardy biofilm 
former, Staphylococcus epidermidis, comprises a large portion of these resident 
commensal bacteria.216,224,225 In the large intestine, several hundred grams of bacteria can 
be found with numbers reaching an astounding 1011 or 1012 cells/gram of tissue 
comprised of hundreds of species.202,216,226 Notably, 60% of fecal solids have been 
shown to be comprised of bacteria.227
Although biofilms are ubiquitous and they tend to dwell in communities that can 
have very high numbers of cells, it may nevertheless be incorrect to assume that wound 
sites or surgical sites only become infected when they are contaminated with high 
number biofilms.  To the contrary, a biofilm, or a portion of biofilm that has broken off, 
that contaminates a wound site may consist of as few as 102 or 104 cells, if not fewer.  
Consider the paradigm of a patient who undergoes elective surgery, such as total 
joint replacement.  After the patient’s skin is prepped, 106 cells/cm3 of normal flora may 
82
be reduced in number to less than 103 cells/cm3 (a 99.9% reduction, which is the most 
common claim of antiseptics).  Note that the majority of these have been shown to reside 
in the biofilm phenotype.  Importantly, groups have shown that even following antiseptic 
treatment, viable cells continue to reside several layers deep in skin,228,229 and Dr. 
Costerton has observed matrix-enclosed bacterial biofilms between stratified squamous 
cells in the distal 5 – 7 layers of human prepped skin (unpublished observations).  During 
surgery, these cells would have direct access to tissue throughout a patient’s integument, 
while an incision is made, and they would also have direct access to the surfaces of 
transcutaneous or other implanted biomaterials.  As there are no data in the literature that 
involve small number biofilms contaminating wound and/or surgical sites, surgeons and 
investigators are left to wonder what effect these might have on the development of 
infection in these scenarios.    
There are myriad other paradigms that could be considered with similar scenarios 
of low numbers of cells within a biofilm contaminating wound and/or surgical sites.  
What remains is the fact that hypothesis driven research needs to be undertaken to 
determine the impact that low number biofilms have on human health as they attach to 
and form on the surface of biomaterial devices.  Furthermore, the author has found no 
comparative study in the literature to determine the effect that fewer versus higher 
numbers of cells in a biofilm, which derive from the same bacterial strain(s), have on the 
formation of biofilms on or near biomaterials.  For now, the understanding of critical 
doses required to cause infection are based solely on concentrations of planktonic 
bacteria.
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3.4 The 105 Rule May Not Apply to Biofilm
Studies have shown that to prevent infection, bacterial loads must be kept below 
105 cells per gram of tissue and this is the rule of thumb used by various clinicians as an 
indicator of infection.214,228,230-232 However, this number is strain dependent and is based 
on planktonic bacterial cell counts.  Citing Bowler,233 Edwards and Harding have stated 
that, “The clinical relevance of the theory that bacterial counts of over 105 represent 
clinical infection has been questioned.”230 The work of Smeltzer et al.234 has helped to 
validate this question.  In a rabbit model of osteomyelitis, they demonstrated that a 
particular strain of S. aureus was able to cause osteomyelitis in 75% of animals at 
concentrations of 2 x 103 whereas a different strain of S. aureus was unable to cause 
infection even at a concentration of 2 x 106. In addition, it may be that smaller numbers 
of cells are required to cause infection if they reside in the biofilm phenotype.  Indeed, 
the ability of low number, mature biofilms to resist antimicrobial treatment may enhance 
our understanding of how bacteria cause infection when initial inocula are on the order of 
thousands or tens of thousands of cells as opposed to the hundreds of thousands or 
hundreds of millions in planktonic form that are commonly used for in vivo studies.     
Wolcott et al.21 have recently undertaken a study wherein they showed that in the 
early stages of development, biofilms were more sensitive to antimicrobials when 
compared to biofilms that had matured for more than 24 or 48 hours.  Their data further 
suggested that even if similar numbers of cells were present, the maturity, and not so 
much the number of cells within the biofilm, had a significant influence on its ability to 
resist antimicrobial perturbations.  Their work was designed to model a specific clinical 
application and effectively addressed those scenarios.  Importantly, however, this work 
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also followed the predominant pattern of biofilm research wherein enormous numbers of 
cells accumulated over time within the biofilm growth system.  
Yet, as mentioned, it may not always be accurate to analyze biofilms as they 
undergo an increase in their number of cells.  Though dynamic, biofilms in real life 
systems typically do not display the same growth rates as those generated under optimal 
conditions in the laboratory.  Rather, in natural systems biofilms increase in cellular 
number over a longer period of time, mature to a level of equilibrium and when 
challenged by modifications in their environment, they respond appropriately.  The 
hypothesis is that these equilibrated, matured, slow growing biofilms are what primarily 
contaminate wound sites, parenteral routes and medical devices within humans.  Thus, to 
model contamination of a wound site with matured, equilibrated biofilms, similar to how 
they are found in nature, studies such as outlined in this dissertation may benefit from 
growing biofilms to threshold levels, allowing them to mature, and then exposing them to 
wound sites, antibiotics or other antimicrobial agents in in vitro and/or in vivo systems.  
3.5 Future Methods of Growing Biofilm for Use as Initial Inocula
Connell et al.235 have recently developed a remarkable method of growing 
biofilms in small numbers using micron sized “lobster traps.”  Although countless 
possibilities exist for in vitro experimentation with these traps, they are currently limited 
in that they are adhered to a solid surface.  However, modifications to the substrate could 
make it possible for them to be used as initial inocula in an in vivo model.
In this dissertation, the development of a membrane biofilm reactor system will 
be shown in Chapter 4.  This reactor was developed to grow biofilms on the surface of 
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polyetheretherketone (PEEK) membranes.40,110 As will be seen in Chapter 4, biofilms of
MRSA were shown to develop into three-dimensional pillar like structures on the surface 
of these membranes. Appendix B and Appendix C are also provided at the end of this 
dissertation to provide the reader with two manuscripts that have been published to date 
demonstrating the development and repeatability of this reactor.  This reactor is the first 
to be developed specifically for growing well-established biofilms that can be used 
specifically as initial inocula in an in vivo animal model.
At this time, with the variety of biofilm reactor devices that are currently 
available, such as the CDC biofilm reactor, the membrane biofilm reactor developed in 
this dissertation, the Drip Flow Biofilm Reactor, and “lobster traps,” the outlook is 
promising for a transition in biofilm investigation to occur from the in vitro paradigm to 
the in vivo setting.
3.6 Concluding Discussion
During the design process of an animal study, in particular an infection model, 
investigators often take careful consideration to select animals that have not been 
influenced by antibiotic feed, those that have not been specially treated in some manner 
at a housing facility, and, depending on the study design, those that have not been 
genetically modified or otherwise altered to influence the outcomes of a study.  In 
contrast, investigators tend to select animals that come from natural environments so as to 
select a group that will model an uninfluenced, random sample.  A similar process should 
be used when selecting bacterial isolates.  These should be derived, as closely as possible, 
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from natural systems and grown under conditions that are conducive to their environment 
and phenotype.  This may be the biofilm phenotype and in other cases, the planktonic.  
In summary, as an isolate(s) is selected for application in an animal model of 
infection, or as one is selected for specific in vitro testing, such as an antimicrobial 
eluting biomaterial, the author recommends that, depending on the specific application, 1) 
the isolate be derived from a primary culture, either from a patient or natural 
environment, that has not been passaged numerous times, 2) that it be grown under 
conditions that will promote biofilm formation to the nearest possible extent as they are 
found in their natural environment and, 3) that biofilms be applied in numbers that, as 
closely as possible, model clinical and/or environmental scenarios to which biomaterials 
may be exposed.
The impact of biofilm-dwelling bacteria on human health is becoming ever more 
apparent.  Chronic wounds are now considered to be the result of acute infection that 
begins with biofilm contamination as opposed to a nonhealing wound that is later 
contaminated and suffers from biofilm formation/infection.62-64,236 Heart disease is now 
indicated to be compounded by biofilm dwelling bacteria from oral plaque that enter the 
vasculature.237,238 Overall human health is believed to be significantly influenced by an 
intricate balance of biofilm dwelling bacteria in gut flora.202 In short, it is difficult to 
overestimate the impact of biofilms on human well-being and disease.
Looking to the future of biofilm and biomaterials research, additional approaches 
for in vitro analyses and design modifications to in vivo models that encompass the use of 
preformed, well-established, sessile communities of mature biofilms that model those 
found in nature, in patients and within the environment, can be envisioned.  As future 
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studies are undertaken to analyze the impact of low number biofilms on infection 
outcomes, results may indicate that less than 105 cells will be required to cause infection.  
If the efficacy of antimicrobials is tested against high and low number biofilms, 
those on the order of 107 to 109 cells and 102 to 104, respectively, it may uncover deeper 
insights into the concentrations of antimicrobial in, for example, antimicrobial eluting 
biomaterials, that are needed to prevent and eradicate biofilm-related infections from 
developing.  We can only wonder at this time how many antimicrobials and antimicrobial 
eluting biomaterials have been prevented from progressing to clinical, home, industrial 
and/or environmental use based on the fact that MIC values, which are primarily the 
result of planktonic cellular response, have been used to determine the amount that was 
needed to eradicate bacteria residing in well-established biofilms.  
The opposite may be true as well.  There is no indication that antibiotics that have 
been put into clinical use have shown efficacy against low and/or high number biofilms 
on implants.  Although this trend may change as an understanding of the role of biofilm 
increases, this paradigm has potentially been a contributing factor to the development of 
antibiotic resistance.  More specifically, in various systems, bacteria residing in biofilms 
may have been exposed to lower concentrations than are needed to prevent their growth 
and eradicate them within in vitro and in vivo systems.  However, a cavalier approach of 
simply increasing dosages of antimicrobials alone or used in eluting biomaterials could 
potentially lead to toxic effects in vivo and cause additional problems.  Thus, future work 
will be needed to elucidate the efficacy and toxicity of antimicrobials used alone or in 
eluting biomaterials against biofilms in translational and clinical studies.
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In summary, the impact that low number biofilms have on human infection as 
well as using well-established, mature biofilms as initial inocula for in vitro and in vivo 
models may help further the optimization of antimicrobial treatments, such as those used 
in coatings on biomaterials.  In addition, the understanding of the impact that biofilms 
from natural systems have as initial contaminants of wounds may also be increased.  
Most importantly, a shift in the use of biofilms for inoculation methods and analytical 
techniques may help biomaterial researchers take a step forward, and thus obtain the 
advantage in the battle against biofilm implant-related infections.
The work that was performed in this dissertation directly addressed these issues 
by using well-established biofilms as initial inocula, optimizing the dosage of a novel 
antimicrobial compound against these biofilms in a translational manner by performing in 
vitro then in vivo work, as well as establishing an animal model of osteomyelitis to 
demonstrate that using biofilms as initial inocula may have the ability to simulate biofilm 
implant-related infections that are seen clinically.
CHAPTER 4
A MEMBRANE BIOFILM REACTOR TO PRODUCE
MATURE BIOFILMS ON THE SURFACE
OF PEEK MEMBRANES FOR THE
IN VIVO ANIMAL MODEL
APPLICATION
4.1 Introduction
Information provided in this chapter is based off a published manuscript.40 This 
manuscript is provided for the reader as Appendix B of this dissertation.  Furthermore, 
the work outlined in this chapter relates directly to Specific Aim 1 outlined in Chapter 2, 
Section 2.4.
In this study, a modified CDC biofilm reactor,239 referred to hereafter as the
membrane biofilm reactor, was developed to grow well-established biofilms on the 
surface of PEEK membranes.  The PEEK membranes were made of crisscrossing threads 
of 200 μm diameter with 300 μm openings.  It was intended that these biofilm-ridden 
membranes be used for the in vitro and in vivo testing that will be outlined in Chapters 5, 
7 and 8. However, prior to using these biofilms for those applications, the repeatability 
of this reactor needed to be confirmed.
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The rationale for modifying the original CDC biofilm reactor to grow biofilms on 
the surface of PEEK membranes was two-fold.  First, the original CDC biofilm reactor 
was designed to grow biofilms on the surface of circular metal discs (1/8” thickness x 
1/2” diameter; referred to as coupons by Biosurface Technologies, Bozeman, MT).  
These coupons can be made of nearly any desired material.  However, they are relatively 
large and may be cumbersome to use in an in vivo model, and they are difficult to remove 
from the CDC biofilm reactor without disturbing the biofilms.  Second, our animal model 
was designed to test the ability of CSA-13 to eradicate biofilms by placing them in 
apposition to an antimicrobial coated orthopaedic device.  It was therefore found that if 
the coupons were used in the intended study design, the coupon(s) may not have allowed
for effective diffusion of the antimicrobial throughout the biofilm community.  
Thus, the CDC biofilm reactor was modified to grow biofilms on the surface of 
PEEK membranes to address these above limitations.  More specifically, the advantages 
of using the membranes included 1) a high surface area material that allowed for 
significant and consistent biofilm growth.  As mentioned, open fractures and other open 
wounds have significant potential to be contaminated with very high inocula of bacteria.  
2) The PEEK membrane used for this study was a thin material that could be placed
easily between bone and a metal orthopaedic device.  3)  The PEEK membrane would 
allow for diffusion of an eluting antimicrobial through the pores of the membrane and 
throughout the biofilm community.
The hypothesis of this study was that mature biofilms of MRSA would develop 
on the surface of PEEK membranes in a repeatable fashion over several runs of the 
reactor.
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4.2 Materials and Methods
4.2.1 Isolate Selection
A freshly cultured, clinical isolate of MRSA was collected from a patient and 
used for this study. More specifically, a patient who underwent knee surgery developed 
infection and an aspirate was sent to ARUP Laboratories, Salt Lake City, UT for 
characterization and susceptibility testing.  The isolate was characterized as MRSA based 
on resistance to penicillin and oxacillin using the Kirby Bauer disc diffusion technique.  
Preliminary work indicated that the isolate was a biofilm former following black colony 
formation on Congo Red agar and detection of the icaADBC gene cluster.
4.2.2 Modified Design of the CDC Biofilm Reactor
The CDC biofilm reactor was purchased from Biosurface Technologies 
(Bozeman, MT).  The original design of the reactor is provided in Figure 4.1A.  A 
modified lid was designed and machined using the University of Utah Chemistry
machine shop.  The modified lid contained four slots into which guillotine-like holders
(20 centimeters (cm) in length with a 3mm groove down the middle of the interior 
portion) made of ultra-UHMWPE were inserted (Figure 4.1B).  Into the guillotine holders 
were placed PEEK membranes that were held in place between two 316L stainless steel 
plates with a 0.64cm2 opening (Figure 4.1B).  A photograph of the membrane reactor is 
provided in Figure 4.1C.  All other aspects of the reactor were the same as the original 
CDC biofilm reactor.
Notably, during the developmental phase of this membrane reactor, Delrin plastic 
was used to machine the various components of the lid and guillotine holders.  However, 
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following multiple autoclave cycles, Delrin was found to decompose into its monomeric 
components of formaldehyde.  The formaldehyde subsequently killed the bacteria in the 
reactor and prevented biofilm formation.  A technical note was published110 describing 
this problem and is provided as Appendix C at the end of this dissertation.
4.2.3 Biofilm Growth in Reactor
The membrane reactor held eight PEEK membranes with two membranes in each 
of the four guillotine holders (see Figure 4.1).  PEEK membranes were first sonicated for 
10 minutes in detergent, rinsed under running reverse osmosis water for 10 minutes, and 
sonicated in reverse osmosis water for 10 minutes and rinsed once again using 70% 
ethanol.  The reactor was then assembled and all components autoclaved prior to use.  
Following ASTM standard E2562-07, the membrane reactor was run under the 
following conditions: approximately 1.5 x 107 bacterial cells were inoculated into 500
mL of brain heart infusion (BHI) broth (modified; catalog # B99070, Fisher Scientific) in 
the biofilm reactor.  The rotator was stirred at 130 rpm and the unit was placed in an 
incubator set at 28.5° Celsius (C) for 24 hours.  A 10% BHI broth (modified) solution 
was then flowed through the reactor at 6.944 mL/min for 24 hours (for a total of 10 L).
4.2.4 Sample Fixation, Dehydration and Imaging
Importantly, the fixation and imaging protocol used for this portion of the study 
was modified from a published protocol that the author published with Dr. Bloebaum 
previously.28 This publication is provided for the reader as Appendix D at the end of the 
dissertation.  Since glutaraldehyde was found in this published study to be a superior 
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fixative for imaging the ECM components of a bacterial biofilm, it was used for this 
study.
To qualitatively observe the biofilms that had developed, 8 membranes were 
fixed, then imaged using SEM.  For imaging preparation, membranes were removed from 
the reactor, placed in 2.5% glutaraldehyde for 24 hours then dehydrated using ascending 
grades of ethanol with 3 x 20 minute exchanges of each up to 100%.  Samples were dried 
in a desiccator overnight, sputter coated with ~3 nm of gold, and imaged using a FEI 
NOVANano SEM 600.
4.2.5 Bacterial Quantification
In order to determine uniformity, following eight separate runs of the membrane
biofilm reactor, a total of 64 PEEK membranes were used to quantify the number of 
bacteria that grew on the surface of each membrane. The membranes from each run were 
randomly assigned to one of two treatment groups (i.e., with 4 membranes per group).
Following growth in the reactor, the 4 membranes in Group 1 were removed from 
the guillotine holders, rinsed 3x in 6 mL of saline, placed on a shaker at 100 rpm for 20 
minutes and allowed to remain stationary for 1.5 hours.  The membranes were then 
vortexed for 1 minute, sonicated at 42k hertz (Hz) for 10 minutes, allowed to recover 
from sonication for 20 minutes and then enumerated using a 10-fold dilution series.  One 
hundred microliters (μL) of each dilution (1:10-1:10,000,000) was plated onto Columbia 
blood agar in duplicate and incubated overnight at 37° C.  The following day, the colony 
forming units (CFU) were counted to determine the number of bacteria per membrane 
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(CFU/membrane).  Fifteen randomly selected membranes were imaged by SEM to 
confirm that bacteria had been removed from the surface.
The rationale for shaking the membranes at 100 rpm for 20 minutes was to model 
the car ride that they would be exposed to when they were transported from the lab to the 
site of animal surgery.  Furthermore, the 4 membranes in Group 1 were allowed to 
remain stationary for 1.5 hours in order to model the time that they would be stationary 
while at the surgical facility and animals were prepped for surgery prior to inoculation.  
Group 2 membranes were treated in the same manner as those in Group 1 with the 
exception that they were allowed to remain stationary for 3 hours as opposed to 1.5 hours 
so as to model the time that they would remain stationary during the first surgery of the 
future animal model.
The density of bacteria in CFU/membrane was recorded for each PEEK 
membrane and then log10 transformed.  For each of the two treatment groups separately,
an Analysis of Variance (ANOVA) was fit, with run as a random effect, to calculate the 
mean and repeatability standard deviation (SD) of the log densities on the PEEK 
membranes over the eight reactor runs.  Another ANOVA, with group as a fixed effect 
and run as a random effect, was used to compare the group means and to calculate the 
repeatability SD for both groups pooled together.  These statistics were used to determine 
if any difference in bacterial response could be seen between membranes that were 
allowed to remain in a dilute broth solution for varying periods of time.  The analyses 




4.3.1 Growth on PEEK Membranes Within the Biofilm Reactor
Images collected of the PEEK membranes following growth, sample fixation and 
dehydration indicated that copious amounts of biofilm formed on the membrane surfaces 
(Figure 4.2A).  Furthermore, each of the three indicators240 that a mature biofilm had 
developed were detected, i.e., significant ECM production (Figure 4.2A and B), three-
dimensional structures of mushroom- or pillar-like formations (Figure 4.2C) and possible 
water channel development (Figure 4.2D) were observed upon SEM analysis. In 
addition, the ECM appeared to act as a scaffold to which the bacteria attached to create a 
“bridge” that connected cells of the biofilm from one strand of the PEEK membrane to 
another (Figure 4.2B).  These results indicated that mature, viable biofilms did form on 
the surface of PEEK membranes when grown within the modified membrane reactor.
Notably, although the temperature of the incubator was set at 28.5° C, the 
recorded temperature of the broth after the first 24 hours of each run was 28.1° ± 1.2° C.
After 48 hours of growth, the broth temperature from each run was 29.8° ± 0.5° C.
4.3.2 Bacterial Quantification
The number of bacteria on each PEEK membrane was quantified following eight 
separate runs of the reactor, with 8 membranes per run, and four membranes randomly 
assigned to each of two treatment groups to confirm uniformity. The data are shown in 
Figure 4.3.
Mean log densities and repeatability SDs for each of the two groups individually 
and also for all 64 membranes pooled together are given in Table 4.1. The table 
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corroborates what is evident in Figure 4.3: the two groups had similar means and 
repeatability SDs.  A 90% confidence interval for the difference of the Group 1 mean log 
density subtracted from the Group 2 mean log density was found to be (0.06, 0.19), 
which indicated statistical equivalence between the two group means at a significance 
level of 5% as long as mean differences up to 0.19 are considered to be negligible.
Taken together, these results show that copious amounts of S. aureus biofilm
formed on the surface of each PEEK membrane within the reactor and that the mean log 
densities for the two treatment groups were statistically equivalent.  Furthermore, the 
biofilm log density exhibited acceptable repeatability from run to run under the 
conditions described.
SEM images of the PEEK membranes that were collected after the quantification 
process indicated that only sparse microcolonies of bacteria remained on the surface.  As 
such, the number of bacteria in the microcolonies was inconsequential with respect to the 
billions of cells that were enumerated (SEM images not shown).    
4.4 Discussion
An increased understanding of the important role of biofilms in device-related and 
chronic infections suggests that in vitro and in vivo studies may be strengthened with the 
use of mature biofilms as opposed to the application of planktonic bacteria alone.  This 
study highlighted the ability of the CDC biofilm reactor to be modified in such a way that 
mature biofilms could be grown on a polymer surface that could later be applied toward
the in vitro and in vivo experiments that were performed in this dissertation.  Taken 
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together, the hypothesis that mature biofilms would develop on the surface of PEEK 
membranes in a repeatable fashion was supported.
Interestingly, during the optimization of the modified reactor, it was found that 
when the unit was placed in an incubator set at 37° C, which resulted in a broth 
temperature of ~38° C, biofilms did not form as well as when they were grown at 28.5° 
C. More specifically, when grown at 37° C, there was no biofilm growth on the PEEK 
membranes by visual observation, whereas at 28.5° C, copious amounts of biofilm could 
be seen.  Since our group was interested in having ~109 cells/membrane, no further runs 
at 37° C were performed.  Nevertheless, this finding was similar to that of Rode et al.241
They found that several clinical and food-related isolates of S. aureus produced biofilms 
optimally near 30° C, but not at 37° C.
It is important to note that the sonication level of 42k Hz that was used to break 
the cells apart in this study were well below lethal levels of sonication when compared to 
what has been reported in the literature.  Previous work by Bill Pitt, PhD has shown that 
sonication above 100k Hz can in fact kill bacterial cells, whereas levels below 100k Hz 
are not detrimental to bacterial biofilms, and can even enhance their ability to develop 
over a 24-hour period.242
The overall mean bacterial log density was 9.51 log CFU/membrane and the 
repeatability SD was 0.213.  As a comparison, in the 13 experiments described by 
Buckingham-Meyer et al.,243 S. aureus ATCC 6538 biofilm grown in the CDC reactor 
on glass coupons exhibited a mean of 8.3 log (CFU/cm2) and a repeatability SD of 0.224
(based on 2 coupons).  In a different set of 12 experiments, Buckingham-Meyer et al.243
grew P. aeruginosa biofilms in the CDC reactor on glass coupons, with a mean of 8.5 log 
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(CFU/cm2) and a repeatability SD of 0.211.  Goeres et al.239 grew P. aeruginosa biofilm 
in the CDC reactor on polycarbonate coupons over 9 experiments and reported a mean of 
7.06 log (CFU/cm2) and a repeatability SD of 0.510 (based on 2 coupons per 
experiments).  Thus, the biofilm bacteria grown on PEEK membranes in the membrane
reactor exhibited acceptable run to run repeatabiliy in this study. At the time that this 
dissertation was written, the membrane biofilm reactor had been run more than 60 times 
with statistically equivalent numbers of cells each time.
In summary, demonstrating that biofilm growth on PEEK membranes was 
repeatable from run to run was an important aspect of this project.  It was important that 
the in vitro testing portion of this work was performed with biofilms that had similar 
numbers of cells.  Furthermore, it would be highly important that individual animals 
received equivalent biofilm challenges.  Therefore, the statistical equivalence of the 
biofilms grown on membranes in each of the treatment groups suggested that if these 
biofilms were used, they would be used reliably and in a repeatable fashion during our in 
vitro and in vivo portions of the study.
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Figure 4.1: Diagrams and photo of the CDC biofilm reactor and membrane biofilm 
reactor. (A) Schematic diagram of the CDC biofilm reactor. The swirling paddle in the 
base of the reactor causes shear forces to be generated as broth circulates in the reactor.  
Shear forces help to increase the mechanical strength of biofilms. (B) Schematic diagram 
of the membrane biofilm reactor lid and guillotine-like holder.  Biofilms grow on the 
surface of PEEK membranes that are held between two metal plates that slide in the 
guillotine-like holders.  (C) Photograph of the completed membrane biofilm reactor.
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Figure 4.2: Images of biofilms in the following Figure were grown on the surface of 
PEEK membranes.  (A) Representative SEM image of the S. aureus biofilm showing 
strands of the EPS network.  (B) Additional image of the EPS providing a scaffold for 
bacterial cells within the biofilm to create a bridge from one surface of the PEEK 
membrane to another.  (C) Representative image showing a three-dimensional structure 
of biofilm extending vertically from the surface of the PEEK membrane.  (D) 
Representative image showing possible water channels within the biofilm structure 
(arrow).  
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Figure 4.3: An individual value plot of the log density of bacteria per PEEK membrane.
Group 1 (O) membranes were those that were allowed to remain stationary for 1.5 hours 
prior to quantification.  Group 2 (|) membranes were those that were allowed to remain 
stationary for 3 hours prior to quantification.  Each point represents 1 membrane.
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Table 4.1: Statistical characteristics for each of the two treatment groups, and both groups 
pooled together.  The standard error (SE) of the mean and the repeatability SD are based 











1 9.45 0.0296 0.2020 17% 83%
2 9.58 0.0297 0.2162 15% 85%
Both 1 
and 2 9.51 0.0203 0.2130 14% 86%
CHAPTER 5
IN VITRO ANALYSIS OF THE CSA-13 ACTIVE RELEASE
COATING TO ERADICATE BIOFILMS OF MRSA
5.1 Introduction
In this portion of the dissertation work, the goal was to test the ability of CSA-13
to elute out of a PDMS polymer as an active release agent and eradicate biofilms of 
MRSA in an in vitro system. As such, this study addressed Specific Aim 2a and 2b as 
outlined in Chapter 2, Section 2.4.  The in vitro system was designed specifically to 
model a clinically relevant scenario.  In other words, it was designed to translate to the 
animal model of a massively contaminated Type IIIB Gustilo open fracture, and 
ultimately to translate to the clinical paradigm.  The hypothesis was that as CSA-13
eluted from the PDMS polymer, it would reduce MRSA cells within the biofilm to a level 
that would be clinically acceptable (this acceptable level will be discussed in the Methods 
section below).
As was discussed in Chapter 2, numerous in vitro experiments have been 
designed to test the efficacy of active release coatings with the intent to model clinically 
relevant paradigms of biofilm implant-related infection.  The limitations of these previous 
tests have been discussed in Chapter 2.
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The flow cell that was designed was machined in such a way that stainless steel 
(SS) plates, coated with a PDMS/CSA-13 conjugate polymer, could be placed in a 
chamber that had a flow of broth running through it at a rate that modeled the flow of 
interstitial fluid in the proximal medial aspect of a sheep tibia,244 which is the anatomical 
location that these coated plates and biofilms were to be tested in the animal model.  This 
provided the ability to test the efficacy of CSA-13 to reduce biofilms of MRSA under 
more physiologically and clinically relevant conditions.  
In summary, this study used an optimized dip method and concentration of CSA-
13 to reduce biofilms of MRSA in vitro to a level that may prevent biofilm implant-
related infection from developing in a future animal model.
5.2 Material and Methods
5.2.1 Stainless Steel Plates
For this study, 316L SS was used to machine plates that were 2 cm x 2 cm with 
2.7 mm screw holes drilled in each corner.  Each plate had a consistent thickness of 1.85 
± 0.01 mm.  On the underside of each plate, a well with a depth of 300 μm and 1.2 cm 
width x 1.2 cm length was machined such that a 1 cm width x 1 cm length PEEK 
membrane could be placed in the well (Figure 5.1).
Prior to dip coating, each plate was grit blasted at 90 psi using fine silica beads in 
a dry blast cabinet to enhance the attachment of PDMS primer and polymer to the metal 
surface.  After grit blasting, the plates were cleaned and passivated following ASTM
standard F86-04. In short, this passivation process involved cleaning and sonicating the 
plates in detergent, exposing them to a 35% nitric acid solution for 30-60 minutes and 
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rinsing/sonicating them in water for 20 additional minutes.  Each plate was allowed to air 
dry prior to dipping.
5.2.2 PDMS (Silicone)
The PDMS polymer that was used for this study was purchased from NuSil 
Technologies (catalog # MED-6607, Carpenteria, CA).  This PDMS is on master file with 
the FDA for use in approved medical devices.  In addition to the reasons described in 
Chapter 2, section 2.6 previously, the rationale for using this specific PDMS was based 
upon several months of testing other PDMS products, other polymer types and various 
dipping methods.  Due to the nature of CSA-13, PDMS polymers that utilized platinum 
catalysts as a catalytic agent for cross linkage could not be used as the platinum was 
poisoned by the nitrogen compounds in the CSA-13.  Furthermore, as was mentioned, 
high temperature vulcanizing PDMS could not be used since CSA-13 melts at ~80°C and 
begins to degrade over time at temperatures above ~150° C.  As was also previously 
discussed, CSA-13 was found to have undesirable release profiles from PU.
Importantly, there have been two provisional patents filed following the 
development of this PDMS coating with CSA-13 incorporated in it and the author is the 
primary inventor on both of these patents.  
5.2.3 PDMS Suspension/Concentration of CSA-13
Over a several month period, varying ratios of PDMS to naphtha (e.g., 0.5:1, 1:1, 









dispersions to develop an optimized formula that would result in a uniform coating as 
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well as reduce the amount of bacteria in MRSA biofilms from greater than 109 CFU to 
less than 102 CFU in a 24-hour period.  
The rationale for using biofilms that contained ~109 CFU was to model the 
number of bacteria that may be present clinically in a Type IIIB open fracture wound that 
is contaminated with roughly 1/3 of a gram of soil.  Recall from Chapter 1 that one gram 
of soil has been shown by Bakken71 and Torsvik et al.70 to contain between 107 and 1010
bacterial cells, the majority of which may reside in the biofilm phenotype.  Obviously, 
~109 bacteria in an open wound might represent a worst case clinical scenario, wherein 
significant amounts of soil and/or bacteria would be present, many of which may be 
compressed between a fraction fixation plate and the bone of a patient.  Modeling a worst 
case scenario was important so that the amount of CSA-13 needed would not be 
underestimated.
Furthermore, the rationale for wanting to reduce biofilms from 109 to less than 102
as an indicator that CSA-13 was effective was based on the CLSI guideline M26-A, 
which suggests that to demonstrate the efficacy, i.e., MIC, of an antimicrobial, it should 
result in a reduction of 105 to 102 CFU within a 24-hour period.  However, these 
guidelines are optimized for planktonic bacteria, which are much more susceptible to 
antimicrobial treatment than those residing in a biofilm.18,21 Since this study intended to 
develop an antimicrobial coating that would eradicate bacteria in the biofilm phenotype, 
the author and technicians optimized the coating to reduce the number of bacteria to 
below the 102 CFU requirement outlined by the CLSI.
Taking these considerations into account the final formula, which was found to 
meet these outlined criteria and which resulted in a consistently uniform coating on the 
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SS plates, was comprised of a 1:1 PDMS:naphtha ratio with an 18% w/w CSA-13 
concentration.  In all cases, an 18% w/w concentration of CSA-13 was the only 
concentration that proved to have the desired antimicrobial efficacy.  Counter intuitively, 
a 20% w/w ratio had lower antimicrobial activity than 18%.  The 20% w/w ratio also 
resulted in poor mechanical properties of the PDMS material.  More specifically, the 
polymer did not cross-link well, it became too pasty to dip into and the PDMS surface 
tended to wrinkle when multiple dips were performed.  In addition, a 1:1 ratio of 
PDMS:naphtha was deemed to result in the most uniform coating with sufficient amounts 
of CSA-13 on the SS plates.  
Naphtha (VM&P) was purchased from Fisher Scientific and CSA-13 was 
manufactured by Dr. Paul Savage’s group at Brigham Young University. To produce a 
CSA-13/PDMS dispersion, jet mill micronized CSA-13 (50-200 nm particle size) was 
added to 10 mL of naphtha solvent and stirred for a minimum of 45 minutes.  Ten mL of 
PDMS dispersion were then added to the suspension for a final 1:1 PDMS:naphtha ratio 
and 18% w/w CSA-13 concentration.  The equation below shows the calculation that was 
used to determine the amount of CSA-13 that was needed to add to a solution for a final 
18% w/w concentration: 
 =  (0.18 ( + ))/0.825
where x equals the amount of CSA-13 in mg/mL and y equals the solids content of PDMS
in mg/mL.  The sum of y+x represented the total solids content of the mixture.  The 
number 0.825 was used to take into account the salt content of the CSA-13 powder.  
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Importantly, y was a known amount that was calculated after taking into account the 
dilution of PDMS after it was added to the naphtha solvent.  Since the naphtha in which 
the PDMS was initially suspended and which was added to the mixture evaporated away 
from the system during the curing process, its presence was considered negligible to the 
final w/w concentration.  In addition, the evaporation of the methylethylketoxime 
byproduct of the condensation cure reaction was considered negligible to the final w/w 
concentration.
After PDMS had been added to the CSA-13:naphtha suspension, it was stirred for 
a minimum of 3 hours.  For those plates that were coated with PDMS only, the PDMS
and naphtha were stirred alone at a 1:1 ratio for a minimum of 3 hours. The dispersions 
were degassed at ~25 inches of mercury (inHg) to remove any air bubbles.   
5.2.4 Dip Coating Procedure
Following passivation, SS plates were first hand dipped into MED-160 primer 
(NuSil Technologies) and allowed to dry for 45 minutes in ambient air and temperature 
on a rotating wheel set at 5 rpm.  The rotating wheel was custom made to hold each plate 
on two prongs that were perpendicular to the face of the wheel.  By rotating the wheel at 
5 rpm, the primer spread across the plate in a uniform manner.    
After priming, SS plates were dipped by hand into a dispersion of PDMS only or 
PDMS with CSA-13.  Plates were placed onto the rotating wheel set at 5 rpm.  This 
process was repeated two more times for a total of three dipped layers on each plate.  
There was a 10-minute interval between each of the dips, which was within the 
recommendations of the manufacturer if multiple dips were to be performed.  
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Importantly, the same person dipped each of the plates under similar room conditions in 
an attempt to reduce lot to lot variability.  After dipping, each SS plate was left on the 
rotating wheel at 5 rpm for 7 days (as per manufacturers recommendation) in a hood
under ambient conditions.  Uniformity of the coating was determined by measuring the 
thickness of the coating in three different areas of the plate using calipers with a 
measuring capacity to 10 μm: the thickness was further confirmed by cutting the coating 
of n=10 plates with a razor blade perpendicular to the plate surface, then measuring the 
thickness with a JEOL-6100 scanning electron microscope. The amount of CSA-13 per 
plate was calculated by weighing each plate before and after it was dipped, subtracting 
the weight of the plate, then multiplying the final coating weight by 0.18 since it was 
added at an 18% w/w concentration.
5.2.5 Flow Cell
A flow cell unit was designed by the author and machined by Biosurface 
Technologies (Bozeman, MT).  The unit consisted of 6 individual chambers, each having 
a 4 cm width x 4 cm length x 2 cm height (Figure 5.2A and 5.2B).  A 1/16 inch inlet was 
machined in the center of each lid that covered each chamber.  A barbed connection was 
used to connect each inlet to 1.42 mm inner diameter Tygon tubing (catalog # EW-
96429-34, Cole Parmer).  One end of the tubing was connected to this barb, the middle 
portion of the tubing passed through a peristaltic pump (Masterflex L/S, catalog # 07523-
80, Cole Parmer), and the other end of the tubing was placed into 10% BHI broth
(modified). As such, the broth could be pulled through the tubing to a chamber of the 
flow cell unit.
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One side of each chamber was further drilled to have a 1/4” outlet hole (see 
Figure 5.2A).  The bottom of the hole was exactly 1 cm up from the bottom of each 
chamber.  A barbed connection was used to connect 1/4” inner diameter silicone tubing
to an effluent bottle (Figure 5.2C).
5.2.6 Biofilm Growth
Biofilms of MRSA were grown on the surface of PEEK membranes using the 
membrane biofilm reactor.
5.2.7 Quantification of MRSA Cells in the Biofilms
The quantitative and qualitative experiments to determine the repeatability, 
number of bacteria and maturity of biofilms on PEEK membranes that were grown with
the membrane biofilm reactor were discussed in Chapter 4.  However, to confirm that the 
published numbers were consistent in this portion of the study, as well as to obtain a 
baseline of the number of CFU that grew on each membrane, two PEEK membranes 
were removed for quantification following each run of the reactor.  The remaining six 
membranes were used in the actual experiment.  
To quantify the CFU per membrane, the same procedure was used as described in 
Chapter 4, section 4.2.5.
5.2.8 Flow Cell Setup/Efficacy of CSA-13 in Thin Films
Following the 48-hour growth period of the biofilm reactor, a PEEK membrane 
was aseptically removed and placed into a well on the underside of a SS plate.  The plate 
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was then secured to an autoclaved piece of bone using sterile cortical bone screws (Figure 
5.2D).  The bone/SS plate/PEEK membrane construct was then placed into a chamber of 
the flow cell unit (see Figure 5.2B).  This procedure was repeated for all six chambers of
the flow cell.  Each chamber was then filled with 20 mL of 10% BHI broth (modified) in 
order to cover the entire bone/PEEK/SS plate construct.  To model the body temperature 
of sheep, the incubator was set at 39° C.  Importantly, CSA-13 has the same activity at 
39° C as it has at 37° C.
Over a 24-hour period, a 10% BHI broth solution was flowed through the flow 
cell at a rate of 4.5 mL/hr.  This flow rate was chosen based on the work of Smith et 
al.,244 which indicated that the rate of interstitial fluid flow in the hind limb of sheep can 
be between 1 mL/hr and 8 mL/hr.  Moreover, the use of BHI broth (modified) was 
important as BHI (modified) is derived from boiled animal tissues.  This broth was 
chosen to more closely model the environment that bacteria and CSA-13 would be 
exposed to in the future in vivo paradigm.
At 4-, 8- and 24-hour time points, a bone/SS plate/PEEK membrane construct was
aseptically removed from a chamber of the flow cell.  The cortical bone screws were 
aseptically removed.  The bone piece was placed into 20 mL of Dey Engley (D/E) broth 
(catalog #DF0819-17-2, Fisher Scientific), the SS plate was placed into 10 mL of D/E 
broth and the PEEK membrane was placed into 5 mL of D/E broth.  The rationale for 
using D/E broth was that it contained lecithin, which is known to deactivate nitrogen 
containing antimicrobial compounds.  In this case, the CSA-13 was deactivated so that it
did not have residual kill against bacteria during the quantification process. The different 
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volumes of D/E broth were used to cover the entire surface of each of the different 
components.
Each bone piece, SS plate and PEEK membrane was vortexed for 1 minute, 
sonicated for 10 minutes and allowed to recover for 20 minutes prior to performing a 10-
fold dilution series to quantify the number of CFU.  Results were calculated to show the 
number of CFU/gram of tissue for the bone samples, CFU/SS plate and CFU/PEEK 
membrane.  In addition, a 100 μL sample of broth was collected from each chamber and 
each effluent bottle to determine the CFU/mL of broth in each.  Since six PEEK 
membranes were present in each flow cell, an n=2 experiments (an n=1 experiment
comprised of a 4-, 8- and 24-hour time point) could be performed per run of the flow cell.  
In total, n=27 experiments were performed.  This included n=9 experiments with 
CSA-13-coated plates tested against MRSA biofilms (test group), n=9 experiments that 
involved PDMS only coated plates with biofilms (positive control group), and n=9 that 
involved PDMS only coated plates with no biofilm on the PEEK membranes (negative 
control group).  The rationale for performing these experiments in groups of 9 was to 
model the number of sheep that would be used in the animal study, wherein 9 sheep 
would be treated in a similar manner as each of the three treatment groups outlined.  As 
such, this study included the proper controls to ensure that PDMS itself did not have an 
antimicrobial effect on the biofilms (positive control group) and that the experiment was 
performed aseptically (negative control group).
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5.2.9 Short Term Elution Kinetics
At each collection time point of 4, 8 and 24 hours, the broth from the chamber and 
from the effluent bottle was collected and analyzed using high pressure liquid 
chromatography/time of flight mass spectrometry (LC/MS) with a reverse phase C18
column to determine the amount of CSA-13 that had eluted out of the coating.  More 
specifically, a 50 μL sample of broth was spiked with 50 μL of a known amount of 
deuterated CSA-13 (dCSA-13), which was mixed with NaOH to remove the positive 
charge from both CSA-13 compounds.  The mixture was resuspended in dichloromethane
to separate the phases, then allowed to dry in order to be resuspended in 60% acetonitrile.  
A 5 μL sample was then injected into the LC/MS instrument and pushed through the 
column over 3 ½ minutes while the acetonitrile concentration was increased from 60% to 
100%.  The ratio of counts from the CSA-13 and dCSA-13 was used to calculate the 
concentration of CSA-13/mL that was present in the original broth sample.
5.2.10 Long Term Elution Kinetics/Residual Antimicrobial Kill
Five CSA-13-coated SS plates were used to determine the amount of CSA-13 that 
eluted out of the PDMS polymer over a 30-day period.  To do so, these five plates were 
placed in five separate chambers of the flow cell.  A 10% BHI broth (modified) solution 
was flowed through the chambers for 30 days.  At 24-hour intervals, the broth was 
collected from the effluent bottles and analyzed using the same LC/MS technique as 
before.
In addition to collecting broth for elution kinetics data, each of the broth samples 
was also used to determine the efficacy of the eluted CSA-13 against planktonic bacterial 
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cells in order to determine the duration of antimicrobial kill that the active release agent 
provided.  This was done by pipetting 990 μL of a broth sample from each of the six 
plates that had eluted over a 15-day period into a test tube followed by 10 μL of water 
that had been adjusted to a 0.5 McFarland.  The final concentration of bacteria was ~5 x 
105 cell/mL.  The rationale for using this amount of bacteria was to coincide with the 
recommendations of CLSI standard M26-A.  Each broth sample was incubated overnight 
at 39° C to model the temperature of a sheep's body.  A 10-fold dilution series was used 
to quantify the number of bacteria that remained in each broth sample.   
5.2.11 Statistical Analysis
To compare the number of CFU that were present in the various samples of the 
CSA-13 (treatment) group and the PDMS only (positive control) group, an independent 
sample t test was used.  This was used based on the fact that in each case, the data sets 
from all samples in the two groups were normally distributed, the data were sampled 
independently, and Levene’s test of equality was statistically insignificant, suggesting 
that there was not a statistically significant difference in the variance of the two groups.
5.3 Results
5.3.1 Dip Coating
Plates that were coated with PDMS only (Figure 5.3A) had a final coating weight 
of 71.4 ± 14.6 mg and a thickness of 97 ± 18 μm.  In contrast, plates that were coated 
with Si/CSA-13 (Figure 5.3B) had a coating thickness of 113 ± 22 μm and a final coating 
weight of 96.3 ± 9.7.  The amount of CSA-13 per plate was calculated to be 17.2 ± 0.61 
115
mg.  Notably, the increase in coating thickness of plates that were dipped in the 
PDMS/CSA-13 suspension compared to those that were dipped in the PDMS only 
suspension was believed to be due to the fact that the PDMS/CSA-13 suspension was 
thicker (more viscous) with the CSA-13 added to it, which appeared to have led to a 
slight increase in the amount of solution adhering to the plates.
5.3.2 Biofilm Quantification
A total of n=36 PEEK membranes from 18 different runs of the biofilm reactor 
were used to quantify the CFU/PEEK membrane in order to obtain a baseline of cells on 
each membrane.  Results showed that, similar to previously published data,40 there were 
9.41 ± 0.35 log10 CFU/PEEK membrane.
5.3.3 Efficacy of CSA-13 in Thin Films
Over the 24-hour period that the 10% BHI broth (modified) was flowed through 
the flow cells, there were 107 ± 6 mL of broth that flowed through each of the chambers. 
Results from the samples that were in chambers with PDMS only coated plates
(positive control group) showed that there was a slight decrease in the number of
CFU/PEEK membrane compared to the number of CFU/PEEK membrane that were
quantified immediately after the 48 hour growth period in the biofilm reactor (Figure 
5.4A). More specifically, there were 7.75 ± 0.75 log10 CFU/PEEK membrane that were
quantified on membranes after 24 hours of exposure to PDMS coated plates (Figure
5.4A). This difference was statistically significant (p<0.05).
116
The broth samples from the chambers and bottles that were collected with the 
PDMS only coated plates had an increase in the number of CFU/mL of broth at each time 
point (Figure 5.4A).  By 24 hours, there were 8.19 ± 0.20 log10 CFU/mL of chamber 
broth and 6.46 ± 1.89 log10 CFU/mL of bottle broth.
Results indicated that those biofilms on PEEK membranes which were placed in
chambers with CSA-13 coated plates (treatment group) had greater than an 8 log10
reduction of bacteria on the surface over a 24-hour period (Figure 5.4B). More
specifically, there were 0.50 ± 0.75 log10 CFU/PEEK membrane after 24 hours. When
compared to the number of bacteria that were on the PEEK membranes used for
quantification, the difference was statistically significant (p<<0.05). The broth samples
collected from chambers that had CSA-13 coated plates had no detectable amounts of 
bacteria after 24 hours in the broth from the chamber or from the bottles (Figure 5.4B).
There were 0.22 ± 0.67 log10 CFU/SS plate detected.
Interestingly, the number of bacteria in the bone samples exposed to CSA-13
increased over the 24-hour period, with 3.49 ± 1.42 log10 CFU/gram of tissue being 
detected in the first 4 hours and 5.27 ± 1.52 log10 CFU/g of tissue being detected after 24 
hours (Figure 5.4B). This was believed to be due to an interaction of the positively
charged CSA-13 with the negatively charged components of the bone. This suggested 
that CSA-13 may have reduced efficacy to kill bacteria that are present in nonviable bone 
samples.
However, there were ~3 log10 more CFU in the bone samples from chambers with 
PDMS only coated plates compared to those bone samples that were in the chambers with
CSA-13 coated plates.  Specifically, after 24 hours, there were 8.41 ± 1.08 log10
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CFU/gram of bone in the PDMS only group, versus 5.27 ± 1.52 log10 CFU/gram of bone 
in the CSA-13 treated samples.  This difference suggested that although CSA-13
appeared to have reduced efficacy in bone, it did have greater efficacy than no CSA-13 at 
all. Furthermore, this difference was statistically significant (p<0.05), as were all of the
differences in bacterial numbers between each of the samples in the positive control 
group and the treatment group when compared with an independent sample t test.
There was no growth in any of the samples from the third group (negative control)
of testing, wherein no bacteria were added to chambers. This confirmed that the process
could be performed aseptically.
5.3.4 Short Term Elution Kinetics
Elution kinetics results indicated that although there was a reduction in the overall 
μg/mL of CSA-13 from 4 hours to 24 hours in the chamber broth and in the bottle broth, 
there was no significant difference in the overall % release of CSA-13 (see Table 5.1), 
which was indicative of zero-order release.  This was likely due to the fact that CSA-13
was saturated in the solution during that time.  In addition, over time, it appeared that 
CSA-13 molecules may have accumulated in the bone samples and the molecules were 
likely interacting with the bacterial cells that were present, which may explain the slightly 
lower overall % release at 24 hours compared to 4 hours and 8 hours.  The overall % 
release was calculated using the total volume of broth that had flowed through the flow 
cell over 24 hours. By 24 hours, approximately 107 mL of broth had flowed through 
each of the chambers and into the effluent bottles and there were approximately 15 mL of 
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broth in the chambers.  No CSA-13 was detected in the broth from those chambers that
had PDMS only coated plates.
5.3.5 Long Term Elution Kinetics/Residual Antimicrobial Kill
Long term elution data indicated that the release of CSA-13 declined in a first-
order fashion over the first five days (Figure 5.5).  After five days, the detection limit of 
the particular LC/MS technique used in this study was surpassed as the broth samples 
contained less than 0.5 μg/mL of CSA-13.  In this portion of the study, by 24 hours there 
were approximately 13 μg/mL of CSA-13 in the broth that was collected and by day 5 
there were approximately 0.69 μg/mL.
Table 5.2 presents the data that were collected by testing the residual 
antimicrobial efficacy of the broth that was collected during the long term elution kinetics 
study.  A reduction of greater than 3 log10 CFU/mL was seen out to day 10. By day 12, 
there was a notable increase in the number of CFU/mL indicating that the concentration 
of CSA-13 in the broth had dipped below bactericidal levels.
5.4 Discussion
In direct response to previous limitations of testing active release coatings, this 
work undertook to test the efficacy CSA-13 as an active release agent to eradicate well-
established biofilms of MRSA in vitro in a flow cell system as opposed to stagnant broth 
solutions.  This was further done by determining the optimum concentration of CSA-13,
as opposed to relying on the MIC values of CSA-13 against planktonic bacteria.  Thus, 
this work was designed to translate to the in vivo paradigm wherein coated SS plates and 
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biofilms were used in the animal model of biofilm-related infection that will be shown in 
Chapter 8.
The results from this work strongly indicated that the use of CSA-13 at an 18 % 
w/w concentration would be efficacious to reduce the number of bacteria in a biofilm to a 
clinically acceptable level.  More specifically, within 24 hours, the number of CFU on the 
PEEK membranes were reduced to less than 1 log10 on average with minimal amounts of 
bacteria cultured from the other components of the flow cell.  Although there were ~105
CFU/gram in the bone samples, it was recognized that this was dead bone that had no 
host immunity. Thus, when used in vivo, bacteria would also be attacked by host immune 
components. Furthermore, in a head-to-head in vitro comparison, vancomycin was used 
as the active release agent of the PDMS coating and performed more poorly with nearly 3
log10 more bacteria in the bone samples compared to CSA-13 (unpublished data).
The fact that the results were repeatable over an n=9 runs was very promising.  
This strongly suggested that the various lots of CSA-13/PDMS dispersions were made in 
a consistent manner, that the dip method was performed in a repeatable fashion and that 
CSA-13 eluted from the silicone of each coated plate.  Furthermore, this suggested that 
when CSA-13 was used as an active release agent in the animal model of n=9 animals, it 
would perform in a repeatable fashion.
A potential limitation of this study was the variability in the amount of CSA-13
that was detected by LC/MS in the broth samples from the short term and long term
elution kinetics.  There were three possible reasons for this.  1) The broth that was used 
for this experiment was an undefined media that contained lipids, carbohydrates, 
electrolytes and other components derived from boiled brains, hearts and tissues of cattle.  
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It has been found that CSA-13 has a lower solubility in this broth (solubility of 35-40 
μg/mL) compared to saline (solubility of 85-90 μg/mL) (unpublished data).  Thus it 
appeared that due to its charge, CSA-13 may have had the potential to interact with the 
various components in the broth, which may have influenced the variability in 
concentrations.  2) Also due to its positive charge, CSA-13 likely interacted with the 
negatively charged components of bone.  This interaction may have also influenced the 
variability in concentration.  3) Although a repeatable jet mill process was used to 
micronize the CSA-13 powder prior to use, CSA-13 had the tendency to create micron 
sized aggregates as the PDMS-based dispersion was being made.  These aggregates 
resulted in varying pore sizes within the PDMS polymer (these pores sizes will be shown 
in Chapter 6).  Thus, the rate of elution may have been influenced by the variation of pore 
sizes that were present.  Future work would need to be undertaken to more thoroughly 
regulate the particle size of CSA-13, but for this project the important factor was that the 
antimicrobial efficacy of a 18% w/w concentration of CSA-13 was able to consistently 
eradicate MRSA biofilms.
In conclusion, when used as an active release agent in this in vitro study, CSA-13
supported the hypothesis that it would reduce biofilms of MRSA to a potentially 
clinically acceptable level.  By reducing the amount of bacteria in MRSA biofilms from 
greater than 109 to less than 101 in 24 hours, this novel antimicrobial compound provides 
significant promise to translate to clinical use.  These promising results became even 
more apparent after the animal work was performed, as will be shown in Chapter 8. 
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Figure 5.1: Image of a stainless steel plate that has a 1 cm x 1 cm PEEK membrane 
inserted into the well that was machined out of the underside of the plate.
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Figure 5.2: Images of the flow cell unit that was designed for in vitro testing.  (A) Image 
of the flow cell unit.  Arrows and descriptions indicate the different components of the 
flow cell.  (B) Image of a single chamber of the flow cell.  (C) Image of the effluent tubes 
and bottles in which broth was collected after it flowed through a flow cell chamber. (D) 
Image of how a SS plate, PEEK membrane and bone piece were constructed in order to 
place them in a chamber of the flow cell unit.
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Figure 5.3: Photographs of SS plates that were coated with PDMS only or PDMS with 
CSA-13. (A) SS plate coated with PDMS only after being dipped in the 1:1 
PDMS:naphtha dispersion, cured for 7 days and sterilized by ETO.  (B) SS plate coated 
with the 1:1 PDMS:naphtha + 18% w/w CSA-13 dispersion, cured for 7 days and 
sterilized by ETO.  The slight jaggedness that can be seen in the inner edges of the holes 
is due to the prongs that were used to hold the plates in place on the spinning wheel as 
they cure.  These plates had a white tint to them due to the presence of CSA-13, which is 
a white powder.
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Figure 5.4: Graphs showing the results of exposing CSA-13 to biofilms of MRSA using 
the flow cell system. (A) Results from the quantification of bacteria that were exposed to 
SS plates coated with silicone only.  These data are presented in log10 transformed 
numbers of CFU/PEEK membrane, CFU/mL of broth, CFU/SS plate and CFU/gram of 
bone tissue.  (B) Results from the quantification of bacteria that were exposed to SS 
plates coated with PDMS/CSA-13.
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Table 5.1: LC/MS data and overall % release calculated from each of the broth samples at 
4, 8 and 24 hours of sample collection.
Broth Sample µg/mL Overall % Release
4 Hour Chamber 66.56 ± 32.4 8.8 ± 4.14 Hour Bottle 16.66 ± 12.48
8 Hour Chamber 57.37 ± 36.89 8.5 ± 3.78 Hour Bottle 19.35 ± 12.62
24 Hour Chamber 23.68 ± 18.86 8.1 ± 3.924 Hour Bottle 9.38 ± 5.25
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Figure 5.5: Release profile of CSA-13 out of the PDMS coating over a five-day period.
By Day 2, the amount of CSA-13 released was less than half of what it was on Day 1.  By 
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Table 5.2: Data outlining the number of log10 transformed bacteria/mL that were present 
in the broth samples collected during the first 15 days of the long term elution study.  
These data suggested that for the first 10 days of release, the amount of CSA-13 in the 
broth samples was sufficient to reduce a 105 inoculum to less than 102 in a 24 hour 
period. By day 12, the number of bacteria increased to greater than ~106 cells/mL, 
suggesting that the levels of CSA-13 were below bactericidal concentrations.  Each day 
of release represented an n=6 broth samples from the n=6 plates that were used for the 
long term elution study.
Day Average Log10CFU/mL ± SD
1 0 ± 0
2 0 ± 0
3 0 ± 0
4 0 ± 0
5 0.82 ± 1.21
6 0.92 ± 1.31
7 1.75 ± 1.88
8 0.22 ± 0.61
9 0.92 ± 1.31
10 1.79 ± 1.89
11 2.70 ± 3.09
12 6.52 ± 6.91
13 7.14 ± 6.97
14 6.18 ± 6.51
15 6.52 ± 6.91
CHAPTER 6
CHARACTERIZATION OF THE CSA-13 ACTIVE
RELEASE COATING
6.1 Introduction
In this portion of the study, which directly addressed Specific Aim 2c as outlined 
in Chapter 2, section 2.4, the active release coating with CSA-13 was characterized using 
durometer measurements, scanning electron microscopy (SEM), attenuated total 
reflectance Fourier transformed infrared spectroscopy (ATR-FTIR), contact angle, tensile 
testing, thermal gravimetric analysis (TGA) and optical profilometry.  The coating with 
PDMS only was also characterized using these techniques with the exception of optical 
profilometry.  These techniques of characterization were performed in order to gain an 
understanding of the physical and chemical properties of the CSA-13/PDMS conjugate
coating.
Characterizing the coating helped to understand its morphology, stability, how 
CSA-13 affected polymerization of the PDMS polymer, and how CSA-13 was released.  
It also helped to file the patent for this product.
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6.2 Materials and Methods
6.2.1 Stainless Steel Plates/Coating Method
The same size and type of SS plates were used in this study as those used in 
Chapter 5. Furthermore, the same dip coating procedure was used to dip coat SS plates 
with dispersions that contained CSA-13 or PDMS only.
6.2.2 PDMS/Concentration of CSA-13
The same MED-6607 PDMS dispersion was used as that discussed in Chapter 5 
and the same 18% w/w CSA-13 concentration was added to the dispersion.  An important 
item of note is that more than 10 lots of dip coated plates (n=20 plates dipped per lot)
were made to confirm that the dipping method showed repeatable outcomes.
6.2.3 Hardness (Durometer) Testing
To determine the hardness of the cured PDMS and PDMS with CSA-13, thin 
films were made from each formulation by  pouring the dispersion into multiple  2 cm x 2 
cm chase containers that had a depth of 2 mm.  The dispersions were allowed to cure for 
a seven-day period (as per the manufacturer's recommendation), and then removed from 
the containers.  Following ASTM standard D2240, multiple films were stacked one on 
top of the other to a height greater than 6 mm.  An Asker XP-A Type A durometer was 
then used to determine the hardness of both material types.
6.2.4 Scanning Electron Microscopy
SEM analysis was used for three purposes.  First, the surface of n=5 plates with 
PDMS only and n=5 plates with PDMS and CSA-13 from three different lots of the dip 
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coating procedure were imaged under secondary electron (SE) mode in an FEI 
NOVANano high resolution SEM.  A total of 25 images per coating type were collected 
from five different areas of each plate to determine the surface morphology of the 
coating.  
Second, backscatter electron (BSE) images (n=5 plates; 5 images per plate) were 
collected using a JEOL-6100 SEM.  These images were subsequently used to measure the 
porosity and pore size distribution of each coating type.  To measure the size of pores 
throughout the bulk of the polymer, a razor blade was used to cut through the polymer to 
the surface of the metal.   
Third, using the JEOL-6100 SEM, energy dispersive X-ray (EDX) analysis was 
performed, again in five areas of n=5 plates coated with PDMS with and without CSA-
13, for elemental mapping to determine particle distribution, particle sizes and particle 
aggregate sizes of CSA-13 throughout the coating.  Again, a razor blade was used to cut 
the polymer and analyze the bulk of the material.  
Importantly, an additional n=5 plates per coating type were placed in a solution of 
10% BHI broth that flowed at a rate of 4.5 mL per hour to model the flow of fluid in the 
anatomical location of the animal model in which these plates were tested.  This flow was 
continued for a 30-day period.  This procedure was done to allow the CSA-13 to be 
eluted out of the coating completely.  Although there was no CSA-13 in those plates 
coated with PDMS only, this experiment was also performed as a control.  After the 30-
day elution period, the coating on each plate was cut at a 45° angle with a razor blade to 
allow the polymer to be analyzed from the top of its surface down to the metal plate.  In 
doing so, SE images were collected to determine the morphology of the coating following 
131
elution and EDX analysis was performed to confirm that there was no residual CSA-13 in 
the top or bottom portions of the coating.
6.2.5 Attenuated Total Reflectance Fourier Transformed
Infrared Spectroscopy
ATR-FTIR spectra were collected using a Thermo Scientific Nicolet 6700 FTIR 
spectrometer.  Spectra were acquired using a single reflection ATR SmartOrbit accessory 
equipped with a single-bounce diamond crystal. The data were then analyzed using 
OmnicTM software (Thermo Scientific).  FTIR spectra were obtained first by collecting a 
baseline reading without any sample on the diamond crystal and followed by analyzing 
five areas per plate on a total of n=5 plates per coating type.  Soxhlet extraction was 
performed with isopropanol for a 48-hour period after plates were analyzed initially.  In 
doing so, the CSA-13 was eluted from the coating.  Plates were then once again analyzed 
by ATR-FTIR to determine if the spectrum would return to the original PDMS only 
profile.
6.2.6 Contact Angle
Contact angle measurements were collected using a KSV Thetalite goniometer.  A 
similar protocol as Hulterstrom et al.245 was used wherein five different areas of a single 
plate were analyzed by placing a drop of millipore water on the surface.  Each drop was 
allowed to sit for 10 seconds prior to reading a measurement.  In total, there were n=5 
plates analyzed for each of the two coating types for a total of 25 contact angle 
measurements of PDMS only and PDMS with CSA-13.
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6.2.7 Tensile Testing
Tensile testing was performed following the ASTM standard D882-10 protocol at 
Nelson Laboratories of Salt Lake City, UT.  Using this standard procedure, the tensile 
strength, percent elongation and modulus of thin plastic materials that have less than a 1 
mm thickness could be determined.  For this work, thin films of PDMS only or PDMS 
with CSA-13 were made by first mixing the dispersions as outlined in Chapter 5.  
Approximately 1.5 mL of each dispersion was poured into a Teflon chase container that 
had a width of 1/2" (1.27 cm) and a length of 5" (12.7 cm) as per the ASTM standard.  
After a 7 day curing period, films were conditioned as per the ASTM standard, i.e., at 23 
± 2° C at 50 ± 10% relative humidity for greater than 40 hours. After measuring the 
thickness, each film was uniaxially strained at a crosshead speed of 20 feet per minute 
until break using an Instron tensometer (model 5565, Instron Corp.).  Ultimate force and 
elongation at break were noted.  The tensile strength was calculated by dividing the 
ultimate force by the cross-sectional area of the thin film. Elastic modulus was calculated 
by dividing the stress by the strain using data points in the linear elastic region. Although 
the ASTM standard suggested that at least n=10 films to be used for testing, in this study 
an n=15 films were used per group.
6.2.8 Thermal Gravimetric Analysis
TGA was performed at Intertek Plastics Technology Laboratories following 
ASTM standard E1131-08.  In short, three samples (7-10 mg) of each cured material type 
were subjected to TGA analysis using a Perkin Elmer Pyris 1 TGA (Perkin Elmer Inc.). 
The samples were initially purged for 5 minutes with nitrogen, then heated in air from 
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25° C to 850° C at a heating rate of 10° C/min.  The flow of air through the furnace 
chamber was controlled at 35 mL/min.
6.2.9 Optical Profilometry
In order to determine the surface roughness and topography of the PDMS coating 
with CSA-13, an optical profilometer (Zygo NewView™ 5032) was used.  The coating 
with PDMS only was unable to be analyzed by optical profilometry because of its 
translucent properties.  Quantification of the 3D surface roughness parameters of the 
PDMS/CSA-13 coating was performed by Metropro™ metrology software (Zygo).  
Similar to the contact angle measurements, an n=5 plates were used from three different 
lots of coated plates, and five areas per plate were imaged at a 20x magnification to 
obtain a total of 25 measurements.
6.3 Results
6.3.1 Dip Coating
Plates that were coated with PDMS only (Figure 5.3) had a final coating weight of 
75.2 ± 11.8 mg and a thickness of 83 ± 12 μm.  In contrast, plates that were coated with 
PDMS/CSA-13 (Figure 5.3B) had a coating thickness of 112 ± 17 μm and a final coating 
weight of 96.4 ± 11.8 mg.  The amount of CSA-13 per plate was calculated to be 17.2 ± 
0.61mg.  These results of dip coating were similar to those provided in Chapter 5, section 
5.3.1.
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6.3.2 Surface Analysis by SEM
SE micrographs of both coating types prior to eluting the CSA-13 out of the
coating are given in Figure 6.1. These images indicated that those plates coated with the 
PDMS only formulation had micron sized concave "dimple-like" features on the 
outermost layer.  The diameter of these dimples ranged from 1-2 μm.  Notably, it was 
confirmed that the small dimple-like structures found on the surface of the PDMS only 
coated plates were not present throughout the bulk of the coating.  This was done by 
cutting the coating with a razor blade and imaging the bulk of the polymer.  The bulk area 
had no detectable porosity, but rather had a uniform structure.  Overall, the PDMS only 
coating (Figure 6.1A) had a markedly smoother surface morphology compared to those 
that had CSA-13 in the coating.  More specifically, it is believed that the presence of 
CSA-13 created a more porous surface with small particles of CSA-13 entrapped in pores 
on the outer most surface of the coating (Figure 6.1B).  These small particles were further 
confirmed to be CSA-13 by EDX analysis (Figure 6.2).
The difference in the surface morphology of both coating types became even 
more apparent after the CSA-13 had been eluted out of the coating. The porosity of the 
PDMS/CSA-13 coating type profoundly increased (Figure 6.1C) after soaking in broth, 
whereas the PDMS only coating composition had no change in its surface morphology 
after being soaked in broth. These results indicated that the presence of CSA-13 in the 
dispersion caused various shapes and sizes of pores to form throughout the PDMS 
polymer coating as it cured.  It is believed that immiscible CSA-13 particles in the PDMS 
dispersion were physically entrapped within the polymer matrix as it cured, and as a 
consequence, pores were formed.  These pores then allowed water to penetrate the 
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coating and release CSA-13.  Importantly, when multiple coatings were cut with a razor 
blade to analyze the cross-sectional morphology of the coatings, the SEM micrographs 
confirmed that the pores were present from the outer most level down to the metal 
surface. 
BSE images that were used to calculate the porosity of the material indicated that 
the PDMS only coating had no detectable porosity (Figure 6.2, top row), whereas the 
coating with CSA-13 had 17% ± 3% porosity (Figure 6.2, middle row).  The pore sizes 
ranged from ~0.5 μm to ~20 μm with an average pore size of 5 ± 8 μm.
Because the PDMS only coating had very similar chemical constitution to CSA-
13, the only defining element that was different and detectable by EDX in the CSA-13
coating compared to the PDMS coating was chlorine (Cl).  Tetra hydrogen chloride is the 
conjugate anion of the CSA-13 compound.  Using EDX mapping with silicone and 
chlorine channels, the location and distribution of CSA-13 throughout the coating were
determined.  The EDX map for chlorine (Figure 6.2) showed that CSA-13 particles 
and/or particle aggregates were predominantly present within the pores of the PDMS film
thereby supporting that CSA-13 particles were what caused the formation of pores in the
PDMS film. These data also pointed out that the distribution of CSA-13 was uniform 
throughout the coating.
The fact that there was no detectable Cl in the top portions of the PDMS polymer 
or throughout the bulk of the polymer after soaking for 30 days in BHI (modified) broth 
indicated that all detectable amounts of CSA-13 had eluted out of the PDMS polymer 
matrix by this period (Figure 6.2, bottom row).  Importantly, EDX analysis was 
performed on one plate that had been soaked in broth for just 24 hours to determine 
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whether Cl was still present.  The data from this test indicated that Cl was present, albeit 
at reduced levels, suggesting that CSA-13 had begun to elute out of the coating.
Moreover, the microbiological data that were shown in Chapter 5 correlated with this 
finding.  More specifically, there were sufficient amounts of CSA-13 eluted from the 
coating to kill bacteria for 10-15 days.  After 10-15 days, bacteria began to grow at 
increased levels in the broth suggesting that the amount of CSA-13 that was released 
decreased gradually until it was below bactericidal concentrations.
6.3.3 Attenuated Total Reflectance Fourier Transformed
Infrared Spectroscopy
The rationale for performing ATR-FTIR was two-fold: first, to gain an 
understanding of IR active chemical bonds (functional groups) within the PDMS only 
and PDMS with CSA-13 coatings and second, to determine if any covalent linkage 
formed between CSA-13 and the PDMS polymer.  The ATR-FTIR spectra of PDMS with 
and without CSA-13 are shown in Figure 6.3. The data showed that there were specific 
differences between the two coating types.  The spectrum of PDMS/CSA-13 samples 
showed characteristic infrared scissoring absorptions of NH2+ and NH3+ at ~1450-1600
cm-1 246 as well as asymmetrical and symmetrical stretching of  -CH2 at ~2940 cm-1 and 
~2850 cm-1, respectively.246 These particular characteristic absorptions were not seen in 
samples that had PDMS only.  Importantly, the fingerprint region (between ~500 cm-1
and ~1200 cm-1) of both coating types was very consistent with what is found in the 
literature involving FTIR spectra of PDMS polymers.246-250
If any potential chemical reaction between PDMS and CSA-13 molecules had 
occurred, based on the known relativities of the functional groups of CSA-13 and PDMS,
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one may have seen the formation of Si-N and/or N-O bonds in the resultant products.  N-
O bonds would have had characteristic infrared absorption bands centered at ~1300 cm-1.
If Si-N bonds were present, they may have shown in the 700-900 cm-1 range of the 
fingerprint region.  As such, the Si-N bonds may have potentially been masked in the 
fingerprint region where Si-C absorption bands were predominant.  For this reason 
Soxhlet extraction was performed in isopropanol for a 48-hour period to elute CSA-13 
out of the coating.  After extraction of CSA-13, ATR-FTIR was performed once again 
and the spectrum was found to be identical to the PDMS only IR spectrum, thus 
indicating that CSA-13 had not covalently bound to the PDMS material.  The EDX 
analysis data further confirmed these results indicating that after CSA-13 was extracted 
from the PDMS material, it was no longer detectable.  Taken together, these data 
suggested that CSA-13 particles and/or particle aggregates were physically 
suspended/present within the PDMS matrix as opposed to being chemically cross-linked.
6.3.4 Contact Angle
Contact angle data indicated that the coating with PDMS only had a hydrophobic 
surface compared to the coating that had CSA-13.  Specifically, the PDMS only coating 
had a contact angle of 113.74° ± 4.14°.  These data were consistent with what has been 
reported in the literature previously with respect to PDMS polymers.245 The coating with 
PDMS/CSA-13 resulted in a reduced contact angle of 84.18° ± 6.33°.  When compared 
using an independent samples t test, these differences were significant (p<0.05).  This 
difference may be attributed to the presence of the positively charged CSA-13 that 
decreased the surface tension or it may have also been partially attributed to the increased 
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roughness of the surface.251,252 Taken together, these data indicated that the coating with 
CSA-13 was more wettable, which may be a unique property that aids in the dissolution 
of the CSA-13 from the coating.
6.3.5 Tensile Testing
Table 6.1 provides the results from tensile testing.  Results indicated that the 
coating with CSA-13 had a statistically significant reduction in tensile strength (p<0.05) 
as well as percent elongation (p<0.05; statistical analysis performed using an independent 
samples t test).  Furthermore, there was an increase in the initial elastic modulus of the 
PDMS material with CSA-13, which was also significantly different (p<0.05).  This 
increase suggested that the PDMS with CSA-13 was stiffer compared to the PDMS only 
films. This may be attributed to the filler effect of CSA-13 within the PDMS matrix of 
the polymer.
6.3.6 Thermal Gravimetric Analysis
The rationale for performing TGA was to determine the thermal stability of the 
PDMS only and PDMS with CSA-13 as well as determine if there were any volatile 
components that were released from each coating type.  Each experiment was run from 
room temperature to 850° C, with close attention being given to the temperature range of 
35° C - 41° C.  This temperature range was chosen because it was within the body 
temperatures of interest for sheep (in vivo model) and humans (potential coating for 
clinical applications).  Results from TGA testing indicated that both of the material types 
were heat stable up to greater than 100° C (Figure 6.4).  
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In both polymers, with and without CSA-13, the first significant onset of weight 
loss was seen at approximately 150° C.  Nevertheless, in both cases, this weight loss was 
well above the temperature range of interest, suggesting that the material was thermally 
stable in the intended use range of 35° - 41° C.
6.3.7 Optical Profilometry
Roughness data measured using optical profilometry indicated that the average 
surface roughness of the PDMS with CSA-13 was 1.30 ± 0.87 μm. In Figure 6.5, a 
representative surface topography is shown that outlines the undulating, porous surface of 
the PDMS with CSA-13.
6.4 Discussion
There are many studies in the literature that have demonstrated the antimicrobial 
efficacy of active release coatings both in vitro and in vivo.  However, aside from the 
limitations of protocols that have been employed to test these coatings, another limiting 
factor of these coatings has been that investigators often have not characterized the 
coating in order to understand their physical and chemical properties.
The goal of this work was to characterize the physical and chemical properties, as
well as determine the reproducibility of the novel active release CSA-13 coating.  Results 
showed that the incorporation of CSA-13 into the PDMS polymer did influence the 
physical and mechanical properties of the PDMS, but it did not appear that that influence 
was adverse to the desired material properties.  No chemical reactivity was observed 
between CSA-13 and the particular PDMS material that was used.  It was found that the 
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coating thickness and amount of CSA-13 in the device coating was consistent over
multiple lots of dip coated plates.  SEM data also showed that the coating morphology 
was consistent from lot-to-lot and that CSA-13 was distributed uniformly throughout the 
PDMS polymer.  
The SEM data demonstrated that CSA-13 particles resided in the pores of the 
PDMS polymer and that the CSA-13 eluted out of the surface and bulk of the polymer 
after being soaked in broth for a 30-day period.  Furthermore, SEM data indicated that 
the PDMS with CSA-13 was highly porous.  The porosity of the material was reflected in 
the reduction in tensile strength of the material.  More specifically, the pores likely served 
as points of stress that led to reduced elongation at break compared to the PDMS only 
films.  In addition, the presence of the particles and particle aggregates seemed to 
influence the stiffness of the material, perhaps by acting as boundaries that interacted 
with polymer movement as the material was pulled under tension.253,254 These particles 
and particle aggregates also appeared to influence the hardness of the material, as 
indicated by the durometer measurements.
Another point of interest was made with regard to the contact angle data that were
collected.  It has been previously suggested that bacterial cells tend to form biofilms more 
readily in patients that have an implanted device with a hydrophobic surface.255 Counter 
intuitively, however, Sousa et al.256 have shown that staphylococci cells grown on the 
surface of hydrophobic polymeric materials have a predominantly hydrophilic surface 
when measured with contact angle.  Thus, although it is believed that bacteria adhere to 
surfaces primarily by the hydrophobic effect, in their conclusion, Sousa et al. suggest that 
other factors likely influence bacterial adhesion to hydrophobic surfaces.
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Data from ATR-FTIR analysis strongly suggested that there were no other 
byproducts in the CSA-13 containing coating other than the CSA-13 additive when 
compared to the PDMS only coating.  In the ATR-FTIR data, the absorption peaks that 
were present in the spectra corresponded to the bonds that were present in both coating 
types with important differences distinguishing the presence of CSA-13 from the PDMS 
only coating.  
The results of this work indicated that the active release agent, CSA-13, was able 
to be incorporated homogeneously into a PDMS dispersion.  After plates were dipped 
into the dispersion, CSA-13 particles caused the PDMS to become porous upon curing.  
The particle and/or particle aggregate sizes in the final cured product corresponded to the 
size of the pores that they formed in the PDMS polymer.  Because the PDMS polymer 
was made porous, water was able to penetrate the pores and facilitate the dissolution and 
diffusion of CSA-13 from the surface and bulk of the coating.  Importantly, although the 
presence of CSA-13 did appear to affect the physical properties of the polymer, the effect 
was not determined significant for this particular application.  The desired mechanical 
properties of the material were maintained.  Finally, the thermal stability of both 
materials as demonstrated by TGA analysis suggested that the materials would remain 
stable in the range of body temperatures of sheep and humans.
In conclusion, several key characteristics of this novel active release coating were 
identified in this study and in the in vitro study from Chapter 5. These include 1) the 
manner by which this coating functioned is based on the fact that particles of CSA-13 are 
uniformly distributed into a medical grade PDMS, and as the PDMS cures, these particles 
create pores in the polymer network.  2) As water penetrated the porous network, it
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caused the dissolution and diffusion of CSA-13 out of the matrix.  3) As outlined in 
Chapter 5, this coating has displayed promising bactericidal activity in vitro and in 
Chapter 8 the in vivo efficacy of this coating will be shown. 4) Results showed that 
differences were seen between the PDMS only polymer and PDMS with CSA-13, but 
none of these differences suggested that they would have deleterious effects on the 
function or stability of the PDMS with CSA-13 in vivo for this particular application.  If 
this coating were to be used in applications wherein shear forces might be present, further 
data would be needed to show its stability under those forces.  Taken together, the 
thermal and mechanical stability, and antimicrobial activity of this novel active release 
coating provide significant promise for it to prevent biofilm implant-related infections 
from developing in orthopaedic and other biomaterial applications.
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Figure 6.1: SEM images of PDMS only and PDMS with CSA-13. (A) Image of the 
PDMS only coating showing the surface morphology of the polymer without CSA-13.
(B) Image of the coating that had CSA-13 in it.  (C) Image of a coating after it was 
soaked in BHI broth (modified) for 12 weeks to allow CSA-13 to elute out of it.  Note the 
extensive amount of pores that were visible after the CSA-13 had eluted out.
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Figure 6.2: BSE and EDX images of the PDMS only and PDMS with CSA-13 coatings.  
(Top Row) BSE images (Grayscale Channel) and elemental maps from EDX analysis (Si 
Channel and Si + Cl Channel) of a PDMS only coating.  Note the lack of porosity in the 
grayscale image as well as the lack of Cl in the Si + Cl channel.  (Middle Row) 
Backscatter electron images of a Si coating with CSA-13.  In the grayscale channel, pores 
can be seen.  These pores were formed by the presence of CSA-13 particles as indicated 
by the presence of Cl precisely in the pores.  (Bottom Row) Images of a coating that had
CSA-13 in it prior to the 30 day elution in BHI broth.  More than 30 areas on n=5 plates 
were analyzed by EDX including areas of coatings that were cut to the metal with razor 
blades to detect CSA-13 in the bottom regions of the polymer.  No Cl was detected in any 
of the eluted samples.
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Figure 6.3: FTIR spectra in the following graph showed the absorption peaks of radiant 
energy by organic molecules in the coating containing CSA-13 (top line) and PDMS
polymer alone (bottom line).  In the top left hand corner, images of CSA-13 and the 
PDMS are provided for the reader to see what bonds were present and how they 
correspond to the spectra.  A detailed description of the bending/scissoring that occurred, 




Table 6.1: This table shows the data that were collected from tensile testing of the PDMS 






at Break (MPa) Elongation (%)
Elastic Modulus
(MPa) 
PDMS Only 2.26 ± 0.58 2.06 ± 0.62 327.72 ± 75.68 1.24 ± 0.69
PDMS with 
CSA-13 0.90 ± 0.33 0.79 ± 0.27 215.78 ± 39.01 3.20 ± 1.39
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Figure 6.4: The following graphs were obtained after TGA was performed on the PDMS 
only and PDMS with CSA-13 materials.  (A) Graph indicating the TGA curve of the 
material that had PDMS and CSA-13.  Note that the material had no significant weight 
loss until approximately 300° C suggesting that the material was stable in the 35°- 41° C 
range.  (B) Graph indicting the TGA curve of the PDMS only material.  This material 
showed no signs of thermal degradation until approximately 380° C, also suggesting that 
it was stable in the 35°- 41° C range.
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Figure 6.5: Images collected during the optical profilometry analysis of the PDMS with 
CSA-13 coating.  (A) Two-dimensional image of the surface of a PDMS coating that had 
CSA-13 added to it.  The blue regions indicated lower areas whereas the pink areas 
indicated high points of the surface.  These surface characteristics were present in all 
samples analyzed.  The black areas that are present are those areas that had vertical 
surfaces in the polymer, which cannot be analyzed by optical profilometry because 
interference patterns do not develop.  (B) Three-dimensional rendition of the same area of 
a surface as in (A).  The black areas were more prominent, yet the model outlined the 
undulating, porous nature of the coating.
CHAPTER 7
ESTABLISHING AN IN VIVO ANIMAL MODEL OF BIOFILM
IMPLANT-RELATED OSTEOMYELITIS TO TEST
COMBINATION BIOMATERIALS USING
BIOFILMS AS INITIAL INOCULA
7.1 Introduction
The animal work presented in this chapter has been accepted for publication and a 
copy of the submitted manuscript is provided as Appendix E at the end of this 
dissertation.  According to a careful literature review, this work represents the first 
animal model in the literature that used well-established biofilms as initial inocula to 
produce a positive signal of infection.  The rationale for developing this model was 
provided in Chapter 3 and relates to Specific Aim 3 from Chapter 2, section 2.4.  In 
addition, the development of this model made it possible to test the CSA-13 active 
release coating in the definitive animal model study that will be presented in Chapter 8.
Based on the observations and information discussed in Chapter 3, it was 
hypothesized that a sizeable portion of biofilm-related infections, including those that 
accompany the use of medical devices, may be the result of contamination with bacteria 
residing in biofilms from natural ecosystems as opposed to planktonic bacteria 
contaminating a site.  If supported, this hypothesis would suggest that using biofilms as 
152
initial inocula, as opposed to planktonic bacteria, to model clinically relevant infection 
scenarios may provide deeper insight into how biofilm-related infections may be treated 
and eradicated using current or novel therapies, such as antimicrobial eluting coatings.
In an attempt to address the sporadic nature of biofilm infection development in 
animal models, wherein planktonic cells are used as initial inocula, the goal of this work 
was to test the above hypothesis and establish a reproducible experimental model of 
biofilm implant-related osteomyelitis in sheep. More specifically, in this study, biofilms 
of MRSA were grown on the surface of PEEK membranes using the membrane biofilm 
reactor discussed in Chapter 4.40 These biofilms were placed in apposition to the 
proximal medial aspect of a sheep tibia, on the bare cortical surface stripped of 
periosteum, and subsequently covered by a simulated fracture fixation plate (Figure 7.1).
As such, this study modeled a massively contaminated Type IIIB Gustilo open fracture,66
wherein, in a worst case clinical scenario, biofilms from natural ecosystems may 
contaminate a wound site and be compressed between bone and a fracture fixation 
plate.257,258
7.2 Materials and Methods
7.2.1 Biofilm Growth
The growth of biofilms in this project was the same as the growth of biofilms in 
all previous studies of this dissertation.  These methods can be found in Chapter 4. To 
transport these membranes, they were kept in 5 mL of BHI broth (modified) and removed
aseptically when they were ready to be placed in apposition to the bone of a sheep.
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7.2.2 Stainless Steel Plates
The SS plates used in this study were machined from the same medical grade 
316L SS and with the same dimensions as those plates presented in Chapter 5 (see 
Figure 5.1).  Prior to implantation, these plates were cleaned and passivated following 
ASTM standard F86-04, then sterilized by autoclave.  Note: no plates were coated with 
PDMS or CSA-13 for this pilot work.
7.2.3 Surgical Procedure and Postsurgical Monitoring
All animal work was performed with approval from the Institutional Animal Care 
and Use Committee (IACUC) and the Environmental Health and Safety (EHS) 
department at the University of Utah.  For this study, 2-3-year-old female Columbia 
Cross sheep, weighing 90 ± 20 kg, were selected.  This species of sheep has a flat area of 
bone on the proximal medial aspect of the tibia with a surface area that was suitable for 
securing of the plates with transcortical screws.  A total of n=10 sheep were used in this 
study with n=5 being treated with biofilm to serve as positive controls of infection 
(Group 1), and n=5 serving as negative controls of infection (Group 2).  The 5 negative 
control sheep were treated with PEEK membranes that had been run through the 
modified CDC biofilm reactor without bacterial inoculation.  
Prior to surgery, the sheep were fasted for >12 hours.  Since the goal of this work 
was to develop a positive signal of infection, no antibiotics were administered.  Sheep 
were initially anesthetized using an intravenous (IV) injection of either ketamine (5 
mg/kilogram (kg)) and diazepam (0.5 mg/kg) or propofol (3-7 mg/kg) to allow for 
endotracheal tube intubation.  Following intubation, the sheep were placed in the supine 
154
position and maintained under anesthesia with isoflurane to effect (ranged from ~2-3%).  
An IV catheter was placed in the left forelimb and 0.9% saline was administered at a rate 
of 10 mL/kg/hour (hr).  Veterinary surgical and equipment technicians monitored the 
sheep’s heart rate, temperature, carbon dioxide and oxygen levels, and respiration 
throughout the procedure.
The right hind limb of each sheep was circumferentially clipped free of hair/wool, 
from immediately above the hoof to the groin, and then scrubbed and prepped with 
betadine and alcohol treatment.  The hoof was isolated in a sterile rubber glove and 
wrapped with sterile VetWrap (Fisher Scientific).  After sterile draping, the proximal 
medial aspect of the leg and the region of the incision was treated with Chloraprep 
(Fisher Scientific) solution to further sterilize the skin.
An anterior midline sagittal incision was made from the region of the tibial 
tuberosity and extending distally, parallel to the anterior margin of the tibia.  This 
incision was placed away from the plate and biofilm implantation site to avoid 
contamination of the site during wound healing.  Dissection was carried medially and 
posteriorly, close to the bone, lifting the skin with the attached subcutaneous tissues from 
the surface of the medial tibial flare.
Since this study modeled a Type IIIB Gustilo open fracture—which may consist 
of periosteal stripping, bone exposure and massive contamination66—a 2 cm x 5 cm area 
of periosteum was removed from the proximal medial aspect of each sheep tibia (Figure 
7.1A).  On the bare cortical surface, the positions of a proximal and distal plate were 
templated by sequentially drilling and placing transcortical screws through a SS plate.  
The screws were not tightened at this stage.  This technique allowed compensating for 
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any irregularity in the “flat surface” of the tibia, tapped each hole and prevented thread 
stripping in the thin bone.  This prepositioning avoided spurious contamination of the site 
when placing the infectious biofilm.
A PEEK membrane (with or without biofilm, depending upon the animal group) 
was aseptically removed from the 5 mL of BHI broth (modified) using sterile forceps.  
The corner of the membrane was touched against a sterile towel, removing excess broth 
but not biofilm, and preventing broth from contaminating the surgical field.  The 
membrane was placed into the well of a SS plate and the fluid that remained on the 
membrane allowed it to adhere to the metal plate due to fluid cohesive forces.
Using careful, aseptic technique, the SS plate/PEEK membrane construct was 
placed in apposition to the tibia with the PEEK membrane residing between the bone and 
plate.  Each plate was secured to the bone using 2.7 mm diameter x 10 mm length cortical 
bone screws (self tapping; catalog #ST270.10, Veterinary Orthopaedic Implants).  This 
process was performed twice in each sheep such that each sheep was treated with two 
PEEK membranes and two plates (Figure 7.1B).  The rationale for using two plates was 
to have one available for microbiological analysis and one for histological analysis at the 
end of the study.  To the best of the surgeons’ ability, the two plates had a space of ~1cm 
between them. However, anatomical variation existed amongst the sheep and not all 
were able to maintain exactly 1 cm of space between them.
After plate placement, a swab of the cortical bone surface was collected to 
determine if bacteria had already begun to dislodge away from the biofilm on the PEEK 
membrane.  The surgical site was closed with interrupted 2-0 Vicryl (catalog #J339H, 
Ethicon) subcutaneous sutures and a running subcuticular 2-0 Proline (catalog #8533H, 
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Ethicon) suture.  A swab of the incision site was taken to determine if bacteria were 
present on the skin.  Prior to wrapping the surgical site, the leg was cleaned with saline 
and isopropyl alcohol to kill bacteria that may have been present on the skin.  This helped 
to reduce the risk of cross contamination throughout the animal facility and between 
animals.
For postoperative analgesia, each sheep was given an epidural dose of morphine 
(0.1 mg/kg) and two fentanyl patches (100 μg/hr) were placed in a shaved area on the left 
forelimb.  An injection of flunixin (1.1 mg/kg) was administered to diminish 
inflammation.  Postanesthesia monitoring extended until the animals could stand on their 
own, as well as eat and drink.
7.2.4 Surgical Follow Up
Throughout the course of the study, each sheep was monitored by the author and 
his team and a veterinarian in the animal quarters to assess any symptoms of pain and 
distress.  Under veterinary supervision, animals that showed signs of pain or distress were 
treated with Buprenex (0.01 mg/kg) or additional fentanyl patches.  If excessive 
inflammation was present, they were further treated with rimadyl (4.4 mg/kg).
Using a clinical grading system, based on the hallmarks of infection: calor (heat), 
rubor (redness), dolor (pain), and tumor (swelling), the sheep were monitored daily for a 
12-week period for these signs of infection.  A daily rectal temperature of each sheep was
taken.  The animals were also monitored for limping, lethargy, irritability, and going “off 
feed” and/or water.  Based on these criteria, a four-tiered clinical grading system was 
established.  
157
Grade I, or no infection, consisted of the signs of healing normally seen with 
surgical trauma and that resolved within 1 to 2 weeks of surgery.  These signs included 
slight redness at the surgical site, mild warmth (to the touch), mild inflammation, a closed 
suture line, healed within 2 weeks, the sheep eating and drinking, a normal rectal 
temperature (for these sheep normal temperature was between 101.5° Fahrenheit (F) and 
102.8° F), and no signs of distress or limping.  A Grade II infection included increased 
redness, a warmer surgical site with moderate inflammation, evidence of suture line 
dehiscence, irritable behavior, normal temperature and not limping.  Sheep were 
euthanized if they displayed signs of a Grade III infection.  This grade was characterized 
by significant redness and palpable heat at the surgical site, an open suture line with 
drainage, significant inflammation, tenderness, lethargy, fever, off feed and/or water, and 
positive bacterial growth on wound culture.  A Grade IV infection was defined, but never 
allowed to develop in any of the animals.  This included excessive heat, excessive 
inflammation, purulent drainage, implant exposure, excessive limping, local tenderness, 
off feed and/or water, lethargy, and fever.
7.2.5 Bone Labeling
As stated by Bloebaum et al.,259 “Fluorochrome labeling is a well established 
method of measuring the mineral apposition rate (MAR), at which osteoid matrix, 
produced by osteoblast cells, is deposited and mineralized to form new bone.”
In this study, calcein fluorochrome (catalog #C-0875, Sigma-Aldrich) was used as 
a nonantibacterial agent to label bone and to calculate the MAR, i.e., the growth rate of 
the sheep bone and also provided an indication of bone viability.  The method by which 
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this works is after the calcein is injected, it is taken up by osteoblast cells and released 
into the matrix of newly forming bone.  After processing, calcein fluorochrome can be 
observed in tissue samples as they are imaged using an excitation wavelength of 495 nm 
and emission of 515 nm.  The imaging that was performed in this study is described in 
section 7.2.10.
Calcein was prepared in reverse osmosis water to a final concentration of 30
mg/mL.  The pH was adjusted to 7.2-7.4, filtered using a 0.22 μm filter for sterility and 
the solution administered IV at 0.33 mL/kg of body weight.  Two separate injections 
were given: one 16 days and one 5 days prior to the established 12-week end point of 
each sheep to create a double label in the bone as well as label viable bone.  The infected 
sheep that were euthanized prior to the 12-week end point did not receive calcein 
injection.
7.2.6 Euthanasia and Microbiological Sample Collection
Sheep were euthanized at the end of 12 weeks, or once a Grade III infection was 
determined to exist.  To euthanize, animals were initially sedated with an IV injection of 
ketamine (5 mg/kg) and diazepam (0.5 mg/kg) in order to collect a 5 mL blood sample 
for microbiological analysis.  Euthanasia was then performed by IV injection of 
beuthanasia (1 mL/4.5 kg) solution.
A swab of the incision site (~1 cm2 area) was taken and streaked onto Columbia 
blood agar for semiquantitative analysis.  More specifically, 1+ growth was defined as 
having growth in the first zone of streaking, 2+ having growth in the second zone and 3+ 
having growth in the third zone.  The agar plate was incubated overnight at 37° C.  Next, 
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the skin at and surrounding the incision site was prepped using chlorhexidine/isopropyl 
alcohol antiseptic.  A scalpel was used to aseptically reopen the incision site and a swab 
of the subdermal tissue was collected to determine if bacteria had penetrated into the soft 
tissues superficial to the plates and PEEK membranes.  This swab was also cultured on 
Columbia blood agar.
One of the SS plates was randomly selected and the underlying PEEK membrane 
was removed and placed into 5 mL of 10% BHI broth (modified).  The sample was
vortexed for 1 minute, sonicated for 10 minutes and allowed to recover in the broth at 
room temperature for 20 minutes (to allow the bacteria to convert from the biofilm to 
planktonic phenotype) before performing a 10-fold dilution series (plated in duplicate) to 
quantify the number of CFU/PEEK membrane.  
The SS plate that had been removed was then secured to the bone once again so 
that radiographs could be taken.  The tibia was then disarticulated and used for gross 
photographic and radiographic analysis.
7.2.7 Gross Photography/Radiography
Gross photography of the soft tissues and bone were collected throughout the 
sampling/dissection process.  Radiographs were obtained using a cabinet x-ray system 
(43855A Model, Faxitron X-Ray Corporation) set at 70 kilovolts (kV) for 2 ½ minutes.  
7.2.8 Tissue Embedment/Sectioning
After radiographic imaging, all of the soft tissue was dissected from the bone with 
the exception of the tissue that was directly over the undisturbed SS plate.  The sample 
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was then fixed in modified Karnovsky’s fixative260 using 3 x 24-hour changes.  
Following fixation, the bone was rinsed in reverse osmosis water for 10 minutes and cut 
into two sections separating the two SS plates from one another.  The plate that had been 
removed in order to access the PEEK membrane for microbiology was again removed 
and the biofilm on the underlying bone imaged with SEM.  The remaining bone section, 
with plate and PEEK membrane intact, was used for histological analysis.
After cutting, both bone samples were placed in 70% ethanol for 24 hours to 
initially dehydrate them.  The bone for SEM imaging was further dehydrated by hand 
using ascending concentrations (from 70%, to 95% to 100%) of ethanol, then coated with 
gold using a Hummer 6.2 sputter coater and imaged using SEM.
The bone sample for histology was also dehydrated using increasing 
concentrations of ethanol.  However, this was performed in a Tissue-Tek VIP (Miles 
Scientific) instrument.  It was then placed into a solution of 80% methylmethacrylate and 
20% N-butyl (the combination of these two solutions is referred to as Solution A), and 
mixed for 5 days to infuse the tissues.  The Solution A was poured out and a fresh aliquot 
of Solution A, mixed with 2.5 g/Liter (L) of perkadox (the catalyst for polymerization), 
was added to the sample.  The sample was kept in a dessicator at 4° C for 7 days.  
Finally, 5 g/L of perkadox was added to another batch of fresh Solution A and exchanged 
for the used mixture in the container and the sample was kept in a desiccator at 4° C for 
an additional 9 days.  Samples were then placed in a new container and Solution A with 5
g/L of perkadox was added and polymerized in 2 cm layers using ultraviolet light.  Each 
layer required 48 hours to fully polymerize.  The final product resulted in a PMMA
embedded sample containing the bone, PEEK membrane, stainless steel plate and soft 
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tissue regions. This embedment procedure has been published by Dr. Bloebaum's group 
previously.261-265
Once embedded, tissue samples were cut using a band saw to remove excess 
PMMA and isolate the area of interest.  Samples were further sectioned into ~2 mm 
sections using a diamond blade water saw.  Radiographs of the sections were obtained 
following the same procedure outlined above.  One face of a section was then polished, 
and gold coated for SEM analysis.   
7.2.9 SEM Analysis
SEM analysis was performed using a JEOL 6100 LaB6 filament SEM to 
qualitatively examine bone and/or biofilm morphology in the region where a SS
plate/PEEK membrane construct was implanted.  For those bone samples that had the SS 
plate removed, secondary electron images were collected of the cortical bone surface to 
examine the morphology of the bone and/or biofilm where the PEEK membrane had been 
present.  For those samples that were sectioned in PMMA, BSE images were collected to 
examine the varying levels of mineralization, how the infection influenced the periosteal 
response in bone, and cortical bone activity.
7.2.10 MAR Analysis
The procedure for collecting MAR data was based on the published work of 
Bloebaum et al.257 In short, after sample sections had been imaged using SEM, the 
polished surfaces were glued to a slide and further ground to ~50-60 μm thickness for 
MAR analysis.  Images were first collected using a mercury lamp Nikon Labophot 
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microscope to detect the presence of calcein double-labeled osteons of the host bone.  
Three slides from each sheep were analyzed.  From each slide, five osteons were 
randomly selected in the cortical/periosteal bone region beneath a SS plate and a total of 
eight measurements were made along the span of each double label using ImagePro Plus 
















n is the total number of 
measurements, and t is the time interval between calcein injections expressed in days.
7.2.11 Histology
For histological analysis, sample slides were further ground to a thickness of 40-
50 μm and stained with hematoxylin and eosin (H&E) stain.  For H&E staining, Mayer’s 
solution was preheated to 50° - 55° C.  Slides were placed in the Mayer’s solution for 5 
minutes, rinsed and dried.  Slides were then placed in Clarifier for 4 minutes, rinsed, 
placed in Bluing Reagent for 4 minutes, rinsed again and dried with a Kimwipe.  Finally, 
slides were counterstained by dripping Acid Fuschin/5% Acetic Acid solution for 35-45 
seconds and dipped in 100% ethanol for 30 seconds.  
Macroscopic images of slides were collected using a Nikon SMZ800 macroscope.  
Higher magnification images were collected using a Nikon Eclipse E600 microscope.  
Using a modified histopathologic grading scale of Smeltzer et al.,234 an outside observer, 
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who was blinded to the samples in the study, examined the slides to determine what level 
of osteomyelitis was present in the bone and or surrounding tissue regions.  Osteomyelitis 
was indicated by the presence of bacteria, as determined by the microbiological analysis, 
in conjunction with chronic inflammation and bone necrosis.  Cortical bone 
growth/response was not an indicator of infection as it was present in all five sheep from 
Group 1 and three from Group 2.  Thus, it appeared to be a normal bone response to the 
surgical trauma and implantation.  The modified Smeltzer et al. grading scale is provided 
in Table 7.1.
7.2.12 Statistical Analyses
From a Kaplan-Meier survival curve, a Log-Rank test was used to examine the 
statistical significance in survival times between those sheep treated with biofilm and 
those that were not.  A separate Log-Rank test was used to compare the time it took for 
animals in both groups to become infected.  Time to infection differed from survival time 
since some sheep in Group 1 survived the full 12 weeks of the study, but displayed signs 
of infection very early on.  
Because the number of bacteria collected from PEEK membranes of those sheep 
in Group 1were not normally distributed, the nonparametric Mann-Whitney U test was 
used, as opposed to a student's t test, to compare the number of bacteria that were 
collected on the PEEK membranes of Group 1 and Group 2 animals.  In all instances, an 
alpha level of 0.05 was established to define statistical significance.  All statistical data 
were analyzed using SPSS 17.0 software.
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7.3 Results
7.3.1 Surgical Follow Up
A survival curve including each of the 10 sheep in this study was plotted using a 
Kaplan-Meier survival curve (Figure 7.2A).  Two of the five sheep in the biofilm treated 
sheep (Group 1) were euthanized at 3 weeks due to a Grade III infection.  The other three 
survived to the 12-week end point, but each of those three sheep displayed Grade II signs 
of infection during the 12-week monitoring period.  Furthermore, each of the five sheep 
in Group 1 displayed signs of inflammation and abscess formation between day 4 and 11 
after surgery.  In contrast, all five of those sheep in Group 2 survived to the 12-week end 
point with minimal acute inflammation and no signs of infection at any point in the study.  
The Log-Rank test indicated that the difference in survival among the two groups was not 
significant (p=0.184).  However, when time to infection was analyzed, there was a 
significant difference (p=0.002) between the groups (Figure 7.2B).  This difference 
corroborated with the microbiological data.
7.3.2 Microbiology
Microbiological data showed that PEEK membranes collected from Group 1 
sheep contained an overall log density of 5.32 ± 5.41 log10 CFU/PEEK membrane.  No 
bacteria were detected on the PEEK membranes of Group 2 sheep.  When compared 
using the Mann-Whitney U test, this difference was statistically significant (p=0.008).  
All of the swabs taken from all animals showed between 1+ and 2+ growth of 
normal flora bacteria at the incision site.  In three out of five of the Group 1 sheep, 
subdermal swabs detected 2+ growth of bacteria in the tissues surrounding the SS plates, 
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whereas swabs taken of the remaining two sheep detected no growth of bacteria.  All of 
the culture swabs collected from Group 2 sheep were negative for growth.
These data indicated that the microbiological findings correlated with the clinical 
observations of the sheep, wherein those treated with biofilm (Group 1) suffered a Grade 
II or higher infection, and those not treated with biofilm (Group 2) did not suffer from 
infection.  
Notably, when removing the SS plates for microbiological analysis, it was 
observed that in each of the five Group 1 sheep, the bone screws had become completely 
loose and in one animal the plates had even shifted position.  This was due to bone 
resorption around the screws, which was a result of infection as indicated by SEM 
analysis and histological results (see sections 7.3.4 and 7.3.6).  No screw or plate 
loosening was observed in Group 2 sheep and it was also interesting to observe that in 
Group 2 sheep, the cortical bone began to grow on/attach to the PEEK membranes, which 
made it difficult to remove them for quantification.  In contrast, the PEEK membranes in 
the infected sheep had no attachment of bone to them and were easily removed.    
7.3.3 Gross Photography/Radiography
Gross photographs provided evidence that an abscess formed in the surgical area 
of Group 1 sheep, whereas no abscess formation was seen in sheep from Group 2 (Figure 
7.3).  Furthermore, signs of infected tissue, including pus and significant inflammatory 
and cortical bone response, could be seen in Group 1 sheep once the skin was resected 
(Figure 7.3B). In contrast, only a thin membrane of tissue grew over the plates in Group 
2 sheep with minimal periosteal/cortical bone response (Figure 7.3D).
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Radiographic evidence also suggested that in Group 1 sheep, “moth eaten,” 
osteomyelitic bone was visible (Figure 7.4A).  This result was particularly apparent in the 
microradiographs that were taken of bone sections after they had been embedded and cut 
(Figure 7.4B).  From these sections a significant cortical bone response and an endosteal 
response indicative of responsive new bone formation could be seen in Group 1 sheep.  
No such response was seen in Group 2 (Figure 7.4C, D).
7.3.4 SEM Analysis
Due to the natural complexity of the cortical bone surface of sheep and 
components that resembled bacteria, it was difficult to confirm that there were biofilm 
dwelling bacteria on the cortical bone surface of Group 1 sheep using SE electron SEM 
imaging.  Although it did appear that the bone surfaces of Group 1 sheep had more 
degradation and trauma when compared to the bone surfaces of Group 2 sheep, the 
differences were not deemed substantial enough to support any conclusions.  On the other 
hand, BSE images of the bone sections were much more indicative of bone trauma and 
infection.  
More specifically, in Group 1 sheep, BSE images indicated that there was a 
considerable amount of bone resorption directly underneath the stainless steel plate 
(Figure 7.5A) and near the bone screws (Figure 7.5B), which supported the observation 
mentioned above that these screws were loose, whereas no signs of bone resorption were 
apparent in any sheep from Group 2 (Figure 7.5C, D).  Furthermore, a much larger gap 
was seen between the cortical bone surface and plate of Group 1 sheep when compared to 
Group 2.  More specifically, the distance from the bone to the plate surface in Group 2 
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was ~20-50 microns, whereas in Group 1 the gap was much larger and ranged from 200-
800 microns.  As will be seen in the histopathological results, this larger gap in Group 1 
sheep was due to fibrous tissue formation and chronic inflammation, which the 
microbiology data confirmed to be the result of infection.
7.3.5 MAR/Bone Viability Analysis
MAR results indicated that in Group 1 sheep, the average bone remodeling rate 
was ~1.5 μm/day.  In Group 2 sheep the average rate was ~1.2 μm/day.  Images of 
double labels in the periosteal regions of Group 1 sheep showed that an intense 
remodeling response was present (Figure 7.6A).  However, typical double labels of 
osteons were seen in the cortical bone regions (Figure 7.6B). No significant response 
was seen in the periosteal regions of sheep in Group 2 and osteon structures were present 
in the cortical bone region indicative of remodeling (Figure 7.6C, D).  Notably, calcein 
double labels further indicated bone viability.
7.3.6 Histology
Sections stained with H&E showed that there was an observable difference 
between the bone and soft tissues of Group 1 and Group 2 sheep.  More specifically, 
when compared to the modified Smeltzer et al. histopathological grading scale (Table
7.1), the three sheep in Group 1 that survived to the 12-week endpoint displayed signs of 
a Grade 4 osteomyelitis as indicated by moderate to severe chronic inflammation with 
significant intramedullary fibrosis and multiple foci of sequestra (Figure 7.7). These 
sheep also displayed Grade 3 cortical bone growth.  The other two sheep in Group 1, 
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which survived to 3 weeks, displayed Grade 3-4 osteomyelitis with Grade 2 cortical bone 
growth.  None of the five sheep in Group 2 showed signs of osteomyelitis and were 
scored with a Grade 0 osteomyelitis.  However, three of the five sheep in Group 2 did 
display Grade 2 cortical bone growth, whereas the other two were scored with Grade 0 
cortical bone growth.  Taken together, these results suggested that cortical bone 
growth/response could have been due to surgical trauma or the presence of infection, yet 
a notable difference in bone morphology was present in those that were infected versus 
those that had a response due to surgical trauma.  More specifically, those that had 
infection showed signs of “moth eaten” bone that had jagged edges due to 
resorption/bacterial presence, whereas those with a cortical bone response due to surgical 
trauma had woven bone formation with little indication that resorption was occurring.
7.4 Discussion
Using biofilms as initial inocula in this study addressed three major limitations, 
which were outlined in Chapter 3, that may accompany the use of planktonic bacteria in 
animal models of infection.  These animal models include those that are designed to 
develop combination products of biomaterial coatings and other antimicrobials.  To 
reiterate, these three limitations are 1) Planktonic cells may be cleared by the immune 
system more readily than cells residing in a biofilm.  Thus, when planktonic cells are 
used in in vivo models, it may be that they are eradicated before they can form biofilms.  
As mentioned, this may contribute to the low reproducibility for the induction of 
osteomyelitis.  2)  It is becoming ever more evident that planktonic bacterial cells are 
more susceptible to antibiotics than those residing in a biofilm.  If antibiotics are 
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administered prophylactically immediately following inoculation, they may affect 
planktonic bacteria more effectively and rapidly than they would biofilm bacteria.  3)  
When planktonic bacteria are added to the body, the possibility exists for them to be 
dispersed rapidly away from the site of initial inoculation due to the presence of flowing 
fluids in the body.  This could dilute the concentration of bacteria per given area—
potentially making it easier for the body to handle the bacterial load and prevent biofilm 
formation in the tissue or on a medical device.
Notably, osteomyelitis developed in all five sheep from Group 1 of this study
treated with biofilm, which strongly supported the hypothesis that using biofilms as 
initial inocula would cause infection.  The hypothesis was further supported, and the data 
made significantly stronger, by the fact that none of the sheep from Group 2 became 
infected.  This 100% vs. 0% rate of infection provided a promising outcome for future 
tests of combination biomaterials for device development to be performed in a repeatable 
fashion using this model.  
Despite these promising results, there is one crucial factor to take into 
consideration.  In the above study, biofilms were grown for a 48-hour period, rinsed to 
remove loosely adherent or nonadherent cells, and transferred in a broth solution prior to 
using them as initial inocula.  These steps were undertaken in an attempt to reduce the 
possibility of having planktonic cells present.  However, the potential still existed that a 
portion of cells present could have been in the planktonic phenotype.  As such, the 
question may arise: was it the biofilm bacteria or the planktonic bacteria that caused 
infection?  Two responses can be given.
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First, it is likely impossible with current technologies to separate all planktonic 
bacteria from those that reside in the biofilm phenotype such that an inoculum with 
biofilm bacteria alone is absolutely definitive.  Yet, it is also unlikely that such a distinct 
separation exists between planktonic and biofilm bacteria in natural ecosystems.  This 
may suggest that using an inoculum that has a mixture of the two, with those in the 
biofilm phenotype being more heavily selected, is clinically relevant.  
Second, an additional animal model of infection has recently been developed in 
Dr. Bloebaum's lab to test the ability of the same MRSA strain as was used in this study 
to cause infection when inoculated in the planktonic phenotype.  When the onset of 
infection was compared between these two animal models, there was a drastic difference 
in the rapidity and severity of infection that set in with the planktonic bacteria.  In that 
instance, none of the animals survived past 11 days.  In contrast, those that were treated 
with biofilms as initial inocula displayed signs of infection that were much less severe 
and which progressed at a much slower pace.  More specifically, those animals displayed 
limited signs of pain or distress even out to 12 weeks, but each of them developed
significant osteomyelitis.
This contrast in the speed and severity of infection may provide clinical evidence 
that using biofilms as initial inocula is more correlative to biofilm-related infections that 
are present in patients.  In patients, biofilm-related infections appear to be latent 
infections that develop slowly over time and which may persist for extensive periods.  
This may be due to the quiescent nature of biofilms and the fact that they have already 
established a community.  Planktonic bacteria have yet to develop a community and it 
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appears that their “goal” in nearly every ecosystem is to find a location to colonize and 
then begin to develop a biofilm community.  
So although this animal model provides a promising step in the direction of using 
biofilms as initial inocula, there are many factors to take into account: a host’s health, the 
pathogenicity of an organism, the ability for an organism to develop into a biofilm, the 
degree of contamination, and the ratio of cells in the planktonic phenotype to those in the 
biofilm phenotype.  Thus, this issue of planktonic vs. biofilm infection is still a limitation 
and will require additional future testing to overcome the challenges of separating the 
bacterial phenotypes before more definitive statements can be made.
Nevertheless, the biofilms in this study appeared to have a gradual adverse,
localized clinical effect on the sheep.  More specifically, osteomyelitis developed slowly, 
and persisted without significant signs of distress in 3 of 5 of the animals in Group 1.
Importantly, there were no sclerosing agents used in this study to promote the 
development of osteomyelitis, whereas in previous studies these noxious agents have 
been commonly used to initially kill bone and/or tissue with the intent to make it more 
susceptible to infection.  In addition, the model in this study also appeared to circumvent 
the problem of low reproducibility for the induction of osteomyelitis, which was cited by 
Gaudin et al. as an important limitation of animal models of osteomyelitis.  
In two of the sheep from Group 1, bacteria were not detected in the surrounding 
tissue regions of the stainless steel plate.  This was likely due to the limited area of 
sampling with the swab culture technique.  Bacteria may not have been in those tissue 
regions, and thus were not detected.  However, bacteria were collected from the PEEK 
membranes of both of these sheep, which corroborated with the SEM, MAR and 
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histopathological data—all of which supported the conclusion that biofilm-related 
infection had developed. 
At least three limitations accompanied this study and will need to be addressed 
with future work.  First, these results are based on the use of a single species of 
microorganism and although the outcomes are hypothesized to be similar to other biofilm 
forming organisms, different organisms may lead to different results.  More specifically, 
although S. aureus is a common cause of metal, device-related infections,59 a wide 
variety of other organisms can cause biofilm-related infections including P. aeruginosa, 
E. faecalis, coagulase negative staphylococci, E. coli, Acinetobacter baumanii, Klebsiella 
pneumoniae and others.  Second, these results will need to be confirmed with other 
material types.  For example, at least one study has shown that titanium implants have 
reduced infection outcomes when compared to stainless steel.266 Third, as this was a 
developmental model to test the ability of biofilms to cause infection, antibiotics were not 
used.  However, if this were a clinical scenario, prophylactic antibiotics would have 
accompanied the implantation of the devices.  Thus, future work will be needed to 
address these limitations.
In conclusion, after a careful literature review and consultation with various 
researchers in the biofilm research community, this appears to be the first animal model 
utilizing well-established, characterized biofilms of MRSA that were grown under fluid 
sheer conditions as initial inocula to produce a positive signal of reproducible biofilm-
related infection.57 As such, the model provides a promising outcome in that it may be 
used by future researchers and clinicians to utilize a reproducible model to examine the 
therapeutic potential of novel systemic antimicrobials and/or antimicrobial coatings on 
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biomedical devices to treat and prevent biofilm-related osteomyelitis, as well as other 
biofilm-related infections.  It may be that the use of this and similar animal models using 
biofilms as initial inocula will result in an important shift in the field of biofilm research 
that adds onto the work that has been done with planktonic bacteria.  This shift may lead 
to the development of novel antimicrobial therapies, such as coatings on devices, that 
could help prevent biofilm-related infections in a more effective manner.  In short, the 
development of this experimental model may have tremendous implications in the future 
of biofilm implant-related infection treatment strategies as well as other biofilm-related 
infections.
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Figure 7.1: Photographs taken during the surgical procedure that was used to secure SS 
plates to the proximal medial aspect of one of the pilot animals.  (A) Photograph of the 
proximal medial aspect of the right tibia demonstrating removal of a 2cm x 5cm area of 
periosteum using a periosteal elevator.  A template was used in each sheep to standardize 
the 2cm x 5cm area that was removed.  (B) Photograph of the final construct with two 
stainless steel plates secured to the proximal medial aspect of the tibia.  There was a 
~1cm gap existed between the two plates and each of the plates had a PEEK membrane in 
the underside well in direct apposition to the bare cortical bone surface.
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Table 7.1: Histological parameters and scoring system.
Intra- and peri-osseous chronic inflammation
0  Not present
1  Minimal to mild chronic inflammation with no significant fibrosis
2  Moderate to severe chronic inflammation with no significant fibrosis
3  Minimal to mild chronic inflammation with significant fibrosis
4  Moderate to severe chronic inflammation with significant fibrosis
Bone necrosis
0  No evidence of necrosis
1  Single focus of necrosis without sequestrum formation
2  Multiple foci of necrosis without sequestrum formation
3  Single focus of sequestrum
4  Multiple foci of sequestra
Cortical bone response
0  No cortical bone response
1  Cortical bone growth that does not extend beyond plate border
2  Cortical bone growth that begins to extend beyond plate border
3  Cortical bone growth that covers a plate part way 
4  Cortical bone growth that covers a plate entirely
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Figure 7.2: Kaplan-Meier curves indicating the survival and time to infection of each 
pilot animal.  (A) Kaplan-Meier survival curve for each sheep in Group 1 and Group2.  
(B) Kaplan-Meier curve of the time it took for each sheep to display signs of infection.
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Figure 7.3: Photographs of sheep tibiae that were taken during necropsies.  Left column: 
photographs of a sheep treated with biofilm.  Right column: photographs of a sheep not 
treated with biofilm.  (A) Representative photograph of the proximal medial aspect of a 
sheep tibia from Group 1 that suffered from infection.  In this particular sheep, this 
abscess developed on day 11 postsurgery.  (B) Once the skin was resected from the 
infected sheep shown in Figure 24A, pus could be seen as well as a significant cortical 
bone/periosteal response in the infected region.  This sheep had positive growth for 
MRSA.  (C) Additional photograph of a sheep tibia from Group 2.  No abscess formation 
was seen in any of the sheep from Group 2.  (D) Once the skin was resected away from 
the sheep tibia shown in Figure 24C, a thin, fibrous membrane was observed to have 
grown over the stainless steel plates.  In addition, the bone had grown up to the edges of 
the plates and no further (Grade 0 cortical bone growth).  The plate that was removed was 
used for microbiological analysis.  No bacteria were detected in/on the tissues or on the 
PEEK membrane.
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Figure 7.4: Radiographs that were collected from pilot sheep at the time of necropsy.  
Left column: radiographs of a sheep treated with biofilm.  Right column: radiographs of a 
sheep not treated with biofilm.  (A) Macroradiograph of the tibia of the sheep 
photographed in Figure 24A.  From this radiograph, the authors were able to detect signs 
of “moth eaten,” osteomyelitic bone.  Similar radiographs were collected from all sheep 
in Group 1.  (B) Once the bone was embedded and sectioned, microradiographs of the 
same sheep from (A) indicated that in addition to mothy cortical bone, a significant 
endosteal response was also present suggesting that infection was present in the 
medullary canal.  (C) No “moth eaten” bone was detected in the radiograph of the sheep 
tibia from Figure 24C.  This same result was seen in all of the sheep from Group 2.  (D) 
Microradiographs of the embedded, sectioned samples from the sheep presented in (C) 
suggested that there was no endosteal or cortical bone response.
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Figure 7.5: SEM images of bone screws and resorption patterns in representative pilot 
sheep.  Left column: BSE images of a sheep treated with biofilm.  Right column: BSE 
images of a sheep not treated with biofilm.  Original magnification for all images was 
20x.  (A) Representative BSE image of a cortical bone surface underneath a stainless 
steel plate of an infected sheep.  Note the resorption away from the bone screw and plate 
itself as well as the abnormal morphology (wispy, moth eaten appearance) of the bone, 
which was believed to be a result of infection.  Darker bone was indicative of bone that
was not yet mineralized, but rather, undergoing remodeling.  (B) Additional BSE image 
from the same sheep as (A) with bone resorption occurring in the distal area of the bone 
screw.  (C) Additional representative BSE image of cortical bone beneath a stainless steel 
plate in a sheep that was not infected.  Note the smooth, morphologic difference in this 
bone compared to that of bone shown in (A).  This bone grew up to the surfaces of the 
bone screw and plate with normal bone morphology.  (D) BSE image of the distal region 
of a bone screw in a sheep from Group 2.  No signs of resorption were present. 
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Figure 7.6: MAR images of periosteal regions and cortical bone regions of pilot sheep.  
Left column: double label images of sheep bone treated with biofilm.  Right column: 
double label images of sheep bone not treated with biofilm.  Original magnification of all 
images was 20x.  (A) Image of calcein double labels in a region directly underneath a 
stainless steel plate of an infected sheep.  This type of remodeling was indicative of bone 
that was attempting to remodel in the presence of infection.  (B) Cortical bone region 
more distal to the stainless steel plate than the image collected in (A).  This image 
indicated that in addition to areas of intense remodeling, there were areas of typical bone 
remodeling within the cortical bone of sheep that were infected.  (C) For comparison, this 
image of calcein double labels was taken in the same region as the image from (A), but in 
a sheep that was not infected.  (D) Also for comparison, this image of calcein double 
labels was taken in the same region as (B), but in a sheep that was not infected.  
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Figure 7.7: Images of histological sections indicating the bone response, sequestrum 
formation and inflammation in representative pilot sheep.  Left column: images of H&E 
stained bone sections from a sheep treated with biofilm.  Right column: images of H&E 
stained bone sections from a sheep not treated with biofilm.  (A) Macroscopic image of 
bone from an infected sheep.  Note the significant cortical bone response, the gap 
between the plate and bone surface, the endosteal bone response and the focus of 
sequestrum in the periosteal region.  Taken together, these tissue responses were 
indicators that infection was present.  Original magnification was 10x.  (B) Microscopic 
image of the sequestrum seen in (A).  The sequestrum had a jagged surface (sign of 
resorption) and large amounts of inflammatory cells in its surroundings; indicators that 
bacteria were present and that chronic inflammation had persisted.  Original 
magnification was 20x.  (C) Macroscopic image of bone from a sheep that was not 
infected.  Note the apparent differences in tissue morphology between this sample and 
that from the infected sheep.  Original magnification was 10x.  (D) Image of a similar 
region of as that analyzed in (B).  Note the lack of sequestrum, resorption or chronic 
inflammation.  In contrast, this bone had normal lamellar structure.  Original 
magnification was 20x.
CHAPTER 8
IN VIVO EFFICACY OF THE NOVEL CSA-13 ACTIVE
RELEASE COATING TO PREVENT BIOFILM
IMPLANT-RELATED OSTEOMYELITIS
8.1 Introduction
In this chapter, data will be provided regarding the definitive animal study that 
was used to test the ability of the novel CSA-13 active release coating to prevent biofilm 
implant-related osteomyelitis.  The work that will be presented in this Chapter 
specifically addressed Aim 3 of the overall study that was outlined in Chapter 2, section 
2.4.  The specific hypothesis of this work was that when used as an active release agent in 
a device coating, CSA-13 would prevent biofilm implant-related osteomyelitis from 
developing in vivo.
8.2 Materials and Methods
8.2.1 Biofilm Growth
The method of growing biofilms for this study was the same as in all of the 
previous studies outlined in this dissertation.40 Specifically, biofilms were grown on 
PEEK membranes as outlined in Chapter 4, placed in 5 mL of 10% BHI broth (modified) 
and inoculated in sheep using the same protocol as the pilot animal study from Chapter 7.  
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8.2.2 Stainless Steel Plate
The SS plates that were used for this study were manufactured to the same 
dimensions, made of the same medical grade SS, processed, dip coated with PDMS or 
PDMS/CSA-13 and cured following the same protocol as outlined in Chapters 4 and 5.
8.2.3 Surgical Procedure and Postsurgical Monitoring
As was the case with the pilot study from Chapter 7, this animal work was 
performed with the approval of the IACUC and EHS department at the University of 
Utah.  The surgical procedure was the same as that outlined in Chapter 7.  The difference 
between the pilot study and this definitive study was that the SS plates were coated in this
portion of the study and the number of animals in each group were expanded. More 
specifically, a total of n=27 animals were separated into three groups of n=9.  Group 1 
sheep were those that were treated with PDMS only coated plates and biofilm (positive
control).  Group 2 sheep received SS plates that were coated with PDMS/CSA-13 and 
biofilm (treatment group) and Group 3 sheep received PDMS only coated plates and no 
biofilm (negative control).  Table 8.1 provides a detailed description of the animals that
were used and their specific treatments. Sheep were monitored on a daily basis using the 
same clinical grading system as outlined in Chapter 7.
8.2.4 Bone Labeling
Calcein was used in this study to double label the bone and determine the MAR in 
these sheep as was done in the pilot study.
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8.2.5 Euthanasia and Sample Collection
Sheep were euthanized once they reached a 12-week end point or a Grade III 
infection.  Microbiological samples, gross photographs, radiographs, MAR analysis, 
SEM analysis and histological analysis were collected and performed following the same 
protocols outlined in Chapter 7. However, in addition to swabbing the incision site and 
subdermal tissues, a swab of the cortical bone surface of each sheep was aseptically taken 
at the time of necropsy to determine if bacteria were still present on the surface of the 
bone.  This swab covered approximately 1/2 inch2 of surface area next to the SS plate that 
was selected for microbiologic analysis.
With respect to histological analysis, in addition to H&E staining, Sanderson's 
rapid bone stain was also used to stain PMMA sections in order to more accurately assess 
tissue response, bone quality, and regions of remodeling.
8.2.6 Statistical Analysis
From a Kaplan-Meier survival curve, a Log-Rank test was used to examine the 
statistical significance in survival times between those sheep treated with biofilm and 
those that were not.  A separate Log-Rank test was used to compare the time it took for 
animals in each Group to become infected.  Time to infection differed from survival time 
since many sheep in Group 1 survived the full 12 weeks of the study, but displayed signs 
of infection very early on.
Because the number of bacteria collected from PEEK membranes were not 
normally distributed, the nonparametric Kruskal Wallis test was used for analysis, as 
opposed to an ANOVA, to compare the number of bacteria that were collected on the 
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PEEK membranes of Group 1, Group 2 and Group 3 animals.  In all instances, an alpha 
level of 0.05 was established to define statistical significance.  All statistical data were
analyzed using SPSS 17.0 software.
8.3 Results
8.3.1 Surgical Follow Up
A survival curve including each of the 27 sheep in this study was plotted using a 
Kaplan-Meier survival curve (Figure 8.1A).  The reason that one sheep in Group 1, two 
sheep in Group 2 and three sheep in Group 3 went slightly longer than the 12-week end 
point was due to logistical reasons for euthanasia.
Three of the nine sheep in the PDMS only/biofilm treated group (Group 1) were 
euthanized early due to a Grade III infection.  Two other sheep in Group 1 were 
euthanized just days prior to the 12-week endpoint, due to the fact that each of them had 
the operative leg break during routine observation.  Both of these breaks occurred in the 
tibia near the inferior SS plate that had been implanted and it was believed that these 
breaks occurred as a result of osteomyelitis (Grade II infection) that had weakened the 
bone.  These five sheep in Group 1 that were euthanized early did not receive a double 
label of calcein.  The remaining four sheep in Group 1 survived to the 12-week end point.  
Each of those four sheep displayed Grade II signs of infection during the 12-week 
monitoring period.  Furthermore, each of the nine sheep in Group 1 displayed signs of 
inflammation and abscess formation between day 3 and 18 after surgery.  
Eight of nine sheep in Group 2 survived to the 12-week end point with minimal 
acute inflammation that resolved within the first week or two and no signs of infection at 
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any point in the study.  One sheep from Group 2 was euthanized at 5 weeks due to a 
chronic limp that was not related to infection, but rather it appeared to have a small, 
incomplete fracture that may have developed due to surgery.  This sheep did not receive a 
calcein double label.  
One sheep from Group 3 had a large abscess develop 11 days following surgery 
and was euthanized as it displayed signs of a Grade III infection.  This sheep likewise did 
not receive a calcein double label.  The remaining eight sheep in Group 3 showed no 
signs of infection and their acute inflammation resolved within one or two weeks 
following surgery. 
The Log-Rank test indicated that there was no statistically significant difference 
in survival times between any of the groups (p=0.122).  There was no statistically 
significant difference in the time to infection between Group 2 and Group 3 sheep 
(p=0.839; Figure 8.1B).  Yet there was a difference in the time to infection between 
Group 1 and both Group 2 (p=0.000) and Group 3 (p=0.000) sheep (Figure 8.1B).  These 
differences corroborated with the microbiological data.
8.3.3 Microbiology
From the swabs that were taken of the subdermal tissues immediately after the SS 
plates had been secured to the bone during surgery, it was found that MRSA bacteria 
were released from the biofilm onto the bone surface and into the surrounding tissues 
within minutes after inoculation for Groups 1 and 2.  No bacteria were cultured from 
those sheep in Group 3 at the time of surgery.
At necropsy, microbiological data showed that all sheep had between 1+ and 2+ 
growth of bacteria on their skin near the incision site.  These were found to be normal
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flora bacteria.  All sheep in Group 1 had between 2+ and 3+ growth in the subdermal 
tissues and from the bone swabs.  No sheep in Group 2 had growth in the subdermal 
tissue.  The one sheep in Group 2 that was euthanized at 5 weeks did have one colony of 
MRSA growth from the bone swab that was taken, whereas none of the remaining eight 
that survived to 12 weeks had growth on the bone surface.  Interestingly, the one sheep 
from Group 3 that had a large abscess and soft tissue infection had no growth in the 
subdermal tissues by culture.  It was concluded that the infecting organism was not 
culturable by the methods used in this study.  However, the clinical indications suggested 
that the tissue was highly infected. One additional sheep from Group 3 had growth of 
Corynebacterium from the bone swab, but never had indications of infection during the 
monitoring period.  No other sheep from Group 3 had growth from the bone swab.
PEEK membranes collected from Group 1 sheep contained an overall log10
density of 6.11 ± 0.89 CFU/PEEK membrane.  No bacteria were detected on the PEEK 
membranes of Group 2 sheep.  There was no detectable growth on the PEEK membrane 
of the sheep in Group 3 that had a soft tissue infection.  However, the same sheep from 
Group 3 that had growth from the bone swab also had 2.39 log10 CFU of Alloiococcus 
otitis and Corynebacterium on a PEEK membrane at the time of necropsy, but again that 
sheep did not show signs of infection during the 12-week monitoring period.  When 
compared using a Kruskal Wallis test with the Mann Whitney U test used for post hoc 
analysis, it was found that there was no difference in bacterial numbers from PEEK 
membranes between Group 2 and Group 3 (p=0.730), whereas there was a difference 
between Group 1 and both Group 2 (p=0.000) and Group 3 (p=0.000).  
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These data indicated that the microbiological findings correlated with the clinical 
observations of the sheep, wherein those treated with biofilm and no CSA-13 (Group 1) 
suffered a Grade II or higher infection, and those treated with biofilm and CSA-13
(Group 2) did not suffer from infection.  One sheep from Group 3 suffered a soft tissue 
infection and another had positive growth on the PEEK membrane and bone swab, but no 
signs of infection.
Notably, when removing the SS plates for microbiological analysis, it was 
observed that in each of the Group 1 sheep, the bone screws had become completely 
loose and in three animals the plates had lifted off the surface of the bone.  This was due 
to bone resorption around the screws, which was a result of infection as indicated by 
SEM analysis and histological results (see SEM and Histology results).  No screw or 
plate loosening was observed in Group 2 or Group 3 sheep and it was also interesting to 
observe that in Group 2 and Group 3 sheep, the cortical bone began to grow on/attach to 
the PEEK membranes, which made it difficult to remove them for quantification.  In 
contrast, the PEEK membranes in the infected sheep had no attachment of bone to them 
and were easily removed.
8.3.4 Gross Photography/Radiographic Analysis
Gross photographs of the sheep limbs provided evidence that an abscess formed 
in the surgical area of Group 1 sheep (Figure 8.2A).  No abscess formation was seen in 
sheep from Group 2 (Figure 8.2C) and only one had abscess formation in Group 3 
(Figure 8.2E).  Furthermore, signs of infected tissue, including pus and necrotic tissue,
could be seen in Group 1 sheep once the skin was resected (Figure 8.2B). In contrast, 
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only a thin membrane of tissue grew over the plates in Group 2 (Figure 8.2D) and Group 
3 (Figure 8.2F) sheep.
Radiographic evidence suggested that in Group 1 sheep, “moth eaten,” 
osteomyelitic bone was visible (Figure 8.3A).  This result was particularly apparent in the 
microradiographs that were taken of bone sections after they had been embedded and cut 
(Figure 8.3B).  From these sections a significant cortical bone response and an endosteal 
response indicative of responsive new bone formation could be seen in Group 1 sheep.  
No such response was seen in Group 2 (Figure 8.3C, D) or Group 3 (Figure 8.3E, F)
sheep.
8.3.5 SEM Analysis
In those sheep treated with biofilm and PDMS only coated plates (Group 1), BSE 
images indicated that there was a considerable amount of bone resorption directly 
underneath the SS plates with sequestrum formation caused by the presence of biofilm
(Figure 8.4A).  Similar patterns of resorption were seen near the bone screws (Figure 
8.4B), which supported the observation mentioned previously that these screws were 
loose due to bone resorption caused by osteomyelitis.  There were no screws loose in 
those sheep treated with CSA-13 (Group 2). In addition, the cortical bone surface that 
had been in direct contact with biofilms on PEEK membranes appeared to be viable in all 
nine sheep from Group 2 (Figure 8.4C).  In the screw regions of Group 2 sheep, bone 
remodeling had occurred consistent with surgical trauma (Figure 8.4D). In those sheep 
that were treated with PDMS only coated plates and no biofilm (Group 3), bone
remodeling was seen directly underneath the SS plates and near the screws similar to the 
CSA-13 treated sheep (Figure 8.4E & F).
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A larger gap of fibrous and inflammatory tissue was seen between the cortical 
bone surface and SS plate of Group 1 sheep when compared to Group 2 or Group 3.  
More specifically, the distance from the bone to the plate surface in Group 1 was ~1,179 
± 1,257 microns.  In Group 2 and Group 3, the gap was 316 ± 382 and 456 ± 313, 
respectively.  As will be seen in the histopathological results, the larger gap in Group 1 
sheep was due to fibrous tissue formation and chronic inflammation related to the 
presence of infection that was confirmed by microbiological sampling.
8.3.6 MAR Analysis
MAR results indicated that in Group 1 sheep, the average bone remodeling rate 
directly underneath the SS plate was 1.71 ± 0.12 μm/day.  In Group 2 sheep the average 
rate was 1.53 ± 0.32 μm/day and in Group 3 sheep, the average was 1.31 ± 0.15 μm/day.  
The MAR of host bone in the cortical region opposite of the SS plates were 1.19 ± 0.09 
for Group 1, 1.06 ± 0.16 for Group 2, and 1.00 ± 0.15 for Group 3.  Images of double 
labels in the periosteal regions of Group 1 sheep showed that an intense remodeling
response was present (Figure 8.5A).  Importantly, no double labels were seen in those 
areas where bone chips/and or sequestra were located (Figure 8.5B, C & D) suggesting 
that the bone chips and sequestra were not viable. This was likely due to the presence of 
biofilm bacteria on PEEK membranes that caused sequestra to form and killed the bone.
Typical double labels of osteons were seen in the cortical bone regions of the host bone
(Figure 8.5E).
In Group 2 sheep, double labeled osteon structures were present in the cortical 
bone region where bacteria had been placed indicative of bone remodeling (Figure 8.5E).
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A similar response was seen in Group 3 sheep and bone was observed growing into the 
interstices of the PEEK membrane (Figure 8.5F).  Notably, calcein double labels
indicated local/regional bone viability in all Groups.
8.3.7 Histological Analysis
Histological sections from Group 1 sheep corroborated with the radiographs and 
SEM images.  There were signs of "moth eaten" bone, a significant inflammatory 
response, and fibrous tissue formation (Figure 8.6A). In addition, multiple foci of 
sequestra were detected and necrotic bone that preceded sequestrum formation was seen 
(Figure 8.6A). Sheep in Group 1 that were euthanized within one or two weeks of 
surgery had early signs of bone resorption and necrosis, but it had not yet progressed to 
the point of sequestrum formation (Figure 8.6B).  Nevertheless, inflammatory cells were 
present in the area where the biofilm-ridden PEEK membrane had been placed, fibrosis 
had occurred and there were signs of responsive new bone formation in the periosteal and 
endosteal regions (Figure 8.6B).
Group 2 sheep did not show signs of necrotic tissue in those regions that were in 
direct contact with PEEK membranes that had biofilms on them (Figure 8.6C).  Rather 
the bone was viable, remodeling and there were few inflammatory cells and a reduced 
fibrous capsule compared to Group 1 sheep (Figure 8.6D).  The results of Group 2 were 
similar in Group 3 sheep (Figure 8.6E & F).
Table 7.1, which was used to grade histological sections in the pilot study from 
Chapter 7, was used once again to grade the histological sections from these sheep.  The 
results for this portion of the study are provided in Table 8.2.  This table shows the 
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number of sheep from each group and the degree to which inflammation, necrosis and 
cortical bone response were present.  Significant inflammation was present in Group 1 
sheep, with mild to moderate inflammation mostly present in Group 2 and Group 3 sheep.  
Seven out of nine sheep from Group 1 had necrotic bone and/or multiple foci of sequestra
underneath SS plates. No sheep from Group 2 showed signs of necrosis or sequestra in 
bone underneath the SS plate.  Likewise, no signs of necrotic bone or sequestra were 
present in Group 3 sheep.  A cortical bone response was present in all sheep near the 
edges of SS plates and was a natural result of surgical trauma.
8.4 Discussion
In order to address previous limitations that have accompanied the development 
of active release coatings (see Chapter 2, section 2.5.3), this study was designed to test a 
novel active release coating by exposing it to well-established biofilms of MRSA as 
opposed to planktonic bacteria.  The fact that CSA-13 was able to prevent infection in 
100% of sheep in Group 2 indicated that the in vitro work (see Chapter 5) was performed 
in a translational manner.  Taken together, these in vitro and in vivo studies have the 
potential to influence the development of antimicrobial coated devices in the future. 
Perhaps the most telling difference between the sheep in Group 1 that were 
treated with PDMS only coated plates and biofilms, and the other two groups of sheep 
was the microbiologic data.  More specifically, the fact that only one colony of bacteria 
was detected in a single sheep in Group 2 and 0% were infected strongly indicated that 
CSA-13 acted as a potent active release agent within the PDMS-based coating system to 
prevent biofilm implant-related osteomyelitis.  Furthermore, the fact that one sheep out of 
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nine (11%) became infected in the negative control group, i.e., those that had PDMS only 
coated implants and no biofilm (Group 3), provided further evidence that CSA-13 had the 
ability to prevent infection that may have been related to the surgical procedure itself.
Sheep in Group 1 displayed multiple signs that were indicative of chronic 
osteomyelitis.  For example, multiple foci of sequestra could be seen from SEM and 
histologic analysis, the bone surface was "moth eaten" in the majority of sheep in that 
Group, very high inocula of bacteria were confirmed to be present in the subdermal 
tissues, on the bone surface and on the PEEK membranes of all nine sheep, and the 
infection seemed to progress slowly over time similar to what has been observed with 
chronic osteomyelitis clinically when biofilm was present.16
No signs of osteomyelitis were present in Group 2 sheep.  In contrast, despite the 
fact that the cortical bone surface in this Group of sheep had been directly exposed to
PEEK membranes that had biofilms grown on them, the bone surface of each sheep 
appeared healthy with signs that bone was remodeling.  This further indicated that CSA-
13 did not have a toxic effect to the bone.  Furthermore, although there was minimal 
foreign body response, the surrounding tissue regions showed no signs that CSA-13 had 
an adverse effect on tissue healing and the ability of bone to remodel.
Despite one soft tissue infection in a sheep from Group 3, no sheep in that Group 
suffered from osteomyelitis and the bone was able to grow throughout the interstices of 
the PEEK membrane, suggesting that the PEEK may have had an osteoconductive effect.  
Similar to the results that were seen in the pilot work to establish this animal 
model, all sheep that were treated with biofilm in Group 1 became infected.  This result 
further established the consistency with which this animal model may be used for future 
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testing of biomaterial device development and chronic osteomyelitis for other types of 
applications.
From the histological grading scale, it was apparent that those sheep with PDMS 
only coated plates and no biofilm had the least amount of inflammation, necrosis and 
cortical bone response.  This was likely due to the fact that Group 1 and Group 2 sheep 
had bacteria present.  Although CSA-13 was able to prevent infection, results from the 
histological grading scale indicated that bacteria still had time to cause a moderate to 
significant inflammatory response to develop in four sheep. Nevertheless, it may be that 
if these animals were monitored for longer than 12 weeks, the inflammation may have 
reduced over time.
In conclusion, the results of this definitive animal study indicated that CSA-13 
may have significant promise to be used as an active release agent to prevent biofilm 
implant-related infections.  Furthermore, in addition to work that is currently being 
performed by Dr. Paul Savage's group, which has demonstrated that CSA-13 has a low 
risk of toxicity, this work demonstrated that CSA-13 may be used safely as an active 
release agent.  As this active release coating is developed further, it may have the ability 
to help reduce rates of infection that adversely affect the use of fracture fixation devices 
as well as other biomedical materials. 
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Table 8.1: Outline of the different groups of sheep, the number of animals in each group, 
the coating type that was present in each and whether or not they were treated with 
biofilm.
Group
(Number of Animals) Coating Type Biofilm Treatment
Group 1 - Positive Control 
(n=9) PDMS Only Biofilm
Group 2 - Treatment Group
(n=9) PDMS/CSA-13 Biofilm
Group 3 - Negative Control 
(n=9) PDMS Only No Biofilm
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Figure 8.1: Kaplan-Meier curves indicating the survival and time to infection of each 
animal in the definitive study group.  (A) Kaplan-Meier survival curve outlining the 
number of weeks that each sheep survived during the course of the study.  (B) Kaplan-
Meier curve indicating the time it took for each sheep to show signs of infection.
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Figure 8.2: Photographs of the tibiae of sheep indicating infection and lack thereof 
amongst the different animal Groups.  (A) Photograph of an abscess that was present in 
the proximal medial aspect of a sheep tibia from Group 1.  (B) Photograph of the 
subdermal tissue of a sheep from Group 1.  Note the presence of necrotic (brown next to 
plate) and inflammatory tissue (yellow).  (C) Photograph of the proximal medial aspect of 
a sheep tibia from Group 2.  (D) Photograph of the subdermal tissue in a sheep that was 
treated with CSA-13.  The yellowing of the plate was likely due to the calcein green that 
was injected.  A thin membrane of tissue had grown over the plates.  (E) Photograph of 
the abscess that was present in the one sheep from Group 3 that had a soft tissue 
infection.  (F) Photograph of the subdermal tissue in a sheep from Group 3.  One plate 
had been removed prior to this picture being taken, but note the thin fibrous membrane 
that was still intact over the other SS plate.
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Figure 8.3: Representative radiographs indicating osteomyelitis and lack thereof in sheep 
from each Group.  (A) Radiograph of the tibia of a sheep from Group 1 that suffered from 
osteomyelitis.  This radiograph is from one of the sheep that broke its leg during a routine 
checkup.  Note the "moth eaten" bone in the inferior and superior regions of the SS plates
(arrows).  (B) Microradiograph of a bone section (Group 1 sheep) that was cut after it had 
been embedded in PMMA.  This radiograph provides evidence for why the bone screws 
were loose in Group 1 sheep; the screws had lost contact with the host bone.  The 
infection had caused the screws to come loose, contributed to resorption of bone 
throughout the cortical bone regions, which led to the "moth eaten" appearance.  (C) 
Radiograph of a tibia from a sheep that was treated with CSA-13-coated plates (Group 2).
(D) Microradiograph of a bone section from a sheep treated with CSA-13-coated plates.  
The edging effect that is seen near the bone screws was consistent in all nine sheep from 
Group 2.  (E) Radiograph of a tibia from a sheep in Group 3.  (F) Microradiograph of a 
bone section from a sheep in Group 3.
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Figure 8.4: SEM images of bone directly underneath SS plates and near cortical bone 
screws in sheep from each Group (all 30x original magnification). (A) SEM micrograph 
of the cortical bone surface directly underneath a SS plate that was from a sheep in Group 
1.  The arrow indicates an area of significant resorption that likely prefaced the formation 
of a sequestrum in the periosteal region.  Resorption was indicated by the presence of 
jagged bone edges as a result of osteoclast activity and infection (as will be seen in the 
Histology section).  Cracks that can be seen in the bone were an artifact of processing.  
(B) SEM micrograph of an area near a bone screw in a sheep from Group 1.  The arrow 
again indicates an area of resorption.  Note the presence of bone chips next to the screw 
and the gap between the bone chips and the resorbed bone surface.  This gap provided an 
indication as to why the screws were loose in Group 1 sheep.  (C) SEM micrograph of a 
cortical bone surface underneath a SS plate from a sheep in Group 2 (CSA-13 treated).  
The bone surface itself looked healthy and had no signs of resorption in the area where 
bacteria had been placed.  (D) The arrow that is facing up in this SEM micrograph 
indicates the jagged border where bone resorption had occurred whereas the arrow that is 
facing down points to the new bone that formed.  The screw was in close contact with the 
bone surface.  (E) SEM micrograph of the cortical bone surface underneath a SS plate 
that had been coated with PDMS only.  Minor areas of remodeling were seen in this 
region of sheep from Group 3.  (F) SEM micrograph of a bone region from a sheep in 
Group 3.  Bone remodeling was seen (arrow), but there were no indications that 
resorption had occurred as it had in Group 2 sheep.  The remodeling in this bone was 
likely a result of surgical trauma, and the bone grew close to the screw surface.
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Figure 8.5: MAR images of infected bone, remodeling bone and cortical bone in 
representative sheep from each Group.  (A) Fluorescent microscope image of calcein 
double labels that were present in the periosteal region directly underneath a SS plate of a 
sheep from Group 1.  Initially, the PEEK membrane that had biofilm grown on it was 
placed in apposition to the host bone. Inflammation and fibrous capsule formation 
caused the PEEK membrane and the SS plate to lift off the surface of the bone.  
Periosteal growth in Group 1 sheep was highly responsive as a result of infection.  (B) 
Polarized light image of a sequestrum in a sheep from Group 1.  (C) Same image as in 
(B), but with fluorescent double labels.  (D) Combined image of (B) and (C).  Areas of 
viable bone and dead bone are labeled.  Viable areas are indicated by the presence of 
calcein labels whereas dead bone is void of double labels.  The PEEK membrane can be 
seen in apposition to the dead host bone.  (E) Fluorescent microscope image of calcein 
double labels in the periosteal/cortical bone region of a sheep from Group 2.  Note the 
lack of periosteal response and typical osteoid growth despite the fact that bacteria had 
been present on the PEEK membrane.  (F) Fluorescent microscope image of the 
periosteal/cortical bone region of a sheep from Group 3.  This image demonstrates how 
the bone grew throughout the interstices of the PEEK membrane without any significant 
periosteal response.
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Figure 8.6: Images of histological sections from representative sheep in each Group.  (A) 
H&E stained section of bone embedded in PMMA.  The SS plate can be seen at the top 
of the picture; the white arrow points to an area of necrotic bone that likely prefaced the 
formation of a sequestrum. The black arrow points to the significant endosteal bone 
response and a similar response could be seen in the periosteal region underneath the 
plate.  (B) Bone section stained with Sanderson's rapid bon stain.  Inflammatory cells and 
a fibrous capsule can be seen in the area where a PEEK membrane with biofilm had been 
placed.  Early signs of bone necrosis were seen in this section as indicated by the wavy 
morphology of the bone that likely preceded resorption.  (C) H&E section of bone from a 
sheep in Group 2.  In contrast to the sheep from Group 1, the bone was healthy even after 
being exposed to a PEEK membrane that had biofilm on it.  (D) Sanderson's bone stain of 
a sheep from Group 2.  Despite the fact that bacteria had been present on the PEEK 
membrane, there was minimal foreign body reaction and the bone surface was healthy.  
New bone formation was indicated by the darker pink area of bone that was not yet 
mineralized.  Mineralized bone is lighter pink after Sanderson's bone staining.  (E) H&E 
section of bone from a sheep in Group 3.  This bone was also healthy in an area where the 
PEEK had been present.  (F) Sanderson's bone stained section from a sheep in Group 3.  
The newly forming bone could be seen integrating throughout the interstices of the PEEK 
membrane.  Inflammatory cells could be seen in this section as a natural response to a 
foreign body (PEEK and SS plate) being present.
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Table 8.2: Results of comparing the histological sections of each sheep to Table 7.1
provided in Chapter 7.  These results indicated that inflammation was present in sheep 
from all groups, with the highest level of inflammation being present in Group 1 sheep.  
Furthermore, bone necrosis was primarily seen in sheep from Group 1.  A cortical bone 
response was also seen in sheep from each group, but this was a normal response to 
surgical trauma.
Inflammation # of Sheep From Group 1
# Sheep From 
Group 2
# Sheep From 
Group 3
0 0 1 5
1 2 4 3
2 3 3 1
3 0 1 0
4 4 0 0
Bone Necrosis
0 2 9 9
1 0 0 0
2 2 0 0
3 0 0 0
4 5 0 0
Cortical Bone 
Response
0 2 2 3
1 3 1 5
2 2 4 0
3 1 1 0




Considered together, the work that was performed in this dissertation has led to or
may lead to five areas of development that have the potential to contribute to the fields of 
bioengineering and biofilm research.  The first was the development of an animal model
that has the potential to contribute to the future development of combination biomedical 
materials with active release antimicrobial coatings, biofilm implant-related infection 
studies, other biofilm-related infection studies and clinical infection prevention strategies.
After a careful literature search, the animal model developed in this project 
appears to be the first model to incorporate well-established biofilms of MRSA that were 
grown under fluid sheer forces in a biofilm reactor as initial inocula in order to model the 
predominant phenotype of bacteria from natural ecosystems that have the potential to 
contaminate open wound sites. One of the most exciting aspects of this model is that it 
may provide additional insight into how biofilm infections develop over time in a slow, 
chronic and somewhat mild fashion similar to what is seen in clinical settings.
The second contribution was the development of an active release coating that 
incorporated a novel antimicrobial compound as its active release agent and which was 
effective in preventing infection in 100% of animals that were treated with viable 
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biofilms of MRSA.  Currently, there are a limited number of biomedical devices or 
products that utilize active release coatings.  As outlined in Chapter 2, it is believed that 
there is a paucity of active release coatings in clinical use due to three important 
limitations. To reiterate, these are a dependence on MIC values to treat biofilm-related 
infections, inaccurate in vitro tests that do not model physiologically relevant 
environments and the use of planktonic bacterial cells as initial inocula as opposed to 
bacteria that reside in the biofilm phenotype as they do in natural ecosystems.  The work 
that was performed in this dissertation addressed each of these limitations and the data 
indicated that in doing so, an active release coating was developed with in vitro and in 
vivo success.  Importantly, the in vivo work in this study, and other work that has been 
performed by Dr. Paul Savage's group (unpublished data), have shown that CSA-13 has 
limited to no toxic effects on host cells and tissues.  These data may have significant 
future implications to translate this coating for FDA approval in human clinical trials.
The third contribution was the development and use of a flow cell system to 
optimize and test the efficacy of an active release coating on SS plates under in vitro
conditions.  The in vitro conditions were specifically designed to model the in vivo 
environment in which the coated SS plates would be tested.  These tests suggested that an 
18% w/w concentration of CSA-13 would be needed to effectively eradicate biofilms of 
MRSA to less than 102 cells in a 24-hour period.  These findings were particularly 
important compared to the preliminary work that was done with the CSA-13 active 
release coating in stagnant broth solutions.  In stagnant broth solution, only 10% w/w 
CSA-13 was needed to reduce MRSA biofilms to similar levels.  Thus, the fact that 
higher amounts of CSA-13 were needed to eradicate biofilms under flow conditions 
205
supported the proposal that when stagnant broth solutions are used by investigators, they 
may not adequately reflect the amount of antimicrobial that may be necessary to eradicate 
biofilms.
The in vitro work further highlighted the fact that MIC values are limited when it 
comes to fighting biofilm implant-related infection.  In this study, the in vitro work 
suggested that the concentration of CSA-13 that was needed to eradicate biofilms ranged 
from approximately 60 μg/mL in the first 4 hours to approximately 20 μg/mL by 24 
hours.  By comparison, the MIC of CSA-13 against planktonic cells of the MRSA isolate 
that was used in this study was found to be 0.25 μg/mL.  In order to kill biofilms of 
MRSA, CSA-13 had to be present in concentrations that were 85x - 240x greater than the 
MIC.  This same trend is very commonly seen with antibiotics as was shown by Nickel et 
al. (refer to Chapter 1) and others.  Their work has shown that it is very common for 
concentrations of antibiotics to be required at several hundred to more than a thousand 
times their MIC values to be even marginally effective against biofilms.
Perhaps the most poignant aspect of the in vitro work that was performed in this 
dissertation was the fact that it translated well to the in vivo animal model.  This was 
shown by the fact that when CSA-13 was used as an active release agent, it was able to 
prevent osteomyelitis in 100% of the animals in which it was tested. These in vivo results 
supported the hypothesis that an 18% w/w concentration of CSA-13 would be sufficient 
to reduce the number of bacteria in a biofilm to clinically acceptable levels. Thus, the in 
vitro system that was developed may be used by other investigators to more effectively 
perform initial in vitro work that is intended to develop biomedical devices with active 
release coatings in a translational manner, though further in vitro and in vivo 
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investigations using different coatings and antimicrobials will be required to confirm this 
hypothesis.
The fourth contribution that has the potential to extend from this project was the 
development of a membrane biofilm reactor.  After a careful literature search, this reactor 
appears to be the first biofilm reactor to have been developed with the specific intent of 
growing biofilms that can be used as initial inocula in an animal model of biofilm-related 
infection.  Importantly, the reproducibility of this reactor directly corresponded to the
protocol that was rigidly followed to grow biofilms on the surface of PEEK membranes.
There are two major benefits that may accompany the development of this reactor and 
they are 1) the size of PEEK membrane can be modified in this reactor to grow 
essentially any number of bacteria that an investigator desires.  2)  An investigator can 
change the type of material such that instead of using PEEK, biofilms could be grown on 
a different type of polymeric material, metallic material or even on a biological 
sample(s).  Thus, this reactor is diverse and has the potential to lead to a variety of 
applications in biofilm research, antimicrobial and combination biomaterials 
development.   
The fifth important aspect of this work that may have the potential to expand the 
literature was the use of a novel antimicrobial compound, CSA-13, that demonstrated 
significant potential to address the limitations of current antibiotic therapies.
Pharmaceutical companies are currently at a standstill with regard to developing 
additional antibiotics and/or antimicrobials for clinical use.  There are three main reasons 
for this standstill.  1)  Regulatory costs are prohibitively expensive for companies to 
produce new drugs.  2)  Companies are concerned that bacteria will quickly develop 
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resistance to any new antibiotic that is introduced, which would ultimately result in 
reduced sales of a product.  3)  Despite the fact that an antimicrobial compound may be 
highly effective against bacteria, manufacturing costs may cripple the ability of a 
compound to be produced on a commercial scale. With the exception of the regulatory 
costs that are associated with drug or device development, CSA-13 may have the ability 
to address the latter two limitations.
Due to its rapid attack and nonspecific method of action against bacteria, CSA-13 
carries a significantly reduced risk of engendering bacterial resistance compared to 
traditional antibiotic compounds.  It can also be manufactured on a commercial scale for 
a fraction of the cost that other compounds require to be manufactured.  In addition, 
based on the results of the animal work in this study, in conjunction with much of the 
testing that has been done by Dr. Savage and his colleagues, CSA-13 appears to have 
limited toxic effects to eukaryotic cells at bactericidal concentrations.  All of these 
properties of CSA-13 are  promising and suggest that it may be effective when used as an 
active release agent of biomedical device coatings.
9.2 Future Work
There are several important projects that need to be performed in order to validate 
and add upon the work that was completed in this dissertation.  To date, the work that has 
been done with CSA-13 has shown that it is a very promising antimicrobial as far its
efficacy is considered. The next step, then, will be to demonstrate that CSA-13 is a safe 
product to use.  Studies to test the safety of CSA-13 are in fact already under way. This 
dissertation encompassed the first half of a NIH-funded project.  The second half of the 
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funded project has been designed to test the safety of CSA-13.  To do so, three tests will 
be performed.  First, the effect of CSA-13 on fracture healing will be determined.  This 
will be done by creating an osteotomized fracture in a group of sheep that will be reduced 
with a fracture fixation plate that is coated with the CSA-13 active release coating.  
Another group of animals will have a fracture reduced with a plate that is uncoated.  At 
the endpoint of this study, the sheep bones will be tested mechanically using a four-point 
bend test to determine the strength of fractures.  As such, it will be determined if CSA-13 
has any adverse effect on fracture healing. Second, in conjunction with fracture healing 
analysis, end organ analysis will be performed. This will be done with tritiated CSA-13.
As samples of end organs and tissues are collected, the amount of CSA-13 will be 
determined by scintillation counting.  The third method by which the safety of CSA-13 
will be determined has already taken place.  This was done by performing surgeries on a 
group of sheep that were treated with SS plates coated with the CSA-13 active release 
coating in the absence of bacteria.  This was done to determine the effect of CSA-13
alone on host tissue(s) in the absence of a fracture and in the absence of bacteria.
In addition to these studies, plans are also underway to test the active release 
coating that was developed in this project on a variety of other biomedical devices 
including total joint replacement devices, intramedullary nails, external fixators, 
catheters, endotracheal tubes, etc.  The efficacy of CSA-13 as a wound care product, 
lavage solution, injectable solution and systemic antimicrobial is also being investigated.
All in all, Dr. Bloebaum's group has met with multiple biomedical device 
companies that have shown tremendous interest in the CSA-13 technology that has been 
developed as part of this dissertation.  At this time, negotiations are currently in progress 
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between venture groups, investors, companies and the University of Utah to develop a
collaborative effort that can translate CSA-13 to clinical applications.  Thus, the future 
outlook is bright for CSA-13 to potentially help millions of patients who suffer from 
biofilm implant-related infections. 
9.3 Conclusion
It is likely safe to say that when Antony van Leeuwenhoek observed animalcules 
for the first time, he did not foresee this day, wherein those animalcules would be defined 
as biofilms that are now known to have dramatic influence on the daily life of each 
human being.  Similarly, if Aristotle were able to now see the functions of the world, he 
would perhaps be dumbfounded that spontaneous generation, or Aristotelian abiogenesis, 
continues to be disproven in dramatic fashion by the copious amounts of data that suggest 
that life does not arise ex nihilo. In stark contrast, Dr. Bill Costerton has had the 
opportunity to directly observe the impact that his research has had on the world.  As 
such, he, along with the rest of the scientific community, has had the ability to see that 
biofilms may adversely or beneficially influence many facets of life.
As far as their beneficial influence is concerned, biofilms aid in sewage treatment, 
plant growth, plant and human waste decomposition, oxygen production, and 
gastrointestinal functions of all known animal species.  Unfortunately, if biofilms come in 
contact with tissues that have not evolved to coexist in a beneficial manner, these tissues 
are at significant risk to become infected due to the fact that biofilms "see" these tissues
as carbon and energy sources.  Infection becomes even more problematic if a biomedical 
device has been implanted in a human patient.  In this instance, in addition to having a 
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carbon and energy source, an abiotic, colonizable surface is presented to biofilms, to 
which they preferentially adhere.  This paradigm leads to biofilm implant-related 
infection that constitutes one of the most difficult-to-treat pathologies in current 
healthcare systems.
Antibiotics are becoming ever more limited in their ability to address this problem 
due to their lack of efficacy against bacteria that reside in the biofilm phenotype.  The 
future outlook is bright, however, as investigators discover and develop novel 
antimicrobial compounds that specifically address the limitations of antibiotics.  One of 
the most promising of these novel antimicrobial compounds is CSA-13. Currently, there 
are multiple NIH-funded studies that are taking place to further test the efficacy of CSA-
13, manufacture it on a commercial scale, and at least one study is taking place to test the 
safety of CSA-13 in human trials.  To date, the results of these projects have strongly 
suggested that CSA-13 will be able to be manufactured on a commercial scale at 
relatively low cost, that it is highly efficacious against planktonic and biofilm bacteria 
both in vitro and in vivo and that it may have limited toxicity in vivo.
Although the author is candidly aware that future testing must be performed to 
validate these findings, there is reason to be optimistic that CSA-13 may be an effective 
alternative to current combination antibiotic therapies; in particular for it to be used in a 
novel active release coating to prevent biofilm implant-related infections in patients who 
are implanted with a biomedical device(s).
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Abstract: One of the most practical strategies that has been
undertaken to ﬁght bioﬁlm implant-related infections has been
the development of coatings on biomaterial devices that can
elute antimicrobials into regions of patients’ tissues. To date, the
majority of animal studies that have been developed to model
infections that accompany the use of these materials have
primarily involved an initial inoculum of planktonic bacterial cells
from batch cultures. Although valuable, data that have been
derived from these experiments may not provide important
clinical insight into how bacteria in well-established, mature
bioﬁlms impact device-related and other clinical infections when
they contaminate a patient site or implanted device. In this
review, a discussion is presented on the impact that a shift in bio-
ﬁlm research may have if initial inocula of well-established,
mature bioﬁlms are used to model biomaterial device-related
infections in animal models. VC 2011 Wiley Periodicals, Inc. J Biomed
Mater Res Part B: Appl Biomater 00B: 000–000, 2011.
Key Words: initial inocula, planktonic, bioﬁlm, future research,
animal model
How to cite this article: Williams DL, Costerton JW. 2011. Using bioﬁlms as initial inocula in animal models of bioﬁlm-related
infections. J Biomed Mater Res Part B 2011: 00B: 000–000.
THE USE OF PLANKTONIC CELLS IN ANIMAL MODELS
Currently, combination biomaterials and coatings are being
developed for the treatment and prevention of bioﬁlm-related
infections. The majority of animal studies that are used to
model infections related to these materials primarily involve
the use of an initial inoculum of planktonic bacterial cells
from batch cultures.1–24 The expectation has been that these
planktonic cells would attach to the surface of a biomaterial,
medical device, or surrounding tissue and subsequently form
a bioﬁlm. Although valuable, data that have been derived
from these experiments may not provide clinicians and
biomaterials scientists additional clinical insight into how
bacteria that reside in well-established, mature bioﬁlms
impact device-related and other human infections when they
initially contaminate an implant site.
Following several decades of important observations
from investigators that bacteria preferentially adhere to
solid surfaces and to one another,25,26 in 1978 Costerton
et al. formally hypothesized that bacteria in nature reside
primarily in the bioﬁlm phenotype.27 Strong support for this
hypothesis continues to be shown in the literature that
involves collecting, analyzing, imaging, and characterizing
bacterial bioﬁlms found in nature, human tissues, and
clinically retrieved devices.28–34 Additionally, since the initial
hypothesis of Costerton et al., estimates have suggested that
99.9% of bacteria in natural ecosystems reside in the
bioﬁlm phenotype.35 Intriguingly, The Centers for Disease
Control has estimated that 65% of all infections in humans
are bioﬁlm related.36 A public announcement from The
National Institutes of Health placed that estimate at 80%
(see announcement PA-07-288).
On the basis of these observations and information, it is
important to consider that when bacteria come in contact
with wound sites, biomaterials, or portals of entry in
humans, that is, inoculate patients, there is strong evidence
to suggest that the majority of these bacteria are inherently
residing in well-established, mature bioﬁlms. A speciﬁc
example of this scenario is that of a patient who suffers
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from a Type IIIB open fracture, which is reduced with a
fracture ﬁxation device.
A Type IIIB severe fracture has been deﬁned by Gustilo
et al.37 as having ‘‘extensive soft-tissue injury loss with peri-
osteal stripping and bone exposure’’ that ‘‘is usually associ-
ated with massive contamination.’’ Rates of infection that
accompany these open fractures reach 50%38–40 and 60%
in at least one reported instance.41 The potential for these
fractures to be massively contaminated is highlighted by the
work of Bakken42 and Torsvik et al.43 who have shown that
even 1 g of soil may contain between 107 or 1010 bacteria,
the majority of which are estimated to reside in the bioﬁlm
phenotype.35 The presence of these bacteria in soil expose
fracture ﬁxation devices to bioﬁlm formation on the surface.
However, in all animal models of open fracture infec-
tions to date, planktonic bacteria have been used as initial
inocula. The same is true for other animal models of bioﬁlm
device-related infections.
LIMITATIONS OF USING PLANKTONIC CELLS AS INITIAL
INOCULA
At least three proposed rationales can be given for why the
use of planktonic cells has potentially limited investigators’
abilities to detect clinically relevant outcomes of device bio-
ﬁlm-related infections. (1) Planktonic cells are more readily
cleared by the immune system than cells residing in a
bioﬁlm.44–46 Furthermore, animals typically have immune
systems that are innately advantaged compared with those
of humans. Thus, when planktonic cells are used in in vivo
models, it may be that the majority are eradicated before
they can form bioﬁlms. This may contribute to the low
reproducibility for the induction of osteomyelitis, which has
been suggested by Gaudin et al.47 as a common problem
with animal models of osteomyelitis. (2) It is well docu-
mented that planktonic bacterial cells are more susceptible
to antibiotics than those residing in a bioﬁlm.48,49 Therefore,
if antibiotics are administered immediately following inocu-
lation, they may affect planktonic cells more effectively than
they would bioﬁlm cells. (3) When planktonic cells are
added to an in vivo system, the possibility exists that they
may be dispersed rapidly away from the site of initial inocu-
lation, which would dilute the concentration of bacteria per
given area—potentially making it easier for the body
to handle the bacterial load and prevent attachment to a
medical device.
In addition to these limitations that may accompany the
use of planktonic cells as initial inocula, investigators have
depended heavily on minimum inhibitory concentrations
(MIC) to determine the dose of antimicrobial that should be
delivered, either from a device coating or intravenously, to
prevent and/or treat bioﬁlm-related infections. The limita-
tion of the MIC value in this speciﬁc instance is that it is
based on data derived from planktonic cells from batch
culture. Speciﬁcally, a MIC is deﬁned by the Clinical and
Laboratory Standards Institute (CLSI) as the dose of antimi-
crobial that is needed to result in a three log reduction
(105 ! 102) of planktonic bacteria over a 24-h period (see
CLSI standard M26-A). Antimicrobial efﬁcacy tests as stand-
ardized by the Environmental Protection Agency (e.g., SOP
Number: MB-09-04 and SOP Number: MB-06-05) are also
based on planktonic bacterial responses. At least one stand-
ard of the American Society for Testing and Materials
(ASTM E645-07) was found to recommend that micro-
bicides be tested against bioﬁlms. Citing these planktonic
cell-based standards, Ceri et al. suggested that additional
standards must be developed to treat and/or prevent recur-
ring and untreatable infections that are the result of bioﬁlm
contamination and/or subsequent bioﬁlm formation on
medical devices.50
NUMBER OF BACTERIA IN A BIOFILM THAT MAY BE USED
AS INITIAL INOCULA
It does not appear that all bioﬁlms carry the same infec-
tious potential and we propose that most have minimal
pathogenicity. If the opposite were true, it is likely that
many more people would suffer from infections including
gingivitis, periodontitis, sinusitis, conjunctivitis, cellulitis,
gastroenteritis, vaginitis, and/or colitis. Each human being is
colonized with billions of bacteria, the majority of which
appear to reside in well-established bioﬁlms.51 As such,
infection may be considered an anomaly that extends
beyond the normal host/bacterial relationship. Infection
may also occur as humans are exposed to well-known
pathogens that reside in bioﬁlms from soil samples, on gro-
cery carts, in food, within the human microbiome, on ofﬁce
desks, in shower heads, women’s purses, grocery bags, and
a plethora of other locations all over the world.
The number of bacteria that should be used as initial inoc-
ula in animal models is application dependent. Conditions
may be considerably different in an animal that is intended to
model a patient of total joint replacement, or some other elec-
tive surgery. Elective surgeries are performed under scrupu-
lously aseptic conditions, yet despite these efforts, rates of
infection still range from 1 to 4% and at times higher.52–59 If
an animal model were used to replicate an elective surgery
scenario for biomaterial development, it may be more appro-
priate to use a low number bioﬁlm as the initial inoculum
than what might be used for a massively contaminated open
fracture model. Additional consideration would also need to
be taken for the inclusion of organisms associated with
human skin. Similarly, the use of planktonic or bioﬁlm bacte-
ria is application dependent.
When bioﬁlms are grown in the laboratory, it is common
to see them reach incredibly high numbers—on the order of
107 or 1010 cells/given area. Bioﬁlms that contain high
numbers of cells can also be found in nature.25,27,29,42,43
Similarly, bacterial cells that have been directly observed on
and in the human body have been shown to reside in the
bioﬁlm phenotype.51,60 Biopsy punches of human skin have
been estimated to contain 106 cells/cm2 and it is well
documented that the hardy bioﬁlm former, Staphylococcus
epidermidis, comprises a large portion of these resident
commensal bacteria.51,61,62 In the large intestine, several
hundred grams of bacteria can be found with numbers
reaching an astounding 1011 or 1012 cells/g of tissue
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comprised of hundreds of species.51,63,64 Notably, 60% of
fecal solids have been shown to be comprised of bacteria.65
Although bioﬁlms are ubiquitous and they tend to dwell
in communities that can have very high numbers of cells, it
may nevertheless be incorrect to assume that wound sites
or surgical sites only become infected when they are conta-
minated with high number bioﬁlms. To the contrary, a bio-
ﬁlm, or a portion of bioﬁlm that has broken off, that con-
taminates a wound site may consist of as few as 102 or 104
cells, if not fewer.
Consider the paradigm of a patient who undergoes elec-
tive surgery, such as total joint replacement. After the
patient’s skin is prepped, 106 cells/cm2 of normal ﬂora may
be reduced in number to less than 103 cells/cm2 (a 99.9%
reduction, which is the most common claim of antiseptics).
Note that the majority of these have been shown to reside
in the bioﬁlm phenotype. Importantly, groups have shown
that even following antiseptic treatment, viable cells con-
tinue to reside several layers deep in skin,66,67 and one of
us (J.W.C.) has observed matrix-enclosed bacterial bioﬁlms
between stratiﬁed squamous cells in the distal ﬁve to seven
layers of human prepped skin (unpublished observations).
During surgery, these cells would have direct access to tis-
sue throughout a patient’s integument, while an incision is
made, and they would also have direct access to the surfa-
ces of transcutaneous or other implanted biomaterials. As
there is no data in the literature that involves small number
bioﬁlms contaminating wound and/or surgical sites, sur-
geons, and investigators are left to wonder what effect these
might have on the development of infection in these
scenarios.
There are myriad other paradigms that could be consid-
ered with similar scenarios of low numbers of cells within a
bioﬁlm contaminating wound and/or surgical sites. What
remains is the fact that hypothesis driven research needs to
be undertaken to determine the impact that low number
bioﬁlms have on human health as they attach to and form
on the surface of biomaterial devices. Furthermore, to our
knowledge, there is no comparative study in the literature
to determine the effect that fewer versus higher numbers of
cells in a bioﬁlm, which derive from the same bacterial
strain(s), have on the formation of bioﬁlms on biomaterials.
For now, the understanding of critical doses required to
cause infection are based solely on concentrations of plank-
tonic bacteria.
THE 105 RULE MAY NOT APPLY TO BIOFILM
Studies have shown that to prevent infection, bacterial loads
must be kept below 105 cells per gram of tissue66,68–71 and
this is the rule of thumb used by various clinicians as an in-
dicator of infection. However, this number is strain depend-
ent and is based on planktonic bacterial cell counts. Citing
Bowler,72 Edwards and Harding have stated that, ‘‘The clini-
cal relevance of the theory that bacterial counts of over 105
represent clinical infection has been questioned.’’68 In addi-
tion, it may be that smaller numbers of cells are required to
cause infection if they reside in the bioﬁlm phenotype.
Indeed, the ability of low number, mature bioﬁlms to resist
antimicrobial treatment may enhance our understanding of
how bacteria cause infection when initial inocula are on the
order of thousands or tens of thousands of cells as opposed
to the hundreds of thousands or hundreds of millions in
planktonic form that are commonly used for in vivo studies.
Wolcott et al.73 have recently undertaken a study
wherein they showed that in the early stages of develop-
ment, bioﬁlms were more sensitive to antimicrobials when
compared with bioﬁlms that had matured for more than 24
or 48 h. Their data further suggested that even if similar
numbers of cells were present, the maturity, and not so
much the number of cells within the bioﬁlm, had a signiﬁ-
cant inﬂuence on its ability to resist antimicrobial perturba-
tions. Their work was designed to model a speciﬁc clinical
application and effectively addressed those scenarios.
Importantly, however, this work also followed the predomi-
nant pattern of bioﬁlm research wherein enormous
numbers of cells accumulated over time within the bioﬁlm
growth system.
Yet, as mentioned above, it may not always be accurate
to analyze bioﬁlms as they undergo an increase in their
number of cells. Although dynamic, bioﬁlms in real life sys-
tems typically do not display the same growth rates as
those generated under optimal conditions in the laboratory.
Rather, in natural systems bioﬁlms increase in cellular
number over a longer period of time, mature to a level of
equilibrium and when challenged by modiﬁcations in their
environment, they respond appropriately. The hypothesis is
that these equilibrated, matured, slow growing bioﬁlms are
what primarily contaminate wound sites, parenteral routes
and medical devices within humans. Thus, to model contam-
ination of a wound site with matured, equilibrated bioﬁlms,
similar to how they are found in nature, studies may beneﬁt
from growing bioﬁlms to threshold levels, allowing them to
mature, and then exposing them to wound sites, antibiotics
or other antimicrobial agents in in vitro and/or in vivo
systems.
FUTURE METHODS OF GROWING BIOFILM
FOR USE AS INITIAL INOCULA
Connell et al.74 have recently developed a remarkable
method of growing bioﬁlms in small numbers using micron
sized ‘‘lobster traps.’’ Although countless possibilities exist
for in vitro experimentation with these traps, they are cur-
rently limited in that they are adhered to a solid surface.
However, modiﬁcations to the substrate could make it possi-
ble for them to be used as initial inocula in an in vivo
model.
Recently, a modiﬁed CDC bioﬁlm reactor system has
been developed to grow bioﬁlms on the surface of polye-
theretherketone (PEEK) membranes. Bioﬁlms of methicillin-
resistant Staphylococcus aureus (MRSA) were shown to de-
velop into three-dimensional pillar like structures on the
surface of these membranes.75,76 In vitro and in vivo work
is currently being performed to test the efﬁcacy of a novel
antimicrobial coating on simulated fracture ﬁxation plates
against these MRSA bioﬁlms. To date, in 14 out of 14 ani-
mals, work has indicated that when these bioﬁlms are used
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as initial inocula in the absence of antimicrobial treatment,
they caused osteomyelitis to develop and persist up to a 12
week end point.
Despite these promising results, there is one crucial fac-
tor to take into consideration. In the above study, bioﬁlms
were grown for a 48-h period, rinsed to remove loosely
adherent or nonadherent cells, and transferred in a broth
solution prior to using them as initial inocula. These steps
were undertaken in an attempt to reduce the possibility of
having planktonic cells present. However, the potential still
existed that a portion of cells present could have been in
the planktonic phenotype. As such, the question may arise;
was it the bioﬁlm bacteria or the planktonic bacteria that
caused infection? Two responses can be given.
First, it is likely impossible with current technologies to
separate all planktonic bacteria from those that reside in
the bioﬁlm phenotype such that an inoculum with bioﬁlm
bacteria alone is absolutely deﬁnitive. Yet, it is also unlikely
that such a distinct separation exists between planktonic
and bioﬁlm bacteria in natural ecosystems. This may sug-
gest that using an inoculum that has a mixture of the two,
with those in the bioﬁlm phenotype being more heavily
selected, is clinically relevant.
Second, an additional animal model is currently being
used to test the ability of the MRSA strain discussed above
to cause infection when inoculated in the planktonic pheno-
type from batch culture. When the onset of infection was
compared between these two animal models, there was a
drastic difference in the rapidity and severity of infection
that set in with the planktonic bacteria. In that instance,
none of the animals survived past 11 days. In contrast,
those that were treated with bioﬁlms as initial inocula dis-
played signs of infection that were much less severe and
which progressed at a much slower pace. More speciﬁcally,
those animals displayed limited signs of pain or distress
even out to 12 weeks, but each of them developed a signiﬁ-
cant osteomyelitic infection.
This contrast in the speed and severity of infection may
provide clinical evidence that using bioﬁlms as initial inoc-
ula is more correlative to bioﬁlm-related infections that are
present in patients. In patients, bioﬁlm-related infections
appear to be latent infections that develop slowly over time
and which may persist for extensive periods.33 So although
these current animal models provide a promising step in
the direction of using bioﬁlms as initial inocula, there are
many factors to take into account: a host’s health, the patho-
genicity of an organism, the ability for an organism to de-
velop into a bioﬁlm, the degree of contamination, the ratio
of cells in the planktonic phenotype to those in the bioﬁlm
phenotype, and so forth. Thus, this issue of planktonic ver-
sus bioﬁlm infection is still a limitation and will require
additional future testing to overcome the challenges of sepa-
rating the bacterial phenotypes before more deﬁnitive state-
ments can be made.
At this time, with the variety of bioﬁlm reactor devices
that are currently available, such as the CDC bioﬁlm reactor,
the modiﬁed CDC bioﬁlm reactor, the Drip Flow Bioﬁlm
Reactor, and ‘‘lobster traps,’’ the outlook is promising for a
transition in bioﬁlm investigation to occur from the in vitro
paradigm to the in vivo setting.
CONCLUDING DISCUSSION
During the design process of an animal study, in particular
an infection model, investigators often take careful consider-
ation to select animals that have not been inﬂuenced by
antibiotic feed, those that have not been specially treated in
some manner at a housing facility, and, depending on the
study design, those that have not been genetically modiﬁed
or otherwise altered to inﬂuence the outcomes of a study.
In contrast, investigators tend to select animals that come
from natural environments so as to select a group that will
model an uninﬂuenced, random sample. A similar process
should be used when selecting bacterial isolates. These
should be derived, as closely as possible, from natural sys-
tems and grown under conditions that are conducive to
their environment and phenotype. This may be the bioﬁlm
phenotype and in other cases, the planktonic.
In summary, as an isolate(s) is selected for application
in an animal model of infection, or as one is selected for
speciﬁc in vitro testing, such as an antimicrobial eluting bio-
material, we recommend that, depending on the speciﬁc
application, (1) the isolate be derived from a primary cul-
ture, either from a patient or natural environment, that has
not been passaged numerous times, (2) that it be grown
under conditions that will promote bioﬁlm formation to the
nearest possible extent as they are found in their natural
environment and, (3) that bioﬁlms be applied in numbers
that, as closely as possible, model clinical and/or environ-
mental scenarios to which biomaterials may be exposed.
The impact of bioﬁlm-dwelling bacteria on human health
is becoming ever more apparent. Chronic wounds are now
considered to be the result of acute infection that begins
with bioﬁlm contamination as opposed to a nonhealing
wound that is later contaminated and suffers from bioﬁlm
formation/infection.77–80 Heart disease is now indicated to
be compounded by bioﬁlm dwelling bacteria from oral pla-
que that enter the vasculature.81,82 Overall human health is
believed to be signiﬁcantly inﬂuenced by an intricate bal-
ance of bioﬁlm dwelling bacteria in gut ﬂora.63 In short, the
impact of bioﬁlms on human well-being and disease cannot
be overestimated.
Looking to the future of bioﬁlm and biomaterials
research, additional approaches for in vitro analyses and
design modiﬁcations to in vivo models that encompass the
use of preformed, well-established, sessile communities of
mature bioﬁlms that model those found in nature, in
patients and within the environment, can be envisioned. As
studies are undertaken to analyze the impact of low number
bioﬁlms on infection outcomes, results may indicate that
less than 105 cells/gram of tissue, or per area, will be
required to cause infection.
If the efﬁcacy of antimicrobials are tested against high
and low number bioﬁlms, those on the order of 107–109
cells and 102–104, respectively, we may uncover deeper
insights into the concentrations of antimicrobial in, for
example, antimicrobial eluting biomaterials, that are needed
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to prevent and eradicate bioﬁlm-related infections from
developing. We can only wonder at this time how many
antimicrobials and antimicrobial eluting biomaterials have
been prevented from progressing to clinical, home, indus-
trial, and/or environmental use based on the fact that MIC
values, which are primarily the result of planktonic cellular
response, have been used to determine the amount that was
needed to eradicate bacteria residing in well-established
bioﬁlms.
The opposite may be true as well. There is no indication
that antibiotics that have been put into clinical use have
shown efﬁcacy against low and/or high number bioﬁlms on
implants. Although this trend may change as an understand-
ing of the role of bioﬁlm increases, this paradigm has
potentially been a contributing factor to the development of
antibiotic resistance. More speciﬁcally, in various systems,
bacteria residing in bioﬁlms may have been exposed to lower
concentrations than are needed to prevent their growth and
eradicate them within in vitro and in vivo systems. However, a
cavalier approach of simply increasing dosages of antimicro-
bials alone or used in eluting biomaterials could potentially
lead to toxic effects in vivo and cause additional problems.
Thus, future work will be needed to elucidate the efﬁcacy and
toxicity of antimicrobials used alone or in eluting biomaterials
against bioﬁlms in clinical studies.
In conclusion, the impact that low number bioﬁlms have
on human infection as well as using well-established,
mature bioﬁlms as initial inocula for in vitro and in vivo
models may help further the optimization of antimicrobial
treatments, such as those used in coatings on biomaterials.
In addition, the understanding of the impact that bioﬁlms
from natural systems have as initial contaminants of
wounds may also be increased. Most importantly, a shift in
the use of bioﬁlms for inoculation methods and analytical
techniques may help biomaterial researchers take a step for-
ward, and thus obtain the advantage in the battle against
bioﬁlm implant-related infections.
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Abstract Bioﬁlm-related infections have become a major
clinical concern. Typically, animal models that involve
inoculation with planktonic bacteria have been used to create
positive infection signals and examine antimicrobial strate-
gies for eradicating or preventing bioﬁlm-related infection.
However, it is estimated that 99.9%of bacteria in nature dwell
in established bioﬁlms.As such, openwoundshave signiﬁcant
potential to becomecontaminatedwith bacteria that reside in a
well-established bioﬁlm. In this study, a modiﬁed CDC bio-
ﬁlm reactor was developed to repeatably grow mature bio-
ﬁlms of Staphylococcus aureus on the surface of
polyetheretherketone (PEEK)membranes for inoculation in a
future animal model of orthopaedic implant bioﬁlm-related
infection. Results indicated that uniform, mature bioﬁlms
repeatably grew on the surface of the PEEK membranes.
Keywords Bioﬁlm  Modiﬁed  Reactor  CDC 
Membrane  Repeatability
Introduction
Bioﬁlms have become a major research interest in recent
years. For example, the role of bioﬁlms in chronic ortho-
paedic device-related infections has been particularly
concerning as highlighted by the failed attempts of ortho-
paedic surgeons to treat patients who are adversely affected
by bioﬁlm formation on and near orthopaedic devices
[3, 5, 16]. These patients often require expensive and
compromising revision surgery, implant removal or, in a
worst case scenario, amputation. Death can also be a
devastating outcome. Bioﬁlm-related infections similarly
affect injured military personnel, in particular, those suf-
fering from severely contaminated blast injuries in the
current Afghanistan and Iraq conﬂicts [13, 14].
In an attempt to prevent these bioﬁlm-related infections
from developing near or on orthopaedic devices, animal
models have been used to create positive infection signals and
to examine antimicrobial strategies for treatment [4, 7, 8, 17].
Typically, these animal models have consisted of implanting
a device in conjunction with inoculation of planktonic (free-
ﬂoating) bacteria near the device. The expectation has either
been that planktonic cells will form a bioﬁlm on or near the
implant and result in bioﬁlm-related infection, or that
planktonic cells alone will develop infection.
However, since the 1978 hypothesis of Costerton et al.
[6] that bacteria in nature preferentially aggregate in bio-
ﬁlms, it has been estimated that approximately 99.9% of
bacteria in nature dwell in bioﬁlms [11, 12]. Moreover,
Bakken [1] has shown that 1 g of fertile soil can contain up
to 5 billion bacterial cells. If contaminated with even 1 or
2 g of soil, it is plausible that open fractures or other types
of open wounds may have signiﬁcant contamination with
very high inocula of bacteria residing in well-established
bioﬁlms. Therefore, in vivo models of infection that
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involve the use of well-established bioﬁlms may contribute
to our understanding of bioﬁlm-related infection as well as
methods of safely eradicating the bioﬁlm and related
infection without surgery and implant removal.
In this study, a modiﬁed CDC bioﬁlm reactor was
developed to grow well-established Staphylococcus aureus
bioﬁlms on the surface of polyetheretherketone (PEEK)
membranes. It is intended for these bioﬁlm-ridden mem-
branes to be used to inoculate future animal models of
bioﬁlm-related infection, pending conﬁrmation that
mature, uniform and viable bioﬁlms can be repeatably
formed on the PEEK membranes.
Materials and Methods
Isolate Selection
A freshly cultured, clinical isolate of methicillin-resistant
S. aureus (MRSA) was collected from a patient and used
for this study. More speciﬁcally, a patient who underwent
knee surgery developed infection and an aspirate was sent
to ARUP Laboratories, Salt Lake City, UT for character-
ization and susceptibility testing. The isolate was charac-
terized as MRSA based on resistance to penicillin and
oxacillin using the Kirby Bauer disc diffusion technique.
Preliminary work indicated that the isolate was a bioﬁlm
former following black colony formation on Congo Red
agar and detection of the icaADBC gene cluster. When
grown as a bioﬁlm and used as initial inocula, bioﬁlms of
this strain caused osteomyelitis in a pilot animal model of
bioﬁlm implant-related infection (unpublished data).
Modiﬁed Design of the CDC Bioﬁlm Reactor
The CDC bioﬁlm reactor was purchased from Biosurface
Technologies (Bozeman, MT). The original design of the
reactor is provided in Fig. 1a. A modiﬁed lid was designed
and machined using a local machine shop. The modiﬁed lid
contained four slots into which guillotine-like holders
(20 cm in length with a 3 mm groove down the middle of
the interior portion) made of ultra-high-molecular-weight-
polyethylene (UHMWPE) were inserted (Fig. 1b). Into the
guillotine holders were placed PEEK membranes that were
held in place between two 316L stainless steel plates with a
0.64 cm2 opening (Fig. 1b). A photograph of the modiﬁed
reactor is provided in Fig. 1c. All other aspects of the
reactor were the same as the original CDC bioﬁlm reactor.
Bioﬁlm Growth in Reactor
The modiﬁed reactor held eight PEEK membranes with
two membranes in each of the four guillotine holders (see
Fig. 1). PEEK membranes were ﬁrst sonicated for 10 min
in detergent, rinsed under running reverse osmosis water
for 10 min, sonicated in reverse osmosis water for 10 min
and rinsed once again using 70% ethanol. The reactor was
then assembled and all components autoclaved before use.
Following American Society for Testing and Materials
(ASTM) standard E2562-07, the modiﬁed reactor was run
under the following conditions: approximately 1.5 9 108
bacterial cells were inoculated into 500 ml of brain heart
infusion (BHI) broth (modiﬁed) in the bioﬁlm reactor. The
rotator was stirred at 130 rpm, and the unit was placed in
an incubator set at 28.5C for 24 h. A 10% BHI broth
(modiﬁed) solution was then ﬂowed through the reactor at
6.94 ml/min for 24 h.
Sample Fixation, Dehydration and Imaging
To qualitatively observe the bioﬁlms that had developed,
eight membranes were imaged using SEM. For imaging
preparation, membranes were removed from the reactor,
placed in 2.5% glutaraldehyde for 24 h and then dehy-
drated using ascending grades of ethanol with 3 9 20 min
exchanges of each up to 100%. Samples were dried in a
desiccator overnight, sputter coated with *3 nm of gold,
and imaged using a FEI NOVANano SEM 600.
On twomembranes, the Filmtracer
TM
LIVE/DEAD stain
(Invitrogen, Carlsbad, CA) was used in conjunction with
confocal laser scanningmicroscopy (CLSM) to qualitatively
observe the degree of live versus dead bacteria on the
membrane. The bioﬁlmswere observed using a FV-1000XY
inverted CLSM microscope with a 609 water objective.
Bacterial Quantiﬁcation
In order to determine uniformity, following eight separate
runs of the modiﬁed bioﬁlm reactor, a total of 64 PEEK
membranes were used to quantify the number of bacteria that
grew on the surface of eachmembrane. Themembranes from
each run were randomly assigned to one of two treatment
groups (i.e., with four membranes per group).
Following growth in the reactor, the four membranes in
Group 1 were removed from the guillotine holders, rinsed
39 in 6 ml of saline, placed on a shaker at 100 rpm for
20 min and allowed to remain stationary for 1.5 h. The
membranes were then vortexed for 1 min, sonicated at
47 kHz and 1.8 W/cm2 for 10 min, allowed to recover
from sonication for 20 min and then enumerated using a
10-fold dilution series. 100 ll of each dilution
(1:10–1:10,000,000) was plated onto Columbia blood agar
and incubated overnight at 37C. The following day, the
colony forming units (cfu) were counted to determine
the number of bacteria per membrane (cfu/membrane).
Fifteen randomly selected membranes were imaged by
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SEM to conﬁrm that bacteria had been removed from the
surface.
The rationale for shaking the membranes at 100 rpm for
20 min was to model the car ride that they will be exposed
to when they are transported from the lab to the site of
animal surgery. Furthermore, the four membranes in Group
1 were allowed to remain stationary for 1.5 h to model the
time that they will be stationary whilst the surgical facility
and animals are prepped for surgery before inoculation.
Group 2 membranes were treated in the same manner as
those in Group 1 with the exception that they were allowed
to remain stationary for 3 h as opposed to 1.5 h so as to
model the time that they will remain stationary during the
ﬁrst surgery of the future animal model.
The density of bacteria in cfu/membrane was recorded
for each PEEK membrane and then log10 transformed. For
each of the two treatment groups separately, an ANOVA
was ﬁt, with run as a random effect, to calculate the mean
and repeatability standard deviation (SD) of the log den-
sities on the PEEK membranes over the eight reactor runs.
Fig. 1 a Schematic diagram of
the CDC bioﬁlm reactor.
b Schematic diagram of the
modiﬁed CDC bioﬁlm reactor
lid and guillotine-like holder.
c Photograph of the completed
modiﬁed CDC bioﬁlm reactor
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Another ANOVA, with group as a ﬁxed effect and run as a
random effect, was used to compare the group means and
to calculate the repeatability SD for both groups pooled
together. These statistics were used to determine if any
difference in bacterial response could be seen between
membranes that were allowed to remain in a dilute broth
solution for varying periods of time. The analyses also
showed the percentage of the repeatability variance
attributable to within- and between-run sources.
Results
Growth on PEEK Membranes Within the Bioﬁlm
Reactor
Images collected of the PEEK membranes following
growth, sample ﬁxation and dehydration indicated that
copious amounts of bioﬁlm formed on the membrane sur-
faces (Fig. 2a). Furthermore, each of the three indicators
Fig. 2 a Representative SEM
image of the S. aureus bioﬁlm.
b Additional image of the EPS
providing a scaffold for
bacterial cells within the bioﬁlm
to create a bridge from one
surface of the PEEK membrane
to another. c Representative
image showing a three-
dimensional structure of the
bioﬁlm extending vertically
from the surface of the PEEK
membrane. d Representative
image showing possible water
channels within the bioﬁlm
structure (arrow). e The LIVE/
DEAD stain showed living
cells as green and dead cells as
red. This image shows a
representative Z projection slice
of the S. aureus bioﬁlm
collected using CLSM and
indicates that the cells within
the bioﬁlm were predominantly
living with an estimated ratio of
live to dead cells being 1000:1.
Original magniﬁcation was 960
(color images can be seen in the
online version or upon request
to the authors)
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that a mature bioﬁlm had developed were detected [10],
i.e., signiﬁcant EPS production (Fig. 2a and b), three-
dimensional structures of mushroom- or pillar-like forma-
tions (Fig. 2c) and possible water channel development
(Fig. 2d) were observed upon SEM analysis. In addition,
the EPS matrix appeared to act as a scaffold to which the
bacteria attached to create a ‘‘bridge’’ that connected cells
of the bioﬁlm from one strand of the PEEK membrane to
another (Fig. 2b). These results indicate that mature bio-
ﬁlms did form on the surface of PEEK membranes when
grown within the modiﬁed membrane reactor.
Notably, although the temperature of the incubator was
set at 28.5C, the recorded temperature of the broth after
the ﬁrst 24 h of each run was 28.1 ± 1.2. After 48 h of
growth, the broth temperature from each run was
29.8 ± 0.5.
Bacterial Quantiﬁcation
The number of bacteria on each PEEK membrane was
quantiﬁed following eight separate runs of the reactor, with
eight membranes per run, and four membranes randomly
assigned to each of two treatment groups to conﬁrm uni-
formity. The data are shown in Fig. 3.
Mean log densities and repeatability SDs for each of the
two groups individually and also for all 64 membranes
pooled together are given in Table 1. The table corrobo-
rates what is evident in Fig. 3: the two groups have similar
means and repeatability SDs. A 90% conﬁdence interval
for the difference of the Group 1 mean log density sub-
tracted from the Group 2 mean log density was found to be
(0.06, 0.19), which indicates statistical equivalence
between the two group means at a signiﬁcance level of 5%
as long as mean differences up to 0.19 are considered to be
negligible.
Taken together, these results show that copious amounts
of S. aureus bioﬁlm formed on the surface of each PEEK
membrane within the reactor and that the mean log den-
sities for the two treatment groups were statistically
equivalent. Furthermore, the bioﬁlm log density exhibited
acceptable repeatability from run to run under the condi-
tions described.
SEM images of the PEEK membranes that were col-
lected after the quantiﬁcation process indicated that only
Fig. 3 An individual value plot
of the log density of bacteria per
PEEK membrane. Group 1
(open circle) membranes were
those that were allowed to
remain stationary for 1.5 h
before quantiﬁcation. Group 2
(open square) membranes were
those that were allowed to
remain stationary for 3 h before
quantiﬁcation. Each point
represents one membrane
Table 1 Statistical characteristics for each of the two treatment groups, and both groups pooled together
Group Mean SE Repeatability SD Percentage contribution
Within run (%) Between run (%)
1 9.45 0.0296 0.2020 17 83
2 9.58 0.0297 0.2162 15 85
Both 1 and 2 9.51 0.0203 0.2130 14 86
The standard error (SE) of the mean and the repeatability SD are based on four membranes per run. These results demonstrate the uniformity of
the bioﬁlm formation on the PEEK membranes
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sparse microcolonies of bacteria remained on the surface.
As such, the number of bacteria in the microcolonies was
inconsequential with respect to the billions of cells that
were enumerated (SEM images not shown).
Discussion
An increased understanding of the important role of bio-
ﬁlms in device-related and chronic infections suggests that
in vitro and in vivo studies may be strengthened with the
use of mature bioﬁlms as opposed to the application of
planktonic bacteria alone. This study highlighted the ability
of the CDC bioﬁlm reactor to be modiﬁed in such a way
that mature bioﬁlms could be grown on a biocompatible
polymer surface that can later be applied towards in vivo
experimentation. Taken together, the hypothesis that
mature bioﬁlms would develop on the surface of PEEK
membranes in a repeatable fashion was supported.
Interestingly, during the optimization of the modiﬁed
reactor, it was found that when the unit was placed in an
incubator set at 37C, bioﬁlms did not form as well as
when they were grown at 28.5C. More speciﬁcally, when
grown at 37C, there was no bioﬁlm growth on the PEEK
membranes by visual observation, whereas at 28.5C,
copious amounts of bioﬁlm could be seen. Since our group
was interested in having *109 cells/membrane, no further
runs at 37C were performed. Nevertheless, this ﬁnding
was similar to that of Rode et al. [15]. They found that
several clinical and food-related isolates of S. aureus pro-
duced bioﬁlms optimally near 30C.
The overall mean bacterial log density was 9.51 log
(cfu/membrane), and the repeatability SD was 0.2130. As a
comparison, in the 13 experiments described by Bucking-
ham-Meyer et al. [2], S. aureus ATCC 6538 bioﬁlm grown
in the CDC reactor on glass coupons exhibited a mean of
8.3 log (cfu/cm2) and a repeatability SD of 0.224 (based on
two coupons). In a different set of 12 experiments, Buck-
ingham-Meyer et al. [2] grew Pseuodomonas aeruginosa
bioﬁlm in the CDC reactor on glass coupons, with a mean
of 8.5 log (cfu/cm2) and a repeatability SD of 0.211.
Goeres et al. [9] grew P. aeruginosa bioﬁlm in the CDC
reactor on polycarbonate coupons over nine experiments
and reported a mean of 7.06 log (cfu/cm2) and a repeat-
ability SD of 0.510 (based on two coupons per experi-
ments). Thus, the bioﬁlm bacteria grown on PEEK
membranes in the modiﬁed CDC reactor exhibited
acceptable run to run repeatability in our study.
Demonstrating that bioﬁlm growth on the PEEK mem-
branes was repeatable from run to run was an important
aspect of this project. More speciﬁcally, if these bioﬁlms of
S. aureus on PEEK membranes are to be used in future
animal models, it is important that individual animals
receive statistically equivalent bioﬁlm challenges. There-
fore, the statistical equivalence of the bioﬁlm grown on
membranes in each of the treatment groups suggests that
these bioﬁlms will be used reliably and repeatably in a
future animal model of device-related infection.
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Staphylococcus epidermidis ATCC 35984
GROWN USING THE CDC
BIOFILM REACTOR
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Abstract: Bacteria flourish in nearly every environment on earth. Contributing to their ability to grow in many
esoteric locations is their development into a biofilm structure. In an effort to more accurately model the growth
environment of biofilms in nature, a Center for Disease Control and Prevention ~CDC! biofilm reactor has been
developed that mimics nature-like shear forces and renewable nutrient sources. To date, there has been no
confirmation by scanning electron microscopy ~SEM! that mature biofilms develop on a surface when grown
using the CDC biofilm reactor. Three different SEM methods were used to collect images of Staphylococcus
epidermidis ATCC 35984 that was to be grown using the CDC biofilm reactor. In addition, two different fixative
techniques were used in each of the imaging methods. Results indicated that after 48 hours of growth in the
reactor, S. epidermidisATCC 35984 does produce a significant network of matrix components and 3Dmushroom-
or pillar-like structures with signs of water channel development. In conclusion, S. epidermidis ATCC 35984
grown using the CDC biofilm reactor does appear to display signs of mature biofilm development. These results
could be important for studies wherein mature biofilms are needed for in vitro and/or in vivo applications.
Key words: biofilm, scanning electron microscopy, fixation, CDC biofilm reactor
INTRODUCTION
Biofilms are “Structured communit~ies! of bacterial cells
enclosed in a self-produced polymeric matrix and adherent
to an inert or living surface” ~Costerton et al., 1999!. Al-
though largely beneficial to human life in performing niche
functions such as biodegradation ~Martinkova et al., 2008!,
oxygen production ~Pringault & Garcia-Pichel, 2000!, and
water treatment ~Modin et al., 2008!, biofilms do have the
negative potential of attaching to biomaterials and sub-
sequently causing biomaterial-related infections in humans
~Costerton, 2007a!.
The pathogenicity of biofilm-dwelling organisms is at
least in part attributed to the development of an extracellu-
lar polymeric substance ~EPS! ~Ammendolia et al., 1999!.
The EPS is highly heterogeneous in its production between
organisms and even bacterial growth conditions ~Uhlinger
& White, 1983; De Beer et al., 1994!. Containing between
90% and 98% water, the matrix expresses highly hydro-
dynamic properties ~Christensen & Characklis, 1990; Schmitt
& Flemming, 1999; Erlandsen et al., 2004!. Furthermore, the
EPS matrix can have a variety of forms from honeycomb
structures ~Thar & Kuhl, 2002; Costerton, 2007d; Schaudinn
et al., 2007! to complex three-dimensional ~3D! networks of
fibers wrapping around the surface of the bacteria ~Erland-
sen et al., 2004!.
Not only has the National Institutes of Health sug-
gested that 80% of all clinical illnesses are biofilm-related, it
is believed that in nature bacteria dwell largely in biofilm
structures ~Costerton, 2007c!. Importantly, and perhaps in-
tuitively, bacterial phenotypes and environments that exist
in nature are not the same as bacteria grown in the lab.
Differences in nutrient source and concentration can affect
bacterial growth rate and biofilm formation. In the lab,
microbiologists select planktonic bacteria for almost every
application from the bulk solution of a broth growth media
or the water surface of an agar plate, whereas the more
naturally occurring biofilm bacteria grow at interfaces, on
ridges, under varying nutrient conditions, and at times
under high shear forces. In summary, the lab environment
does not always accurately reflect the natural life cycle of
pathogenic or other bacteria ~Costerton, 2007c!.
In an attempt to address these limitations, novel tech-
nologies have been developed that propose to grow biofilms
in the lab under more natural conditions while maintaining
repeatable results ~Goeres et al., 2005!. One such technology
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is the Centers for Disease Control and Prevention ~CDC!
biofilm reactor. The CDC biofilm reactor is a reliable exper-
imental tool for growing a standard biofilm with former
evaluation of the repeatability of the procedure ~Goeres
et al., 2005!.
In essence, this unit supplies a continuous flow of nutri-
ent broth through a beaker that contains a swirling paddle
that exposes bacteria growing on “coupons” to shear forces.
The setup mimics at least two nature-like environments—a
renewable nutrient source ~the concentration of which the
user can adjust as desired! and shear forces that are exposed
to the growth substrate and biofilm itself. Previous imaging
studies have involved bacteria that were grown using the
previously described traditional growth methods ~Erlandsen
et al., 2004; Priester et al., 2007!. However, to date there has
not been visual observation by scanning electron micros-
copy ~SEM! to confirm that bacteria grown using the CDC
biofilm reactor develop into a mature biofilm, i.e., a biofilm
that displays significant EPS production, mushroom- or
pillar-like structures, and water channel connections ~Jiang
& Pace, 2006!. Thus, in this study three types of SEM and
two fixation techniques were used to observe the biofilm
matrix of Staphylococcus epidermidis ATCC 35984, a known
heavy matrix producer, grown using the CDC biofilm reac-
tor. It was hypothesized that this biofilm grown using the
CDC biofilm reactor would display characteristics that re-
flect a mature biofilm structure. It was further hypothesized
that when fixed with a glutaraldehyde-based fixative solu-
tion, the EPS would be preserved more readily than with
formalin fixation.
A promising field of SEM imaging has been developed
that provides the ability to image a biological or other-
wise “wet” sample without any preparatory techniques—
hypothetically resulting in an image of the sample in its
more natural, water-containing condition. These imaging
methods are termed environmental SEM ~ESEM! and vari-
able pressure, or low vacuum SEM. ESEM conditions in-
clude chamber pressures in the range of 20 Torr whereas
low vacuum conditions function at around 2 Torr. The
purpose of these conditions is to circumvent the need for
fixing, dehydrating, and/or coating a sample, which, in the
case of biofilms, are believed to alter the morphology of the
matrix ~Little et al., 1991; Fassel & Edminston, 1999;
Priester et al., 2007!. However, previous reports have also
found that with ESEM damage to biofilms from the beam is
evident after only a few minutes of imaging ~Little et al.,
1991; Priester et al., 2007!.
Another mode of SEM imaging requires high vacuum
~104–1010 Torr! conditions to image a sample making
fixation, dehydration, and coating techniques essential. Nev-
ertheless, it has recently been shown that cationic dyes and
metal stains, in conjunction with cellular fixation and de-
hydration techniques, may preserve the biofilm matrix to
allow for qualitative interpretation of connection points,
matrix structures, and distribution of the components ~Er-
landsen et al., 2004!. Moreover, Priester et al. ~2007! deter-
mined that even ESEM images of biofilm are enhanced after
fixation and cationic dye treatment, albeit without dehydra-
tion of the sample.
Therefore, to compare the various SEM imaging tech-
niques, a standard JEOL JSM-6100 lanthanum hexaboride
~LaB6! filament SEM, a FEI high-resolution NOVA Nano-
SEM, and the FEI Quanta 600 ESEM were used to observe
the biofilm matrix of S. epidermidis ATCC 35984 grown
using the CDC biofilm reactor.Moreover, because many lab-
oratories use 10% buffered formalin or 2.5% glutaraldehyde
combined with other chemicals to fix biological specimens,
biofilms were treated with one of these two fixative tech-
niques for comparison of matrix preservation.
MATERIALS AND METHODS
Coupon Passivation
The CDC biofilm reactor ~Biosurface Technologies, MT!
uses “coupons” that have a 12
_-in. diameter and 18
_-in. height
on which to grow biofilms ~Fig. 1!. The biofilms develop on
the faces of the coupons as they are exposed to shear forces
by a swirling paddle in the base of the reactor. The coupons
can be made of nearly any desired material. For this study,
commercially pure titanium ~cpTi! coupons were used ~Bio-
surface Technologies, Bozeman, MT! to model titanium
that is used in implants for joint replacement devices. Prior
to growing biofilm on them, the coupons were passivated by
first washing them and sonicating them for 10 min in a
store-bought detergent. The coupons were then rinsed in
running reverse osmosis water, cleaned and sonicated for
another 10 min in Alconox detergent, rinsed again in the
Figure 1. Schematic diagram of the CDC biofilm reactor. Biofilms
are grown on the surface of coupons in the base of the reactor. In
addition, biofilms are exposed to shear forces as the paddle ~vane!
swirls broth media across the surface of the coupons.
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same, and placed in ;35% solution of nitric acid for
30 min. Following nitric acid passivation, coupons were
soaked in reverse osmosis water for 10 min then rinsed in
running water of the same for an additional 10 min. All
equipment, including the coupons, was autoclaved prior to
use.
Bacterial Growth
S. epidermidis ATCC 35984 was chosen because of its use in
various orthopaedic experiments and its significant produc-
tion of a slimy layer. The isolate was first grown on Colum-
bia blood agar ~Hardy Diagnostics, Santa Maria, CA!. From
a fresh 24 h culture, a 0.5 McFarland standard of the
bacteria was made, which equates to ;1.5  108 bacteria/
mL. One mL of the McFarland standard was then inocu-
lated into 500 mL of tryptic soy broth ~TSB; Becton
Dickinson and Company, Franklin Lakes, NJ! in the CDC
biofilm reactor. The reactor was placed on a hot plate set at
388C, a rotation of 130 rpm, and incubated 24 h. Following
this initial 24 h incubation, a continuous flow of 10% TSB
was flushed through the reactor at ;5.8 mL/min for an-
other 24 h. The coupons were then removed and exposed to
one of two fixation procedures or imaged immediately in
the ESEM.
Glutaraldehyde Fixative
Erlandsen et al. ~2004! have shown that low voltage, high-
resolution images of biofilm can be observed by SEM with
the addition of cationic dyes to fixative solution to enhance
the attachment of osmium tetroxide ~OsO4!, which aids in
fixation and sample conductivity, to the EPS matrix. Thus,
in this experiment Ruthenium Red was used as a cationic
dye. After running the CDC biofilm reactor, three of the
coupons having biofilm grown on them and one untreated,
control coupon were initially exposed to a pre-fixative solu-
tion containing 2.5% glutaraldehyde ~Ted Pella, Redding,
CA!, 50 mM L-lysine monohydrochloride ~Sigma, St. Louis,
MO! and 0.75% Ruthenium Red ~Ted Pella! in 0.2 M
cacodylate buffer, pH 7.4 ~Electron Microscopy Sciences,
Hatfield, PA!. Coupons were soaked in the prefixative for
20 min followed by a 24 h treatment in the same fixative
solution excluding the 50 mM L-lysine as per the protocol
of Priester et al. ~2007!.
Coupons were rinsed in cacodylate buffer 3 for 10 min,
placed in a 2% solution of osmium tetroxide ~OsO4; Ted
Pella! in cacodylate buffer for 2 h and rinsed with cacodyl-
ate buffer 3 for 10 min ~hereafter, this cationic dye/2.5%
glutaraldehyde/OsO4 treatment routine is simply referred to
as 2.5% glutaraldehyde fixative!. Following the final rinse,
the coupons were placed in increasing concentrations of
ethanol, from 70% to 95% to 100%, 3 for 20 min each.
Coupons were then dried in a desiccator. Two coupons
containing biofilm were coated with gold or carbon prior to
imaging. One biofilm-containing coupon was left uncoated
for imaging under low vacuum conditions in the NOVA
NanoSEM. The control, non-biofilm-containing coupon was
imaged under low vacuum conditions in the same instru-
ment to determine if artifacts from the fixation procedure
were present.
Formalin Fixative
After running the CDC biofilm reactor, three coupons hav-
ing biofilm grown on them and one untreated, control
coupon were placed in 10% buffered formalin for 24 h and
dehydrated in the same manner as the 2.5% glutaraldehyde
fixative procedure. Coupons were dried in a desiccator. Two
coupons containing biofilm were coated with gold or car-
bon prior to imaging. One biofilm-treated coupon was left
uncoated for imaging under low vacuum conditions in the
NOVA NanoSEM. The control, non-biofilm-containing cou-
pon was also imaged under low vacuum conditions to
determine if artifacts developed from the fixation procedure.
ESEM Imaging
Following the 48 h growth period in the CDC biofilm
reactor, three coupons were removed, placed in 0.9% sterile
saline and imaged by ESEM within 30 min of removal.
Double-sided carbon sticky tabs were used to attach the
coupon to a standard stub ~Ted Pella! for mounting onto
the stage of the Quanta 600 ESEM. Images were collected
with an accelerating potential of 10–20 keV, chamber pres-
sure of 1–20 Torr and 60–100% humidity. Secondary elec-
tron images were collected using a gaseous secondary electron
detector.
Low Vacuum Imaging
Two uncoated coupons containing biofilms that were treated
with either 2.5% glutaraldehyde or 10% buffered formalin
were imaged using a NOVA NanoSEM 600 at 7 keV and a
chamber pressure of 0.5–2 Torr. Secondary electron images
were collected using a secondary electron Helix detector.
High Vacuum Imaging
Following the 2.5% glutaraldehyde and 10% buffered forma-
lin fixation procedures, one coupon each containing biofilm
was coated with carbon or gold resulting in a coating layer
of approximately 6–8 nm and 4–5 nm, respectively. Biofilms
were imaged in a NOVA NanoSEM 600 at 2 keV accelerating




Initial images were collected at 10 keV and a pressure of
1 Torr. However, the biofilm charged and the images did not
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resolve well. Therefore, the pressure and accelerating poten-
tial were increased to 5.29 Torr and 20 keV, respectively.
Notably, no sharp image could be collected with greater
than an original magnification of 10,000 ~Fig. 2!.
Consistent with previous experiments using ESEM im-
aging ~Little et al., 1991; Priester et al., 2007!, the biofilm of
S. epidermidis ATCC 35984 was damaged by the beam after
only a few minutes making it difficult to collect useful
images ~Fig. 2!. Nevertheless, the smooth, undulating sur-
face that was seen indicated that a 3D structure of biofilm
encapsulated in a slimy substance was present—suggesting
that a mature biofilm had developed on the surface of the
coupon ~Jiang & Pace, 2006!.
Low Vacuum Imaging
Images of secondary electrons collected using the Helix
detector indicated that without any coating, the structures
of the S. epidermidis ATCC 35984 biofilm treated with the
2.5% glutaraldehyde fixative could be resolved to a nm scale
~Fig. 3!. Importantly, under low vacuum conditions the
10% buffered formalin did not appear to preserve the
matrix components on the surface of cells ~Fig. 4! to
the same degree as 2.5% glutaraldehyde ~Fig. 5!.
The EPS matrix displayed a fibrous network of prod-
ucts similar to what Erlandsen et al. ~2004! described as
helical duplexes wrapping around cells ~Fig. 3! in addition
to a mesh of components that appeared to connect cells one
to another and create an outer shell of protection to spo-
radic areas of the biofilm ~Fig. 6!. The significant produc-
tion of EPS by the cells indicated that mature biofilms had
developed on the surface of the coupons.
Finally, control coupons that did not contain biofilm,
but that were treated with either 2.5% glutaraldehyde or
Figure 4. Low vacuum secondary electron image collected of the
S. epidermidis ATCC 35984 biofilm fixed with formalin. Note the
smooth appearance of the cellular surface and the lack of fibers or
matrix structures extending off the surface or between cells.
Figure 2. Holes ~dark circles! were punctured into the biofilm of
S. epidermidis ATCC 35984 by the beam after only a few minutes
of imaging at 20 keV, 100% humidity, and 5.29 Torr.
Figure 3. Secondary electron image of an uncoated biofilm of S.
epidermidis ATCC 35984 under low vacuum conditions. At;150k
original magnification, nanostructures of the matrix can be seen
with components overlaying and attaching to cells ~arrows!.
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10% buffered formalin, were imaged under low vacuum.
These were to determine if artifacts developed that may
result in a misinterpretation of the biofilm matrix or other
cellular structures. Results indicated that no residue of any
kind was left on the coupons by either treatment.
High Vacuum Imaging
Although the images collected with the NOVA NanoSEM
600 under low vacuum were sharp enough to see nanostruc-
Figure 5. Low vacuum secondary electron image of the S. epider-
midis ATCC 35984 biofilm fixed with 2.5% glutaraldehyde. Arrows
indicate portions of the matrix components connecting cells one
to another and extending off the surface.
Figure 6. Under low vacuum conditions, a mesh of matrix com-
ponents is observed. Not only does the mesh connect cells one to
another, but it also encapsulates cells, likely protecting them from
environmental perturbations.
Figure 7. Backscatter electron image of a 2.5% glutaraldehyde-
fixed biofilm taken under high vacuum with the vCD detector in
the NOVA NanoSEM. Compared to the images collected at low
vacuum, the image does appear to be sharper and have greater
contrast with reduced charging artifacts.
Figure 8. Backscatter electron image of a 10% buffered formalin-
fixed biofilm taken at high vacuum with the vCD detector in the
NOVA NanoSEM. Fewer matrix components can be seen than the
2.5% glutaraldehyde-fixed biofilm. Compared to the images col-
lected at low vacuum, the image does appear to be sharper and
have a greater contrast with reduced charging artifacts.
Observing Biofilm Matrix: CDC Biofilm Reactor 147
	
tures of the biofilm matrix, the images collected of 2.5%
glutaraldehyde and 10% buffered formalin-fixed biofilms at
high vacuum with the vCD detector were not altered by
charging and had much higher resolution and sharpness
~Figs. 7, 8!. In addition, greater detail of the fibers of the
EPS matrix could be seen. The fibers had rounded edges,
areas that were significantly bundled with a net-like appear-
ance, with other areas having a single fiber spanning the
distance of one or several cells ~Fig. 7!.
Importantly, while imaging biofilms that had been
fixed with either 2.5% glutaraldehyde fixative or 10%
buffered formalin, those coated with gold did appear to
produce sharper, more defined images when compared to
carbon-coated biofilms ~Figs. 9, 10!. Notably, it was thought
that the OsO4 used in the 2.5% glutaraldehyde-treated
biofilms was responsible for helping to create a sharper
contrast image when compared to 10% buffered formalin-
fixed biofilms, but after comparing a gold-coated, 10%
buffered formalin-fixed biofilm that was not treated with
OsO4 to a gold-coated, 2.5% glutaraldehyde-fixed biofilm,
the contrast and sharpness appeared to be quite similar
~Fig. 11!.
Figure 9. A: Carbon-coated biofilm of S. epidermidis ATCC 35984 fixed with 10% buffered formalin. B: Gold-coated
biofilm of the same organism fixed with 10% buffered formalin. Note the sharper image and more defined contrast in
the biofilm coated with gold ~B!.
Figure 10. A: Carbon-coated biofilm of S. epidermidis ATCC 35984 fixed with 2.5% glutaraldehyde. B: Gold-coated
biofilm of the same organism fixed with 2.5% glutaraldehyde. Note the sharper image and more defined contrast in the
biofilm coated with gold ~B!.
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Consistent throughout each of the imaging techniques
was the identification of mushroom- or pillar-like struc-
tures and signs of water channels that are indicators of
mature biofilm development ~Fig. 12! ~Jiang & Pace, 2006!.
Interestingly, the 10% buffered formalin-fixed biofilms ap-
peared to display what may have been nanofibers extending
between cells, but this may have been shrinkage artifact
~Fig. 13!.
After comparing several of the biofilms that had been
fixed with 2.5% glutaraldehyde or 10% buffered formalin, it
was determined that the 2.5% glutaraldehyde-fixed biofilms
may contain and preserve more matrix components, but at
least some matrix components were maintained by both
fixation procedures ~Fig. 14!. From the various images, it
Figure 11. A: Biofilm of S. epidermidis ATCC 35984 that has been fixed using 10% buffered formalin and coated with
gold. B: Biofilm of the same organism that has been fixed 2.5% glutaraldehyde and coated with gold. Notice the similar
contrast and sharpness between the images.
Figure 12. Representative image of a mushroom-like structure
that is typical of the biofilm formations that were seen in this
study. Note that the top of the mushroom is blurry and in-focus
regions are near the coupon surface indicating a vertical rising of
the mushroom toward the viewer. Sample was fixed with 10%
buffered formalin and coated with carbon.
Figure 13. Arrows indicate nanofibers that could be seen within
the biofilm structure. These wires appear to connect the cells to
one another as well as to the surface of the coupon.
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appeared that the EPS components provided significant to
moderate coverage of the bacterial cells within the biofilm,
supporting previous data that suggests the EPS matrix plays
an important role in protecting the cells from environmen-
tal perturbations and antimicrobial therapies ~De Beer et al.,
1994!. Interestingly, within the biofilm structures, there
were signs of a significant amount of bacterial growth.
Indeed, thousands of cells were observed in a dividing state
with areas of cellular attachment still being present ~Fig. 14A!.
DISCUSSION
Images of a S. epidermidis ATCC 35984 biofilm grown using
the CDC biofilm reactor system were collected using three
separate SEM methods: ESEM, low vacuum imaging and
high vacuum imaging. In addition, biofilms that had been
fixed using either 2.5% glutaraldehyde or 10% buffered
formalin were compared with the hypothesis that glutaral-
dehyde would preserve the biofilm matrix more so than
10% formalin. This hypothesis was developed due to the
lack of data regarding this direct comparison of biofilm
fixation in the literature. Finally, gold-coated, carbon-
coated, and uncoated biofilms were analyzed in conjunction
with these fixation techniques under the hypothesis that
biofilms grown on the surface of titanium coupons within
the CDC biofilm reactor would develop into maturity.
The images collected using ESEM indicated that the
biofilm was damaged by the beam after only a few minutes—
similar to previous findings ~Little et al., 1991; Priester et al.,
2007!. In addition, sample charging was a problem, and no
Figure 14. A: Gold-coated biofilm fixed with 10% buffered formalin. Signs of bacterial growth are indicated by the
bacterial cells that are dividing. This is a representative image of the thousands of cells that were seen dividing.
B: Gold-coated biofilm fixed with 2.5% glutaraldehyde. C: Carbon-coated biofilm fixed with 10% buffered formalin.
D: Carbon-coated biofilm fixed with 2.5% glutaraldehyde. Notice that slightly more matrix components seem to be
preserved in the 2.5% glutaraldehyde-treated biofilms.
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high magnification images with high resolution could be
collected. However, it must be noted that the quality of
images collected using ESEM or SEM can be largely user-
dependent. Therefore, it is important to mention that four
different users attempted to work with this biofilm under
ESEM conditions and the images provided are the sharpest
that were able to be taken. In summary, consistent with
previous findings ~Priester et al., 2007!, in its current state
of technology, without cationic dyes or some fixation, ESEM
does not appear to have the capacity to image biofilms such
that the micro or nanostructures of the matrix can be
viewed. Indeed, with ESEM alone it was difficult to eluci-
date the structure of this biofilm matrix beyond its global
appearance and shape. However, these data could be very
informative in a different application. Nevertheless, the
ESEM images did not resolve the biofilm matrix to a level
that allowed us to determine if the fixation and dehydration
of the biofilms had changed its morphology as has been
reported previously ~Little et al., 1991; Fassel & Edminston,
1999; Priester et al., 2007!.
The images collected in this study suggest that 2.5%
glutaraldehyde-fixed biofilm matrix is preserved sufficiently
to obtain information concerning its topographical charac-
teristics, connection points with both the cells and substrate
as well as nanostructures of the matrix itself. In contrast,
biofilms fixed with 10% buffered formalin displayed a lack
of matrix components suggesting that formalin, with only
one reactive group per molecule, does not preserve the
biological components to the same level as 2.5% glutaralde-
hyde. In both cases, however, cellular division could be seen
at the surface of the biofilm suggesting that even after 48 h
of growth, the biofilms were rapidly dividing.
Importantly, the EPS matrix and 3D structure of bio-
films can vary significantly from one growth environment
to another. Other studies have observed the wide variety of
biofilm morphologies that can exist in clinical and environ-
mental applications ~Costerton et al., 1978; Litzler et al.,
2007; Schaudinn et al., 2007!. At times, 3D mushroom- or
pillar-like formations of biofilms are not seen ~Erlandsen
et al., 2004; Priester et al., 2007!, whereas in this study they
were seen. The observation that biofilms grown in the CDC
biofilm reactor developed significant EPS and mushroom-
like structures was promising. More specifically, as reports
highlight the ever-increasing rate of bacterial resistance to
antibiotics with biofilms providing even greater resistance
~Nickel et al., 1985! and high rates of genetic material
exchange ~Cvitkovitch, 2001; Costerton, 2007b!, the use of
well-established, mature biofilms in in vivo models of clini-
cally relevant infections is important. Thus, the production
of mature biofilms in a standardized biofilm reactor system
~Goeres et al., 2005! provides strong potential to produce
mature biofilms that can be used in in vivo applications of
implant-related and other chronic infections.
One limitation to this study, however, was that prepara-
tory techniques for SEM imaging did cause water loss and
shrinkage of the biological samples. Because of the well-
known fact that dehydration can alter biological morphol-
ogy, the ability to observe water channels throughout the
mushroom- or pillar-like structures biofilms was limited.
Thus, although ravines, ridges, and crevices were replete
throughout mushroom- or pillar-like structures, it could
not be concluded that these were water channels, but could
be artifacts from shrinkage and water loss. However, the
ravines do suggest that water channels may have been
present and in combination with significant EPS products
and mushroom- or pillar-like structures, there is strong
evidence to suggest that mature biofilms did form.
It is becoming apparent that biofilm matrices come in a
variety of structures such as the production of honeycomb-
like structures or fibrous networks of the S. epidermidis
isolate observed in this study. Thus, phenotypic characteris-
tics are species dependent, but may also change with matu-
ration of the biofilm. Herein the biofilm was grown for only
48 h, and in future it will be interesting to see what the
matrix looks like after 5 or more days of growth in the CDC
biofilm reactor.
In conclusion, biofilms grown using the CDC biofilm
reactor were found to produce EPS matrix components
displaying cell-cell and cell-surface connections as well as
mushroom- or pillar-like structures with signs of water
channel development. Thus, the hypothesis that bacteria
grown in the reactor would produce EPS and show signs of
mature development was supported. These data suggest that
biofilms grown in this reactor may be useful for future
animal models that are used for translational research
applications.
CONCLUSIONS
The production of mature biofilms in a laboratory setting is
important for in vitro and in vivo research applications.
More specifically, planktonic bacteria used in in vitro or in
vivo studies may not be suitable indicators of what might
occur in a biofilm community or biofilm-related infection,
respectively. Thus, the indications from this study that bio-
films grown in the CDC biofilm reactor reach maturity are
important as they suggest that these biofilms may be ap-
plied in future investigations that, for example, might in-
volve the prevention of biofilm-related infections that
surround orthopaedic devices or other implant materials.
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Abstract: Currently, the majority of animal models that are
used to study bioﬁlm-related infections use planktonic bacterial
cells as initial inocula to produce positive signals of infection in
biomaterials studies. However, the use of planktonic cells has
potentially led to inconsistent results in infection outcomes. In
this study, well-established bioﬁlms of methicillin-resistant
Staphylococcus aureus were grown and used as initial inocula
in an animal model of a Type IIIB open fracture. The goal of the
work was to establish, for the ﬁrst time, a repeatable model of
bioﬁlm implant-related osteomyelitis, wherein bioﬁlms were
used as initial inocula to test combination biomaterials. Results
showed that 100% of animals that were treated with bioﬁlms
developed osteomyelitis, whereas 0% of animals not treated
with bioﬁlm developed infection. The development of this ex-
perimental model may lead to an important shift in bioﬁlm and
biomaterials research by showing that when bioﬁlms are used
as initial inocula, they may provide additional insights into how
bioﬁlm-related infections in the clinic develop and how they
can be treated with combination biomaterials to eradicate and/
or prevent bioﬁlm formation. VC 2012 Wiley Periodicals, Inc.
J Biomed Mater Res Part A: 00A:000–000, 2012.
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INTRODUCTION
After a careful literature review, it appears that currently,
the majority of animal models that are used to study bio-
ﬁlm-related infection use planktonic bacterial cells as initial
inocula to produce positive signals of infection.1–24 The ex-
pectation has been that planktonic bacteria would, depend-
ing on the animal model, attach to host tissue or a medical
device and subsequently form a bioﬁlm. These animal mod-
els have been crucial in the development of novel therapeu-
tic agents to treat and prevent bioﬁlm-related and other
infections. However, although the value of these animal
models cannot be underestimated, the use of planktonic
bacteria as initial inocula has provided inconsistent results
in the repeatability of infection development. More speciﬁ-
cally, results have shown that when planktonic cells are
used as initial inocula, without any antimicrobial interven-
tion, rates of infection are inconsistent between 47 and
100%.1–24 In addition to these inconsistencies, these models
have potentially limited biomaterials scientists, clinicians,
and other investigators from obtaining additional insights
into the effect that bacteria might have if they contaminate
a site while residing in well-established, mature bioﬁlms.
In 1978, Costerton et al.25 provided a general hypothesis
that bacteria in nature reside predominantly in the bioﬁlm
phenotype. Since that time, data have indicated that 99.9%
of bacteria in natural ecosystems reside in the bioﬁlm phe-
notype.26 Similar data have been derived from samples that
have been collected from patients, retrieved medical devi-
ces, and other sources.27–33 Moreover, the Centers for
Disease Control has stated that 60% of all infections are
bioﬁlm-related.34 A public announcement of The National
Institutes of Health placed that estimate at 80% (see
announcement PA-07-288). In addition to these estimates,
chronic wounds are now considered to be the result of
acute infection that begins with bioﬁlm contamination
as opposed to a nonhealing wound that is later
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contaminated.35–38 A review article has been published dis-
cussing this concept of using bioﬁlms as initial inocula.39
Based on these observations and information, the
authors hypothesized that a sizeable portion of bioﬁlm-
related infections, including those that accompany the use
of medical devices, may be the result of contamination with
bacteria residing in bioﬁlms from natural ecosystems as
opposed to planktonic bacteria contaminating a site. If sup-
ported, this hypothesis would suggest that using bioﬁlms as
initial inocula, as opposed to planktonic bacteria to model
clinically relevant infection scenarios, may provide deeper
insight into how bioﬁlm-related infections may be treated
and eradicated using current or novel therapies, such as
antimicrobial eluting coatings.
In an attempt to address the sporadic nature of bioﬁlm
infection development in animal models, wherein planktonic
cells are used as initial inocula, the goal of this work was to
test the above hypothesis and establish a reproducible ex-
perimental model of bioﬁlm implant-related osteomyelitis in
sheep. More speciﬁcally, in this study, bioﬁlms of methicil-
lin-resistant Staphylococcus aureus (MRSA) were grown on
the surface of polyetheretherketone (PEEK) membranes
using a modiﬁed CDC bioﬁlm reactor.40,41 These bioﬁlms
were placed in apposition to the proximal medial aspect of
a sheep tibia, on the bare cortical surface stripped of perios-
teum, and subsequently covered by a simulated fracture ﬁx-
ation plate. As such, this study modeled a massively conta-
minated Type IIIB Gustilo open fracture, wherein, in a worst
case clinical scenario, bioﬁlms from natural ecosystems may
contaminate a wound site and be compressed between bone
and a fracture ﬁxation plate.
MATERIALS AND METHODS
Bioﬁlm growth
For this study, a fresh, clinical isolate of MRSA was used.
This isolate was collected from the knee of an infected
patient and passaged less than three times on Columbia
blood agar. The isolate was conﬁrmed to be one that formed
bioﬁlms as indicated by the presence of the icaADBC gene
cluster, black colony growth on Congo Red agar, and direct
imaging of its growth on PEEK membranes using scanning
electron microscopy (SEM). To grow the bioﬁlms on PEEK
membranes, a modiﬁed CDC bioﬁlm reactor was used. The
development and repeatability of growing bioﬁlms in this
reactor, as well as SEM images of the bioﬁlms, have been
published previously.40,41
In short, bioﬁlms were grown by ﬁrst inoculating the re-
actor with 500 mL of modiﬁed brain heart infusion (BHI)
broth that contained 1 mL of a 0.5 McFarland standard of
the MRSA isolate. In this instance, a 0.5 McFarland standard
equated to 107 cells/mL. Following inoculation, the reac-
tor was incubated on a hot plate set at 34C for a 24-h pe-
riod. After the initial 24-h growth period, a ﬂow of dilute
(10%) BHI broth was ﬂowed through the reactor for an
additional 24 h using a peristaltic pump set at a rate of
6.94 mL/min. With the hot plate set at 34C, the broth tem-
perature was 30.2C 6 0.7C during the ﬁrst 24 h and 30C
6 0.8C during the second 24 h.
After the 48-h growth period, eight PEEK membranes
(the reactor held a total of eight membranes) containing
MRSA bioﬁlms were removed from the reactor, rinsed 3 in
sterile PBS and transferred to 5 mL of BHI broth. The bio-
ﬁlms were then transported to the surgical suite for inocula-
tion into animals. Two surgeries were performed on any
given surgery day, which required the use of four PEEK
membranes (two per animal). At the end of each surgery
day, the remaining four PEEK membranes were used to
quantify the number of bacteria that were present. Each
PEEK membrane was found to have an average of 5.05 
109 6 2.07  109 (9.67 6 0.18 when log10 transformed) col-
ony forming units (CFU) of bacteria. These numbers were
not signiﬁcantly different from the previously published
numbers of bacteria that grew on these PEEK membranes.
The quantiﬁcation process to determine the number of
bacteria was published previously. In brief, PEEK mem-
branes were vortexed for 1 min, sonicated for 10 min, and
plated on tryptic soy agar using a 10-fold dilution series to
quantify the number of CFU per membrane.
Stainless steel plates
To model a clinically relevant material that is used in frac-
ture ﬁxation plates, 316-L stainless steel (SS) plates were
used as simulated fracture ﬁxation plates. Each plate was
machined to 2  2 cm with a height of 1.85 mm. The plates
had a hole, measuring 2.7 mm in diameter, drilled in each
corner. On the underside of each plate, a well was machined
to a depth of 300 lm with 1.2 cm  1.2 cm dimensions.
The purpose of this well was to provide a contained area to
place a PEEK membrane (Fig. 1). Before implantation, plates
were cleaned and passivated following American Society of
Testing and Materials standard F86-04 and then sterilized
by autoclave.
FIGURE 1. Photograph of a 316L stainless steel plate. The well
machined out of the underside was used to hold a PEEK membrane
(shown in well).
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Surgical procedure and postsurgical monitoring
All animal work was performed with approval from the
Institutional Animal Care and Use Committee and the Envi-
ronmental Health and Safety department at the University
of Utah. For this study, 2–3-year-old female Columbia Cross
sheep, weighing 90 6 20 kg, were selected. This species of
sheep had a ﬂat area of bone on the proximal medial aspect
of the tibia with a surface area that was suitable for secur-
ing of the plates with transcortical screws. A total of n ¼ 10
sheep were used in this study with n ¼ 5 being treated
with bioﬁlm to serve as positive controls of infection (Group
1) and n ¼ 5 serving as negative controls of infection
(Group 2). The ﬁve negative control sheep were treated
with PEEK membranes that had been run through the modi-
ﬁed CDC bioﬁlm reactor without bacterial inoculation.
Before surgery, the sheep were fasted for >12 h.
Because the goal of this work was to develop a positive sig-
nal of infection, no antibiotics were administered. Sheep
were initially anesthetized using an intravenous (IV) injection
of either ketamine (5 mg/kg) and diazepam (0.5 mg/kg)
or propofol (3–7 mg/kg) to allow for endotracheal tube intu-
bation. Following intubation, the sheep were placed in the
supine position and maintained under anesthesia with iso-
ﬂurane to effect (ranged from 2 to 3%). An IV catheter was
placed in the left forelimb, and 0.9% saline was administered
at a rate of 10 mL/kg/h. Veterinary surgical and equipment
technicians monitored the sheep’s heart rate, temperature,
carbon dioxide and oxygen levels, and respiration throughout
the procedure.
The right hind limb of each sheep was circumferentially
clipped free of hair/wool, from immediately above the hoof
to the groin, and then scrubbed and prepped with betadine
and alcohol treatment. The hoof was isolated in a sterile rub-
ber glove and wrapped with sterile VetWrap (Fisher Scien-
tiﬁc). After sterile draping, the proximal medial aspect of the
leg and the region of the incision were treated with Chlorap-
rep (Fisher Scientiﬁc) solution to further sterilize the skin.
An anterior midline sagittal incision was made from the
region of the tibial tuberosity and extending distally, parallel
to the anterior margin of the tibia. This incision was placed
away from the plate and bioﬁlm implantation site to avoid
contamination of the site during wound healing. Dissection
was carried medially and posteriorly, close to the bone, lift-
ing the skin with the attached subcutaneous tissues from
the surface of the medial tibial ﬂare.
Because this study modeled a Type IIIB Gustilo open
fracture—which may consist of periosteal stripping, bone
exposure, and massive contamination—a 2  5-cm area of
periosteum was removed from the proximal medial aspect
of each sheep tibia [Fig. 2(A)]. On the bare cortical surface,
the positions of a proximal and distal plate were templated
by sequentially drilling and placing transcortical screws
through each plate. The screws were not tightened at this
stage. This technique allowed compensating for any irregu-
larity in the ‘‘ﬂat surface’’ of the tibia, tapped each hole, and
prevented thread stripping in the thin bone. This preposi-
tioning avoided spurious contamination of the site when
placing the infectious bioﬁlm.
A PEEK membrane (with or without bioﬁlm, depending
upon the animal group) was aseptically removed from the 5
mL of BHI broth using sterile forceps. The corner of the
membrane was touched against a sterile towel, removing
excess broth but not bioﬁlm, and preventing broth from
contaminating the surgical ﬁeld. The membrane was placed
into the well of a SS plate, and the ﬂuid that remained on
the membrane allowed it to adhere to the metal plate due
to ﬂuid cohesive forces.
Using careful, aseptic technique, the SS plate/PEEK
membrane construct was placed in apposition to the tibia
with the PEEK membrane residing between the bone and
plate. Each plate was secured to the bone using 2.7 mm di-
ameter  10 mm length cortical bone screws (self-tapping;
catalog #ST270.10, Veterinary Orthopaedic Implants). This
process was performed twice in each sheep, such that each
sheep was treated with two PEEK membranes and two
plates [Fig. 2(B)]. The rationale for using two plates was to
have one available for microbiological analysis and one for
histological analysis at the end of the study. To the best of
the surgeons’ ability, the two plates had a space of 1 cm
between them; however, anatomical variation existed
amongst the sheep and not all were able to maintain exactly
1 cm of space between them.
FIGURE 2. A: Photograph of the proximal medial aspect of the right tibia demonstrating removal of a 2  5 cm area of periosteum using a peri-
osteal elevator. A template was used in each sheep to standardize the 2  5 cm area that was removed. B: Photograph of the ﬁnal construct
with two stainless steel plates secured to the proximal medial aspect of the tibia. There was a  1 cm gap between the two plates, and each of
the plates had a PEEK membrane in the underside well in direct apposition to the bare cortical bone surface. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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After plate placement, a swab of the cortical bone surface
was collected to determine if bacteria had already begun to
dislodge away from the bioﬁlm on the PEEK membrane. The
surgical site was closed with interrupted 2–0 Vicryl (catalog
no. J339H, Ethicon) subcutaneous sutures and a running sub-
cuticular 2–0 Proline (catalog no. 8533H, Ethicon) suture. A
swab of the incision site was taken to determine if bacteria
were present on the skin. Before wrapping the surgical site,
the leg was cleaned with saline and isopropyl alcohol to kill
bacteria that may have been present on the skin. This helped
to reduce the risk of cross contamination throughout the ani-
mal facility and between animals.
For postoperative analgesia, each sheep was given an
epidrual dose of morphine (0.1 mg/kg), and two fentanyl
patches (100 lg/h) were placed in a shaved area on the left
forelimb. An injection of ﬂunixin (1.1 mg/kg) was adminis-
tered to diminish inﬂammation. Postanesthesia monitoring
extended until the animals could stand on their own as well
as eat and drink.
Surgical follow up
Throughout the course of the study, each sheep was moni-
tored by the authors’ team and a veterinarian in the animal
quarters to assess any symptoms of pain and distress.
Under veterinary supervision, animals that showed signs of
pain or distress were treated with Buprenex (0.01 mg/kg)
or additional fentanyl patches. If excessive inﬂammation
was present, they were further treated with rimadyl (4.4
mg/kg).
Using a clinical grading system, based on the hallmarks
of infection: calor (heat), rubor (redness), dolor (pain), and
tumor (swelling), the sheep were monitored daily for a 12-
week period for these signs of infection. A daily rectal tem-
perature of each sheep was also taken. The animals were
also monitored for limping, lethargy, irritability, and going
‘‘off feed’’ and/or water. Based on these criteria, a four-
tiered clinical grading system was established.
Grade I, or no infection, consisted of the signs of healing
normally seen with surgical trauma and that resolved within
1–2 weeks of surgery. These signs included slight redness
at the surgical site, mild warmth (to the touch), mild inﬂam-
mation, a closed suture line, healed within 2 weeks, the
sheep eating and drinking, a normal rectal temperature (for
these sheep normal temperature was between 101.5 and
102.8F), and no signs of distress or limping. A Grade II
infection included increased redness, a warmer surgical site
with moderate inﬂammation, evidence of suture line dehis-
cence, irritable behavior, normal temperature, and not limp-
ing. Sheep were euthanized if they displayed signs of a
Grade III infection. This grade was characterized by signiﬁ-
cant redness and palpable heat at the surgical site, an open
suture line with drainage, signiﬁcant inﬂammation, tender-
ness, lethargy, fever, off feed and/or water, and positive bac-
terial growth on wound culture. A Grade IV infection was
deﬁned, but never allowed to develop in any of the animals.
This included excessive heat, excessive inﬂammation, puru-
lent drainage, implant exposure, excessive limping, local ten-
derness, off feed and/or water, lethargy, and fever.
Bone labeling
As stated by Bloebaum et al.,42 ‘‘ﬂuorochrome labeling is a
well-established method of measuring the mineral apposi-
tion rate (MAR), at which osteoid matrix, produced by
osteoblast cells, is deposited and mineralized to form new
bone.’’
In this study, calcein ﬂuorochrome (catalog no. C-0875,
Sigma-Aldrich) was used as a nonantibacterial agent to label
bone and to calculate the MAR, that is, the growth rate of
the sheep bone. The method by which this works is after
the calcein is injected, it is taken up by osteoblast cells and
released into the matrix of newly forming bone. After proc-
essing, calcein ﬂuorochrome can be observed in tissue sam-
ples as they are imaged using an excitation wavelength of
495 nm and emission of 515 nm. The imaging that was per-
formed in this study is described in the ‘‘MAR analysis’’ sec-
tion below.
Calcein was prepared in reverse osmosis water to a ﬁnal
concentration of 30 mg/mL. The pH was adjusted to 7.2–
7.4, ﬁltered using a 0.22-lm ﬁlter for sterility, and the solu-
tion administered IV at 0.33 mL/kg of body weight. Two
separate injections were given: one 16 days and one 5 days
before the established 12-week end point of each sheep to
create a double label in the bone. The infected sheep that
were euthanized before the 12-week end point did not
receive calcein injection.
Euthanasia and microbiological sample collection
Sheep were euthanized at the end of 12 weeks, or once a
Grade III infection was determined to exist. To euthanize,
animals were initially sedated with an IV injection of keta-
mine (5 mg/kg) and diazepam (0.5 mg/kg) in order to col-
lect a 5-mL blood sample for microbiological analysis. Eu-
thanasia was then performed by IV injection of beuthenasia
(1 mL/4.5 kg) solution.
A swab of the incision site (1 cm2 area) was taken and
streaked onto Columbia blood agar for semiquantitative
analysis. More speciﬁcally, 1þ growth was deﬁned as having
growth in the ﬁrst zone of streaking, 2þ having growth in
the second zone, and 3þ having growth in the third zone.
The agar plate was incubated overnight at 37C. Next, the
skin at and surrounding the incision site was prepped using
chlorhexidine/isopropyl alcohol antiseptic. A scalpel was
used to aseptically reopen the incision site, and a swab of
the subdermal tissue was collected to determine if bacteria
had penetrated into the soft tissues superﬁcial to the plates
and PEEK membranes. This swab was also cultured on Co-
lumbia blood agar.
One of the SS plates was randomly selected, and the
underlying PEEK membrane was removed and placed into 5
mL of 10% BHI broth. The sample was vortexed for 1 min,
sonicated for 10 min, and allowed to recover in the broth at
room temperature for 20 min (to allow the bacteria to con-
vert from the bioﬁlm to planktonic phenotype) before per-
forming a 10-fold dilution series to quantify the number of
CFU/PEEK membrane.
The SS plate that had been removed was then secured
to the bone once again, so that radiographs could be taken.
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The tibia was then disarticulated and used for gross photo-
graphic and radiographic analysis.
Gross photography/radiography
Gross photography of the soft tissues and bone was collected
throughout the sampling/dissection process. Radiographs
were obtained using a cabinet X-ray system (43855A Model,
Faxitron X-Ray Corporation) set at 70 kV for 21/2 min.
Tissue embedment/sectioning
After radiographic imaging, all the soft tissue was dissected
from the bone with the exception of the tissue that was
directly over the undisturbed SS plate. The sample was then
ﬁxed in modiﬁed Karnovsky’s ﬁxative using 3  24 h
changes. Following ﬁxation, the bone was rinsed in reverse
osmosis water for 10 min and cut into two sections separat-
ing the two SS plates from one another. The plate that had
been removed in order to access the PEEK membrane for
microbiology was again removed, and the bioﬁlm on the
underlying bone imaged with SEM. The remaining bone sec-
tion, with plate and PEEK membrane intact, was used for
histological analysis.
After cutting, both bone samples were placed in 70%
ethanol for 24 h to initially dehydrate them. The bone for
SEM imaging was further dehydrated by hand using ascend-
ing concentrations (from 70 to 95 to 100%) of ethanol,
then coated with gold using a Hummer 6.2 sputter coater,
and imaged using SEM.
The bone sample for histology was also dehydrated using
increasing concentrations of ethanol. However, this was per-
formed in a Tissue-Tek VIP (Miles Scientiﬁc) instrument. It
was then placed into a solution of 80% methylmethacrylate
and 20% N-butyl (the combination of these two solutions is
referred to as Solution A) and mixed for 5 days to infuse the
tissues. The Solution A was poured out, and a fresh aliquot
of Solution A, mixed with 2.5 g/L of perkadox (the catalyst
for polymerization), was added to the sample. The sample
was kept in a dessicator at 4C for 7 days. Finally, 5 g/L of
perkadox was added to another batch of fresh Solution A
and exchanged for the used mixture in the container, and the
sample was kept in a desiccator at 4C for an additional 9
days. Samples were then placed in a new container, and Solu-
tion A with 5 g/L of perkadox was added and polymerized in
2 cm layers using ultraviolet light. Each layer required 48 h
to fully polymerize. The ﬁnal product resulted in a polyme-
thylmethacrylate (PMMA) embedded sample containing the
bone, PEEK membrane, SS plate, and soft tissue regions.
Once embedded, tissue samples were cut using a band
saw to remove excess PMMA and isolate the area of inter-
est. Samples were further sectioned into 2 mm sections
using a diamond blade water saw. Radiographs of the sec-
tions were obtained following the same procedure outlined
earlier. One face of a section was then polished and gold
coated for SEM analysis.
SEM analysis
Scanning electron microscopy (SEM) analysis was performed
using a JEOL 6100 LaB6 ﬁlament SEM to qualitatively exam-
ine bone and/or bioﬁlm morphology in the region, where a
SS plate/PEEK membrane construct was implanted. For those
bone samples that had the SS plate removed, secondary elec-
tron images were collected of the cortical bone surface to
examine the morphology of the bone and/or bioﬁlm where
the PEEK membrane had been present. For those samples
that were sectioned in PMMA, backscatter electron (BSE)
images were collected to examine the varying levels of min-
eralization, how the infection inﬂuenced the periosteal
response in bone, and cortical bone activity.
MAR analysis
The procedure for collecting MAR data was based on the
published work of Bloebaum et al.42 In short, after sample
sections had been imaged using SEM, the polished surfaces
were glued to a slide and further ground to 50–60 lm
thickness for MAR analysis. Images were ﬁrst collected
using a mercury lamp Nikon Labophot microscope to detect
the presence of calcein double-labeled osteons of the host
bone. Three slides from each sheep were analyzed. From
each slide, ﬁve osteons were randomly selected in the corti-
cal/periosteal bone region beneath a SS plate, and a total of
eight measurements were made along the span of each dou-
ble label using ImagePro Plus software. The MAR of bone
was calculated using the formula:
MAR ðlm=dayÞ ¼ RxðeÞðp=4Þ=nt
where Rx is the sum of all the measurements between dou-
ble labels, e is the micrometer calibration factor (lm), (p/4)
is the obliquity correction factor, n is the total number of
measurements, and t is the time interval between calcein
injections expressed in days.
Histology
For histological analysis, sample slides were further ground
to a thickness of 40–50 lm and stained with H&E stain. For
H&E staining, Mayer’s solution was preheated to 50–55C.
Slides were placed in the Mayer’s solution for 5 min, rinsed,
and dried. Slides were then placed in Clariﬁer for 4 min,
rinsed, placed in Bluing Reagent for 4 min, rinsed again,
and dried with a Kimwipe. Finally, slides were counter-
stained by dripping acid fuschin/5% acetic acid solution for
35–45 s and dipped in 100% ethanol for 30 s.
Macroscopic images of slides were collected using a
Nikon SMZ800 macroscope. Higher magniﬁcation images
were collected using a Nikon Eclipse E600 microscope.
Using a modiﬁed histopathologic grading scale of Smeltzer
et al.,43 an outside observer, who was blinded to the sam-
ples in the study, examined the slides to determine what
level of osteomyelitis was present in the bone and or sur-
rounding tissue regions. Osteomyelitis was indicated by the
presence of bacteria, as determined by the microbiological
analysis, in conjunction with chronic inﬂammation and bone
necrosis. Cortical bone growth/response was not an indica-
tor of infection as it was present in all ﬁve sheep from
Group 1 and three from Group 2. Thus, it appeared to be a
normal bone response to the surgical trauma and
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implantation. The modiﬁed Smeltzer et al.43 grading scale is
provided in Table I.
Statistical analyses
From a Kaplan–Meier survival curve, a Log-Rank test was
used to examine the statistical signiﬁcance in survival times
between those sheep treated with bioﬁlm and those that
were not. A separate Log-Rank test was used to compare
the time it took for animals in both groups to become
infected. Time to infection differed from survival time,
because some sheep in Group 1 survived the full 12 weeks
of the study, but displayed signs of infection very early on.
Because the number of bacteria collected from PEEK
membranes of those sheep in Group 1 were not normally
distributed, the nonparametric Mann–Whitney U test was
used, as opposed to a Student’s t test, to compare the num-
ber of bacteria that were collected on the PEEK membranes
of Group 1 and Group 2 animals. In all instances, an alpha
level of 0.05 was established to deﬁne statistical signiﬁ-




A survival curve including each of the 10 sheep in this study
was plotted using a Kaplan–Meier survival curve [Fig. 3(A)].
Two of the ﬁve sheep in the bioﬁlm-treated sheep (Group 1)
were euthanized at 3 weeks due to a Grade III infection. The
other three survived to the 12-week end point, but each of
those three sheep displayed Grade II signs of infection during
the 12-week monitoring period. Furthermore, each of the ﬁve
sheep in Group 1 displayed signs of inﬂammation and
abscess formation between day 4 and 11 after surgery. In
contrast, all ﬁve of those sheep in Group 2 survived to the
12-week end point with minimal acute inﬂammation and no
signs of infection at any point in the study. The Log-Rank
test indicated that the difference in survival among the two
groups was not signiﬁcant (p ¼ 0.184). However, when time
to infection was analyzed, there was a signiﬁcant difference
(p ¼ 0.002) between the groups [Fig. 3(B)]. This difference
corroborated with the microbiological data.
Microbiology
Microbiological data showed that PEEK membranes col-
lected from Group 1 sheep contained an overall log density
of 5.32 6 5.41 log10 CFU/PEEK membrane. No bacteria
were detected on the PEEK membranes of Group 2 sheep.
When compared using the Mann–Whitney U test, this differ-
ence was statistically signiﬁcant (p ¼ 0.008).
All the swabs taken from all animals showed between
1þ and 2þ growth of normal ﬂora bacteria at the incision
site. In three of ﬁve of the Group 1 sheep, subdermal swabs
TABLE I. Histological Parameters and Scoring System
Intra- and periosseous chronic inﬂammation
0 Not present
1 Minimal to mild chronic inﬂammation with no signiﬁcant
intramedullary ﬁbrosis
2 Moderate to severe chronic inﬂammation with no signiﬁ-
cant intramedullary ﬁbrosis
3 Minimal to mild chronic inﬂammation with signiﬁcant in-
tramedullary ﬁbrosis
4 Moderate to severe chronic inﬂammation with signiﬁcant
intramedullary ﬁbrosis
Bone necrosis
0 No evidence of necrosis
1 Single focus of necrosis without sequestrum formation
2 Multiple foci of necrosis without sequestrum formation
3 Single focus of sequestrum
4 Multiple foci of sequestra
Cortical bone response
0 No cortical bone response
1 Cortical bone growth that does not extend beyond plate
border
2 Cortical bone growth that begins to extend beyond plate
border
3 Cortical bone growth that covers a plate part way
4 Cortical bone growth that covers a plate entirely
FIGURE 3. A: Kaplan–Meier survival curve for each sheep in Group 1 and Group 2. B: Kaplan–Meier curve of the time it took for each sheep to
display signs of infection.
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detected 2þ growth of bacteria in the tissues surrounding
the SS plates, whereas swabs taken of the remaining two
sheep detected no growth of bacteria. All the culture swabs
collected from Group 2 sheep were negative for growth.
These data indicated that the microbiological ﬁndings
correlated with the clinical observations of the sheep,
wherein those treated with bioﬁlm (Group 1) suffered a
Grade II or higher infection, and those not treated with bio-
ﬁlm (Group 2) did not suffer from infection.
Notably, when removing the SS plates for microbiological
analysis, it was observed that in each of the ﬁve Group 1
sheep, the bone screws had become completely loose, and,
in one animal, the plates had even shifted position. This
was due to bone resorption around the screws, which was a
result of infection as indicated by SEM analysis and histo-
logical results (see below). No screw or plate loosening was
observed in Group 2 sheep, and it was also interesting to
observe that in Group 2 sheep, the cortical bone began to
grow on/attach to the PEEK membranes, which made it dif-
ﬁcult to remove them for quantiﬁcation. In contrast, the
PEEK membranes in the infected sheep had no attachment
of bone to them and were easily removed.
Gross photography/radiography
Gross photographs of the sheep limbs provided evidence
that an abscess formed in the surgical area of Group 1
sheep, whereas no abscess formation was seen in sheep
from Group 2 (Fig. 4). Furthermore, signs of infected tissue,
including pus and signiﬁcant inﬂammatory and cortical
bone response, could be seen in Group 1 sheep once the
skin was resected [Fig. 4(B)]. In contrast, only a thin mem-
brane of tissue grew over the plates in Group 2 sheep with
minimal periosteal/cortical bone response.
Radiographic evidence also suggested that in Group 1
sheep, ‘‘moth eaten,’’ osteomyelitic bone was visible [Fig.
5(A)]. This result was particularly apparent in the microra-
diographs that were taken of bone sections after they had
been embedded and cut [Fig. 5(B)]. From these sections, a
signiﬁcant cortical bone response and an endosteal
response indicative of responsive new bone formation could
be seen in Group 1 sheep. No such response was seen in
Group 2 [Fig. 5(C,D)].
SEM analysis
Because of the natural complexity of the cortical bone sur-
face of sheep and components that resembled bacteria, it
was difﬁcult to conﬁrm that there were bioﬁlm dwelling
bacteria on the cortical bone surface of Group 1 sheep using
secondary electron SEM imaging. Although it did appear
that the bone surfaces of Group 1 sheep had more degrada-
tion and trauma when compared with the bone surfaces of
Group 2 sheep, the differences were not deemed substantial
FIGURE 4. Left column: photographs of a sheep treated with bioﬁlm. Right column: photographs of a sheep not treated with bioﬁlm. A: Repre-
sentative photograph of the proximal medial aspect of a sheep tibia from Group 1 that suffered from infection. In this particular sheep, this ab-
scess developed on day 11 postsurgery. B: Once the skin was resected from the infected sheep shown in Figure 4A, pus could be seen as well
as a signiﬁcant cortical bone/periosteal response in the infected region that showed signs of osteomyelitis. This sheep had positive growth for
MRSA. C: Additional photograph of a sheep tibia from Group 2. No abscess formation was seen in any of the sheep from Group 2. D: Once the
skin was resected away from the sheep tibia shown in Figure 4C, a thin, ﬁbrous membrane was observed to have grown over the stainless steel
plates. In addition, the bone had grown up to the edges of the plates and no further (Grade 0 cortical bone growth). The plate that was removed
was used for microbiological analysis. No bacteria were detected in/on the tissues or on the PEEK membrane. [Color ﬁgure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
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enough to support any conclusions. On the other hand, BSE
images of the bone sections were much more indicative of
bone trauma and infection.
More speciﬁcally, in Group 1 sheep, BSE images indi-
cated that there was a considerable amount of bone resorp-
tion directly underneath the SS plate [Fig. 6(A)] and near
the bone screws [Fig. 6(B)], which supported the observa-
tion mentioned earlier that these screws were loose,
whereas no signs of bone resorption were apparent in any
sheep from Group 2 [Fig. 6(C,D)]. Furthermore, a much
larger gap was seen between the cortical bone surface and
plate of Group 1 sheep when compared with Group 2. More
speciﬁcally, the distance from the bone to the plate surface
in Group 2 was 20–50 lm, whereas in Group 1, the gap
was much larger and ranged from 200 to 800 lm. As will
be seen in the histopathological results, this larger gap in
Group 1 sheep was due to ﬁbrous tissue formation and
chronic inﬂammation—which the microbiology conﬁrmed to
be the result of infection.
MAR analysis
MAR results indicated that in Group 1 sheep, the average
bone remodeling rate was 1.5 lm/day. In Group 2 sheep,
the average rate was 1.2 lm/day. Images of double labels
in the periosteal regions of Group 1 sheep showed that an
intense remodeling response was present [Fig. 7(A)].
FIGURE 5. Left column: radiographs of a sheep treated with bioﬁlm. Right column: radiographs of a sheep not treated with bioﬁlm. A: Macrora-
diograph of the tibia of the sheep photographed in Figure 4(A). From this radiograph, the authors were able to detect signs of ‘‘moth eaten,’’ os-
teomyelitic bone. Similar radiographs were collected from all sheep in Group 1. B: Once the bone was embedded and sectioned,
microradiographs of the same sheep from (A) indicated that in addition to ‘‘moth eaten’’ cortical bone, a signiﬁcant endosteal response was also
present, suggesting that infection was present in the medullary canal. C: No ‘‘moth eaten’’ bone was detected in the radiograph of the sheep
tibia from Figure 4(C). This same result was seen in all of the sheep from Group 2. D: Microradiographs of the embedded, sectioned samples
from the sheep presented in (C) suggested that there was no endosteal or cortical bone response. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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However, typical double labels of osteons were seen in the
cortical bone regions [Fig. 7(B)]. No signiﬁcant response
was seen in the periosteal regions of sheep in Group 2, and
osteon structures were present in the cortical bone region
indicative of remodeling [Fig. 7(C,D)]. Notably, calcein dou-
ble labels further indicated bone viability.
Histology
Sections stained with H&E showed that there was an
observable difference between the bone and soft tissues of
Group 1 and Group 2 sheep. More speciﬁcally, when com-
pared with the modiﬁed Smeltzer et al.43 histopathological
grading scale, the three sheep in Group 1 that survived to
the 12-week endpoint displayed signs of a Grade 4 osteomy-
elitis as indicated by moderate to severe chronic inﬂamma-
tion with signiﬁcant intramedullary ﬁbrosis and multiple
foci of sequestra (Fig. 8). These sheep also displayed Grade
3 cortical bone growth. The other two sheep in Group 1,
which survived to 3 weeks, displayed Grades 3–4 osteomye-
litis with Grade 2 cortical bone growth. None of the ﬁve
sheep in Group 2 showed signs of osteomyelitis and were
scored with a Grade 0 osteomyelitis. However, three of the
ﬁve sheep in Group 2 did display Grade 2 cortical bone
growth, whereas the other two were scored with Grade 0
cortical bone growth. Taken together, these results sug-
gested that cortical bone growth/response could have been
due to surgical trauma or the presence of infection; yet, a
notable difference in bone morphology was present in those
that were infected versus those that had a response due to
surgical trauma. More speciﬁcally, those that had infection
showed signs of ‘‘moth eaten’’ bone that had jagged edges
due to resorption/bacterial presence, whereas those with a
cortical bone response due to surgical trauma had woven
bone formation with little indication that resorption was
occurring.
DISCUSSION
Using bioﬁlms as initial inocula in this study addressed at
least three major limitations, which have been reviewed
previously,39 that may accompany the use of planktonic bac-
teria in animal models of infection, such as those that are
designed to develop combination products of biomaterial
coatings and other antimicrobials. (1) Planktonic cells may
be cleared by the immune system more readily than cells
residing in a bioﬁlm. Thus, when planktonic cells are used
in in vivo models, it may be that they are eradicated before
they can form bioﬁlms. As mentioned, this may contribute
to the low reproducibility for the induction of osteomyelitis.
(2) It is becoming ever more evident that planktonic bacte-
rial cells are more susceptible to antibiotics than those
FIGURE 6. Left column: BSE images of a sheep treated with bioﬁlm. Right column: BSE images of a sheep not treated with bioﬁlm. Original
magniﬁcation for all images was 20. A: Representative BSE image of a cortical bone surface underneath a stainless steel plate of an infected
sheep. Note the resorption away from the bone screw and plate itself as well as the abnormal morphology (wispy, moth-eaten appearance) of
the bone, which was believed to be a result of infection. Darker bone was indicative of bone that was not yet mineralized, but rather, under-
going remodeling. B: Additional BSE image from the same sheep as (A) with bone resorption occurring in the distal area of the bone screw. C:
Additional representative BSE image of cortical bone beneath a stainless steel plate in a sheep that was not infected. Note the smooth, morpho-
logic difference in this bone compared to that of bone shown in (A). This bone grew up to the surfaces of the bone screw and plate with normal
bone morphology. D: BSE image of the distal region of a bone screw in a sheep from Group 2. No signs of resorption were present.
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residing in a bioﬁlm. If antibiotics are administered prophy-
lactically immediately following inoculation, they may affect
planktonic bacteria more effectively and rapidly than they
would bioﬁlm bacteria. (3) When planktonic bacteria are
added to the body, the possibility exists for them to be dis-
persed rapidly away from the site of initial inoculation due
to the presence of ﬂowing ﬂuids in the body. This could
dilute the concentration of bacteria per given area—poten-
tially making it easier for the body to handle the bacterial
load and prevent attachment to tissue or a medical device.
Notably, osteomyelitis developed in all ﬁve sheep from
Group 1 of this study treated with bioﬁlm, which strongly
supported the hypothesis that using bioﬁlms as initial inoc-
ula would cause infection. The hypothesis was further sup-
ported, and the data made signiﬁcantly stronger by the fact
that none of the sheep from Group 2 became infected. This
100 versus 0% rate of infection provided a promising out-
come for future tests of combination biomaterials for device
development to be performed in a repeatable fashion using
this model.
The bioﬁlms in this study appeared to have a gradual
adverse clinical effect on the sheep. More speciﬁcally, osteo-
myelitis developed slowly and persisted without signiﬁcant
signs of distress in three of ﬁve of the animals in Group 1.
This may be similar to bioﬁlm-related infections that are
seen clinically. In patients, bioﬁlm-related infections can
take months or years to develop and may persist without
signiﬁcant morbidity or mortality.32 This may be due to the
quiescent nature of bioﬁlms and the fact that they have al-
ready established a community. Planktonic bacteria have yet
to develop a community, and it appears that their ‘‘goal’’ in
nearly every ecosystem is to ﬁnd a location to colonize and
then begin to develop a bioﬁlm community.44
Importantly, there were no sclerosing agents used in
this study to promote the development of osteomyelitis,
whereas in previous studies, these noxious agents have
been commonly used to initially kill bone and/or tissue
with the intent to make it more susceptible to infection.45–48
In addition, the model in this study also appeared to circum-
vent the problem of low reproducibility for the induction of
osteomyelitis, which was cited by Gaudin et al.49 as an im-
portant limitation of animal models of osteomyelitis.
In two of the sheep from Group 1, bacteria were not
detected in the surrounding tissue regions of the SS plate.
This was likely due to the limited area of sampling with the
swab culture technique. Bacteria may not have been in
FIGURE 7. Left column: double-label images of sheep bone treated with bioﬁlm. Right column: double-label images of sheep bone not treated
with bioﬁlm. Original magniﬁcation of all images was 20. A: Image of calcein double labels in a region directly underneath a stainless steel
plate of an infected sheep. This type of remodeling was indicative of bone that was attempting to remodel in the presence of infection. B: Corti-
cal bone region more distal to the stainless steel plate than the image collected in (A). This image indicated that in addition to areas of intense
remodeling, there were areas of typical bone remodeling within the cortical bone of sheep that were infected. C: For comparison, this image of
calcein double labels was taken in the same region as the image from (A), but in a sheep that was not infected. D: Also for comparison, this
image of calcein double labels was taken in the same region as (B), but in a sheep that was not infected. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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those tissue regions and thus were not detected. However,
bacteria were collected from the PEEK membranes of both
of these sheep, which corroborated with the SEM, MAR, and
histopathological data—all of which supported the conclu-
sion that infection had developed.
At least three limitations accompanied this study and
will need to be addressed with future work. First, these
results are based on the use of a single species of microor-
ganism, and although the outcomes are hypothesized to be
similar with other bioﬁlm forming organisms, different
organisms may lead to different results. More speciﬁcally,
although S. aureus is a common cause of metal, device-
related infections,50 a wide variety of other organisms can
cause bioﬁlm-related infections including Pseudomonas aeru-
ginosa, Enterococcus faecalis, coagulase negative staphylo-
cocci, Escherichia coli, Acinetobacter baumanii, Klebsiella
pneumoniae, and others. Second, these results will need to
be conﬁrmed with other material types. For example, at
least one study has shown that titanium implants have
reduced infection outcomes when compared with SS.51
Third, as this was a developmental model to test the ability
of bioﬁlms to cause infection, antibiotics were not used.
However, if this were a clinical scenario, prophylactic antibi-
otics would have accompanied the implantation of the
devices. Thus, future work will be needed to address these
limitations.
In conclusion, to the authors’ knowledge, this is the ﬁrst
animal model using bioﬁlms as initial inocula to produce a
positive signal of reproducible bioﬁlm-related infection. As
such, the model provides a promising outcome in that it
may be used by future researchers and clinicians to use a
reproducible model to examine the therapeutic potential of
novel systemic antimicrobials and/or antimicrobial coatings
on biomedical devices to treat and prevent bioﬁlm-related
osteomyelitis as well as other bioﬁlm-related infections. It
may be that the use of this and similar animal models using
bioﬁlms as initial inocula will result in an important shift in
the ﬁeld of bioﬁlm research that adds onto the work that
has been done with planktonic bacteria. This shift may lead
to the development of novel antimicrobial therapies, such as
coatings on devices, that could help prevent bioﬁlm-related
infections in a more effective manner. In short, the develop-
ment of this experimental model may have tremendous
implications in the future of bioﬁlm implant-related infec-
tion treatment strategies as well as other bioﬁlm-related
infections.
The content is solely the responsibility of the authors
and does not necessarily represent the ofﬁcial views of the
FIGURE 8. Left column: images of H&E-stained bone sections from a sheep treated with bioﬁlm. Right column: images of H&E-stained bone
sections from a sheep not treated with bioﬁlm. A: Macroscopic image of bone from an infected sheep. Note the signiﬁcant cortical bone
response, the gap between the plate and bone surface, the endosteal bone response and the focus of sequestrum in the periosteal region. Taken
together, these tissue responses were indicators that infection was present. Original magniﬁcation was 10. B: Microscopic image of the
sequestrum seen in (A). The sequestrum had a jagged surface (sign of resorption) and large amounts of inﬂammatory cells in its surroundings;
indicators that bacteria were present and that chronic inﬂammation had persisted. Original magniﬁcation was 20. C: Macroscopic image of
bone from a sheep that was not infected. Note the apparent differences in tissue morphology between this sample and that from the infected
sheep. Original magniﬁcation was 10. D: Image of a similar region of as that analyzed in (B). Note the lack of sequestrum, resorption or
chronic inﬂammation. In contrast, this bone had normal lamellar structure. Original magniﬁcation was 20.[Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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